Official Protocol Title:  
NCT number:  [STUDY_ID_REMOVED] 
Document Date:  29-Mar-2017A Phase IIa, Randomized, Double-Blind, Placebo-
Controlled Clinical Trial of the Efficacy
and Safety of MK-[ADDRESS_1134426]:   MK -8189 1
Protocol/Amendment No.: 005-01 
MK-8189-005-01 Final Protocol 29-Mar-2017
ConfidentialTHIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., 
WHITEHOUSE STATION, NJ, U.S.A.
SPONSOR:
[COMPANY_006] Sharp & Dohme Corp., a subsidiary  of [COMPANY_006] & Co., Inc. 
(hereafter referred to as the Sponsor 
or [COMPANY_006])
One [COMPANY_006] Drive
P.O. Box [ADDRESS_1134427] information can be found in the Investigator Trial File
Binder (or equivalent) .
TITLE:
A Phase IIa, Randomized, Double- Blind, Placebo -Controlled Clinical Trial of the Efficacy 
and Safet y of MK-8189 using Risperidone as an Active Control inSubjects Experiencing an 
Acute Epi[INVESTIGATOR_819136]:   118,[ADDRESS_1134428] NUMBER:   Not Applicable 
  04MZQR 
  04YKSX
Product:   MK-8189 2
Protocol/Amendment No.: 005-01 
MK-8189 -005-01 Final Protocol 29-Mar-2017
ConfidentialTABLE OF CONTENTS
SUMMARY OF CHANGES ................................................................................................ 10
1.0 TRIAL SUMMARY .................................................................................................. 13
2.0 TRIAL DESIGN ........................................................................................................ 13
Trial Design ........................................................................................................... 13 2.1
Trial Diagram ........................................................................................................ 15 2.2
3.0 OBJECTIVE(S) & HYPOTHESIS(ES) .................................................................. 15
Primary Objective(s) & Hypothesis(es) .............................................................. 15 3.1
Secondary Objective(s) & Hypothesis(es) ........................................................... 16 3.2
Other Objectives (e.g., Tertiary, Exploratory, etc.) ........................................... 16 3.3
4.0 BACKGROUND & RATIONALE .......................................................................... [ADDRESS_1134429] Population .................................... 17 4.2.1
Rationale for Dose Selection/Regimen/Modification ......................................... 18 4.2.2
[IP_ADDRESS] Rationale for the Use of Comparator/Place bo............................................. 19
Rationale for Endpoints ...................................................................................... 19 4.2.3
[IP_ADDRESS] Efficacy  Endpoints ....................................................................................... 19
[IP_ADDRESS] Safety  Endpoints .......................................................................................... 20
[IP_ADDRESS] Pharmacokinetic Endpoints ......................................................................... 20
[IP_ADDRESS] Pharmacod ynamic Endpoints ....................................................................... 21
[IP_ADDRESS] Planned Exploratory  Biomarker Research ................................................... 21
[IP_ADDRESS] Future Biomedical Research ........................................................................ 21
Benefit/Risk ........................................................................................................... 22 4.3
5.0 METHODOLOGY ................................................................................................... 22
Entry Criteria ........................................................................................................ 22 5.1
Diagnosis/Condition for Entry  into the Trial ...................................................... [ADDRESS_1134430]:   MK-8189 3
Protocol/Amendment No.: 005-[ADDRESS_1134431] Exclusion Criteria .................................................................................. 25 5.1.3
Trial Treatment(s) ................................................................................................ 28 5.2
Dose Selection/Modification .............................................................................. 29 5.2.1
[IP_ADDRESS] Dose Selection (Preparation) ....................................................................... 29
[IP_ADDRESS] Dose Modification (Escalation/Titration/Other) .......................................... 29
Timing of Dose Administration .......................................................................... 30 5.2.2
Trial Blinding/Masking ....................................................................................... 30 5.2.3
Randomization or Treatment Allocation ............................................................ 30 5.3
Stratification .......................................................................................................... 31 5.4
Concomitant Medications/Vaccinations (Allowed & Prohibited) .................... 31 5.5
Rescue Medications & Supportive Care ............................................................. 33 5.6
Diet/Activity/Other Considerations ..................................................................... [ADDRESS_1134432] Withdrawal/Discontinuation Criteria ................................................... [ADDRESS_1134433] Replacement Strategy ............................................................................. 36 5.9
Beginning and End of the Trial ........................................................................... 36 5.10
Clinical Criteria for Early Trial Termination ................................................... 36 5.11
6.0 TRIAL FLOW CHART ........................................................................................... 37
7.0 TRIAL PROCEDURES ........................................................................................... 40
Trial Procedures ................................................................................................... 40 7.1
Administrative Procedures .................................................................................. 40 7.1.1
[IP_ADDRESS] Informed Consent ......................................................................................... 40
[IP_ADDRESS].1 General Informed Consent .................................................................... 40
[IP_ADDRESS].2 Consent and Collection of Specimens for Future Biomedical 
Research ................................................................................................ 41
[IP_ADDRESS] Inclusion/Exclusion Criteria ........................................................................ 41
[IP_ADDRESS] Subject I dentification Card .......................................................................... 41
[IP_ADDRESS] Medical History ........................................................................................... 41
[IP_ADDRESS].1 Substance/Alcohol/Smoking History / Social History ........................... 41
[IP_ADDRESS] Psychiatric History ....................................................................................... [ADDRESS_1134434]:   MK-8189 4
Protocol/Amendment No.: 005-01 
MK-8189 -005-01 Final Protocol 29-Mar-2017
Confidential7.[IP_ADDRESS] Psychiatric Intake Evaluation and MI NI.............................................. 42
[IP_ADDRESS] Identify  External Contact [CONTACT_6451] ................................................................ .43
[IP_ADDRESS] Prior and Concomitant Medications Review ............................................... 43
[IP_ADDRESS].1 Prior Medications .................................................................................. 43
[IP_ADDRESS].2 Concomitant Medications ..................................................................... 43
[IP_ADDRESS] Assignment of Screening Number ............................................................... 43
[IP_ADDRESS] Assignment of Treatment/Randomization Number ..................................... 44
[IP_ADDRESS] Interactive Voice Response Sy stem/Integrated Web Response Sy stem ...... 44
[IP_ADDRESS] Trial Medication Dispensing ........................................................................ 44
[IP_ADDRESS] Trial Compliance (Medication/Diet/Activity /Other) ................................... 44
Clinical Procedures/Assessments ........................................................................ 45 7.1.2
[IP_ADDRESS] Physical Assessments/Examinations ........................................................... 45
[IP_ADDRESS].1 Physical Examination/Neurological Examination ................................ 45
[IP_ADDRESS].2 Body Height/Weight/Waist Circumference .......................................... 46
[IP_ADDRESS].3 12-Lead Electrocardiogram .................................................................. 46
[IP_ADDRESS].4 Vital Signs............................................................................................. 46
[IP_ADDRESS] Clinical Assessment ..................................................................................... 46
[IP_ADDRESS].1 Positive and Negative Symptom Scale (PANSS) ................................ .47
[IP_ADDRESS].2 Clinical Global I mpression Scale -Severity (CGI -S)............................. 47
[IP_ADDRESS].3 C-SSRS ................................................................................................ .47
[IP_ADDRESS].4 Monitoring of Extrapy ramidal Sy mptoms ............................................ 48
Laboratory  Procedures/Assessments .................................................................. 49 7.1.3
[IP_ADDRESS] Laboratory  Safet y Evaluations (Hematology, Chemistry  and Urinaly sis)..49
[IP_ADDRESS] Pregnancy  Testing ........................................................................................ 51
[IP_ADDRESS] Urine Alcohol Drug Screen ......................................................................... 51
[IP_ADDRESS] Pharmacokinetic/Pharmacody namic Evaluations ........................................ 52
[IP_ADDRESS].1 Blood Collection for Plasma MK -8189 ................................................ 52
[IP_ADDRESS] Planned Genetic Anal ysis Sample Collection .............................................. 52
[IP_ADDRESS] Future Biomedical Research ........................................................................ 52
Other Procedures ................................................................................................ .52 7.1.4
[IP_ADDRESS] Withdrawal/Discontinuation ........................................................................ 52
[IP_ADDRESS].[ADDRESS_1134435]:   MK-8189 5
Protocol/Amendment No.: 005-01 
MK-8189 -005-01 Final Protocol 29-Mar-2017
Confidential7.1.4.2 Blinding/Unblinding .................................................................................... 53
[IP_ADDRESS] Domiciling ................................................................................................... 53
[IP_ADDRESS] Calibration of Critical Equipment ................................................................ 53
[IP_ADDRESS] Administer Trial Medication ........................................................................ 54
Visit Requirements .............................................................................................. 54 7.1.5
[IP_ADDRESS] Screening ...................................................................................................... 54
[IP_ADDRESS].1 Hospi[INVESTIGATOR_819137] ........................................................... 55
[IP_ADDRESS] Treatment Period Visit 2 through Visit 6 ..................................................... 56
[IP_ADDRESS] Telephone Contact [CONTACT_322096] .................................................................... 57
[IP_ADDRESS] Post-Treatment Contact (phone and visit) ................................................... 57
Assessing and Recording Adverse Events .......................................................... 57 7.2
Definition of an Overdose for This Protocol and Reporting of Overdose to 7.2.1
the Sponsor .......................................................................................................... 58
Reporting of Pregnancy  and Lactation to the Sponsor ....................................... 59 7.2.2
Immediate Reporting of Adverse Events to the Sponsor .................................... 59 7.2.3
[IP_ADDRESS] Serious Adverse Events ............................................................................... 59
[IP_ADDRESS] Events of Clinical I nterest ............................................................................ 60
Evaluating Adverse Events ................................................................................. 61 7.2.4
Sponsor Responsibility  for Reporting Adverse Events ...................................... 64 7.2.5
TRIAL GOVERNANCE AND OVERSIGHT ................................................... 64 7.3
Scientific Advisory  Committee ........................................................................... 64 7.3.1
Executive Oversight Committee ......................................................................... 64 7.3.2
Data Monitoring Committee ............................................................................... 64 7.3.3
8.0 STATISTICAL ANALYSIS PLAN ........................................................................ 64
Statistical Analysis Plan Summary ..................................................................... 65 8.1
Responsibility for Analyses/In -House Blinding ................................................. 66 8.2
Hypotheses/Estimation ......................................................................................... [ADDRESS_1134436]:   MK-8189 6
Protocol/Amendment No.: 005-[ADDRESS_1134437] of Baseline Factors ........................................... 75 8.10
Compliance (Medication Adherence) .................................................................. [ADDRESS_1134438]/Destruction/Returns and Reconciliation .............................................. [ADDRESS_1134439] Records ..................................................................... 78 10.1.2
Confidentiality  of Investigator Information ........................................................ 78 10.1.3
Confidentiality  of IRB/IEC I nformation ............................................................. [ADDRESS_1134440]:   MK-8189 7
Protocol/Amendment No.: 005-[ADDRESS_1134441] for Clinical Trials ........................................................ 85 12.1
Collection and Management of Specimens for Future Biomedical 12.2
Research ................................................................................................................. 87
Pharmacogenetics Informational Brochure for IRBs/IECs & 12.3
Investigational Site Staff ...................................................................................... 93
Approximate Blood/Tissue Volumes Drawn/Collected by [CONTACT_75316] 12.[ADDRESS_1134442] Tables ..................... 124
13.0 SIGNATURES ......................................................................................................... 125
Sponsor's Representative ................................................................................... [ADDRESS_1134443]:   MK -8189 8
Protocol/Amendment No.: 005-[ADDRESS_1134444] OF TABLES
    
Table 1 Trial Treatment ................................................................................................... 28
Table 2 Prohibited Medications during the Treatment Period......................................... 32
Table 3 Medications and Procedures Permitted during the Treatment Period ................. 33
Table 4 Laboratory  Tests ................................................................
................................. 50
Table 5 Evaluating Adverse Events ................................................................................. 62
Table 6 Analy sis Strategy  for Key  Efficacy  Variables .................................................... 69
Table 7 Analy sis Strategy for Safety  Parameters ............................................................. 71
Table 8 Operating Characteristics of the Futility  Analy sis†............................................ 73
Table 9 Power† (%) Under Various Assumptions With 215 Subjects 
Randomized if Futility  Analy sis is Not Performed ............................................ 74
Table 10 Power† (%) Unde r Various Assumptions With [ADDRESS_1134445]:   MK -8189 9
Protocol/Amendment No.: 005-[ADDRESS_1134446]:   MK -8189 10
Protocol/Amendment No.: 005-01 
MK-8189-005-01 Final Protocol 29-Mar-2017
ConfidentialSUMMARY OF CHANGES
PRIMARY REASON(S
) FOR THIS AMENDMENT:
Section Number (s) Section Title (s) Description of Change (s) Rationale
5.5 Concomitant 
Medications/Vaccinations 
(Allowed & Prohibited), 
Table 2Prohibited medications added These changes were made to 
enhance the usefulness of the 
table.
5.5 Concomitant 
Medications/Vaccinations 
(Allowed & Prohibited), 
Table 3Dosage of lorazepam or 
lorazepam equivalents 
decreased. Added text 
instructing sites to avoid using 
“PRN” when entering dosage 
in the CRFThese changes were made to 
reduce the dosage of 
benzodiazepi[INVESTIGATOR_819138], and to 
promote reporting of daily  
dosage administe red.
ADDITIONAL CHANGE (S)FOR THIS AMENDMENT:
Section Number (s) Section Title (s) Description of Change (s) Rationale
5.1.[ADDRESS_1134447] Exclusion Criterion 5 “Or” changed to “and” Clarification
5.1.[ADDRESS_1134448] Exclusion Criterion 19 “Known” inserted before 
“serological evidence”Clarification
5.8.1 Discontinuation of Treatment Delete “confirmed” from text 
“the subject has a confirmed 
positive serum pregnancy  test.”Clarification 
  04MZQR 
  04YKSX
Product:   MK -8189 11
Protocol/Amendment No.: 005-01 
MK-8189-005-01 Final Protocol 29-Mar-2017
ConfidentialSection Number (s) Section Title (s) Description of Change (s) Rationale
6.0 Trial Flow chart assessments, 
footnotesChanges in assessments and 
some assessment wording. Revisions better encapsulate 
actions needed at these 
assessme nts; footnotes revised 
for clarit y 
[IP_ADDRESS].1 Psychiatric Intake Evaluation 
and MINIDelete “vendor” from phrase
external vendor’s SDMETo make consistent with the 
rest of the protocol . 
[IP_ADDRESS] Laboratory  Tests ( Table 4 ) Addition of creatinine 
phosphokinase total analy te, 
and other clarificationsClarification
[IP_ADDRESS] Pregnancy  Testing Section revised to provide 
clarity  on use of urine 
pregnancy  tests and results 
confirmation through serum 
pregnancy  testingConsistent with rest of protocol
[IP_ADDRESS] Urine Alcohol Drug Screen Added text to align with other 
protocol sectionsConsistency
[IP_ADDRESS] Calibration of Critical 
EquipmentAdded text regarding ECG 
equipment calibration
documentation .Minor correction
[IP_ADDRESS] Screening Added sentence regarding 
re-screensClarification 
[IP_ADDRESS].[ADDRESS_1134449]:   MK -8189 12
Protocol/Amendment No.: 005-01 
MK-8189-005-01 Final Protocol 29-Mar-2017
ConfidentialSection Number (s) Section Title (s) Description of Change (s) Rationale
12.4  Approximate Blood/Tissue 
Volumes Drawn/C ollected by  
[CONTACT_819188] d Visit 4 prolactin 
collection. Consistency  with Trial Flow 
Chart
12.4 Approximate Blood/Tissue 
Volumes Drawn/Collected by  
[CONTACT_819189]“At the discretion of the 
investigator” added to HIV / 
hepatitis screen.Clarification , alignment with 
flow chart update
12.5 Abbreviations Expand edone abbreviation, 
added another. 
Global Minor spelling, grammar, 
and/or sty le changes throughout 
document 
  04MZQR 
  04YKSX
Product:   MK-8189 13
Protocol/Amendment No.: 005-[ADDRESS_1134450]’s last study -related phone call or visit.
Duration of Participation Each subject will participate in the trial for approximately 7weeks, 
from the time the subject signs the Informed Consent Form (ICF) 
through the final contact.  After a Screening visit and tapering of 
prohibited medications of 3 ( +4)days, each subject w ill be receiving 
assigned treatment for approximately 4weeks.  Afterthe end of 
treatment ,each subject will be follow ed for 14days.
A list of abbreviations used in this document can be found in Section 12. 5.
2.0TRIAL DESIGN
Trial Design 2.1
This is a randomized, placebo -controlled, parallel -group, multi -site, double -blind trial of 
MK- 8189 with placebo using risperidone as an active control in adult subjects experiencing 
anacute epi[INVESTIGATOR_114331] , according to the criteria specified in the Diagnostic and 
Statistical Manual of Mental Disorders (DSM -5 ™), and to be conducted in conformance 
with Good Clinical Practices.
This trial will be up to 7weeks in duration, with up to [ADDRESS_1134451] of a Screening /tapering period (up to1week long) ,a 4-week treatment 
period , and a 14-day follow -up period. Subjects could be admitted to the hospi[INVESTIGATOR_307] /inpatient 
unit as early  as the day of consent signing but no later than the evening of Screening visit 
assessment collection completion.   Subjects may continue as an inpatient in this trial 
throughout the active treatment period.Randomization Ratio 2:2:1 (MK -8189 :placebo :risperidone) 
  04MZQR 
  04YKSX
Product:   MK -8189 14
Protocol/Amendment No.: 005-01 
MK-8189-005-01 Final Protocol 29-Mar-2017
ConfidentialAt Baseline (Visit 2/Day 1),subject eligibility  will be reassessed and subjects found to be 
eligible to participate in the study will be randomly  assigned to aninvestigational product
(IP)treatment grou p: MK-8189, placebo , or risperidone in a 2:2:1 distributio n, respectivel y .
This is a double -dummy design.  The initial IP dose of MK-8189 will start  
 The initial dose of risperidone will start at 2mgQD
and titrate up to 6 mgQD.  Initial dosing and titration of IPover the 7 day  titration period are 
described in Section [IP_ADDRESS] 
(Dose Modification [ Escalation/Titration/Other ]).
Subjects who discontinue or complete the treatment period will have 2follow -
upphone call
visits (post treatment Days 3 and 14) and a follow -up clinic visit (post treatment Day 7) after 
their last dose of IP.
The primary  endpoint will betheassessment of symptoms of schizophrenia, as measured by 
[CONTACT_331902] (PANSS) at 4 weeks, as well as safet y and 
tolerability .  The secondary  endpoint will assess the severit y of schizophrenia at 4 weeks, as 
measured by [CONTACT_87793]- Severity  of Illness (CGI -S) score . Exploratory  
endpoints will include the proportion of PANSS total responders ( ≥30% reduction in PANSS 
total score), as well as the mean change from baseline to 4 weeks in the PANSS negative and 
positive subscale scores.
Specific procedures to be performed during the trial, as well as their prescribed times and 
associated visit windows, are outlined in the Trial Flow Chart - Section 
6.0. Details of each 
procedure are provided in Section 7.0 – Trial Procedures.
A standing internal Data Monitoring Committee (siDMC), which is comprised of members 
of Sponsor Senior Management, 
none of whom are directly  associated with the conduct of 
this trial,will evaluate the unblinded safet y and efficacy data to assess the overall risk and 
benefit to trial participants when approximately  25%, 50% and 75% of the subjects have had 
the opportunity to complete the study .
An interim unbli nded efficacy  (futility )analysis will be considered unless more than 50% of 
the subjects have been enrolled [ADDRESS_1134452] , would occur when 50% of the subjects have completed or 
discontinued IPtreatment and include all data collected (including partial data from subjects 
who were randomized, but did not yet have the opportunity  tocomplete the study ).  The 
siDMC w ould review the analysis results and recommend whether the study  should continue. 
  04MZQR
CCI 
  04YKSX
Product:   MK-8189 15
Protocol/Amendment No.: 005-01 
MK-8189 -005-01 Final Protocol 29-Mar-2017
ConfidentialTrial Diagram 2.2
The trial design is depi[INVESTIGATOR_6517] 1. 
Figure 1Diagram of P N-005 Study  Structure
3.0OBJECTIVE(S) & HYPOTHESIS(ES)
Primary Objective(s) & Hypothesis (es) 3.1
In male or female subjects with schiz ophrenia according to the DSM -5™ criteria who are 
≥18 to ≤50 y ears of age, and currently  experiencing an acute epi[INVESTIGATOR_114331]:
 
  04MZQR 
  04YKSX
Product:   MK-8189 16
Protocol/Amendment No.: 005-01 
MK-8189 -005-01 Final Protocol 29-Mar-2017
Confidential(1) Objective :To evaluate the efficacy  of MK -8189 compared toplacebo after 4 weeks of 
treatment as measured b y the PANSS total score .
Hypothesis:   MK- 8189 is superior to placebo in reducing the overall symptoms of 
schizophrenia as assessed by  [CONTACT_819190] 
4weeks of treatment.
(2) Objective:   To evaluate the safet y and tolerability  of MK -8189.
Secondary Objective(s) & Hyp othesis(es) 3.2
In male or female subjects with schiz ophrenia according to the DSM -5™ criteria who are 
≥18 to ≤50 y ears of age, and currently  experiencing an acute epi[INVESTIGATOR_114331]:
(1) Objective:   To evaluate the efficacy  of MK -8189 compared toplacebo after 4weeks of 
treatment as measured b y the CGI -S score.
Hypothesis:   MK- 8189 is superior to placebo in improving global functioning as 
assessed b y the mean change from baseline in CGI-S score after 4weeks of treatment.
Other Objectives (e.g. ,Tertiary, Exploratory, etc.) 3.3
In male or female subjects with schizophrenia according to the DSM -5™ criteria who are 
≥18 to ≤50 y ears of age, and currently  experiencing an acute epi[INVESTIGATOR_114331]:
(1) Objective: To evaluate the efficacy  of MK -8189 compared to placebo after 4 weeks of 
treatment as measured b y the proportion of PANSS total responde rs (≥30% reduction in 
PANSS total score).
(2) Objective: To evaluate the efficacy  of MK -8189 compared to placebo after 4 weeks of 
treatment as measured by [CONTACT_819191].
(3) Objective: To evaluate the efficacy  of MK -8189 compared toplacebo after 4 weeks of 
treatment as measured by [CONTACT_819192].
(4) Objective: To evaluate the efficacy  of risperidone compared toplacebo (for assay  
sensitivity ) after 4 weeks of treatment as measured by  [CONTACT_819193].
(5) Objective:   To assess the plasma pharmacokinetics of multiple doses of MK-8189 
administered as monotherap y.
(6) Objective:   To explore the relationship between genetic variation and response to the 
treatment(s) administered. Variation across the human genome will be analyzed for 
association with clinical data collected in this study. 
  04MZQR 
  04YKSX
Product:   MK-8189 17
Protocol/Amendment No.: 005-01 
MK-8189 -005-01 Final Protocol 29-Mar-2017
Confidential4.0BACKGROUND & RATIONALE
Background 4.1
Refer to the Investigator’s Brochure (IB) for detailed background information on MK- 8189 .
Pharmaceutical and Therapeutic Background 4.1.1
MK- 8189 is a potent and selective  that is 
being developed as a novel therapeutic for the treatment of schizophrenia.  
 
 
 
 
  
 
 
Information on Other Trial -Related Therapy 4.1.2
Risperidone is indicated for the treatment of schizophrenia. Efficacy  was established in 4 
short -term trials in adults, 2 short -term trials in adolescents (ages 13 to 17 y ears), and 1long-
term maintenance trial in adults. See Appendix 12.6for label information .  The goal of the 
current trial is to detect the clinical efficacy of MK-[ADDRESS_1134453] Population 4.2.1
This study  will evaluate the efficacy  and safet y of MK-8189 in subjects experiencing an 
acute epi[INVESTIGATOR_819139]-5 ™ criteria .
Schizophrenia is a chronic debilitating disorder consisting of 3symptom domains, including 
positive symptoms (eg, psychosis, hallucinations and delusions), negative symptoms (e.g., 
apath yandamoti vation), and cognitive impairment (e.g., impaired memory andplanning). 
The prevalence of schizophrenia is low but the disease burden is high.  Schizophrenia affect s
about 1% of the population globall y. It is believed that disruption of corticostriatal signaling, 
stemming from increased dopamine and decreased glutamate neurotransmission, results in 
the positive symptoms of schizophrenia, and may also contribute to cognitive impairment. 
Atypi[INVESTIGATOR_819140] "gold standard" medications used for the treatment of 
schizophrenia.  However, a substa ntial portion of patients with schizophrenia are not 
adequatel y treated by [CONTACT_819194] ~70% of patients switch medications within a 
year due to either a dissatisfaction with efficacy  ora general lack of tolerability  due to a wide  
  04MZQR
CCI
CCI 
  04YKSX
Product:   MK-8189 18
Protocol/Amendment No.: 005-01 
MK-8189 -005-01 Final Protocol 29-Mar-2017
Confidentialarray  of advers e events.  The major adverse events associated with these medications include 
weight gain/metabolic effects, extrapy ramidal effects, increased prolactin secretion and 
sedation.
MK- [ADDRESS_1134454] of clinical trials up to 6 weeks in duration.  In the nonclinical toxicology 
program, there were no target organ toxicities identified in the 6-week toxic ity studies in rats 
or monkey s.  MK- 8189 was well-tolerated in adults with schizophrenia for up to 14 days 
(both mono and add -on therapy ) at doses up to 16 mg.
The results of this study  will be used to determine if MK -8189 is efficacious in the treatment 
of schizophrenia and has a safet y profile supportive of continued clinical development.
In order to assess the efficacy  and safety  of MK-8189 in schizophrenia, subjects with 
schizophrenia who are currentl y experiencing an acute epi[INVESTIGATOR_819141].
The Positive and Negative Syndrome Scale (PANSS) is a 30-item clinician -rated instrument 
for assessing the symptoms of schizophrenia and will be used as the primary  efficacy  
endpoint measure . The scale was developed to assess positive and negative symptoms of 
schizophrenia as well as general psychopathology . The PANSS is a well-characterized, 
standardized measurement technique used for measuring symptom severity  of patients with 
schizophrenia and is widely  used in the stud y of ant ipsychotic therap y. 
Rationale for Dose Selection/Regimen /Modification 4.2.[ADDRESS_1134455]:   MK-8189 19
Protocol/Amendment No.: 005-01 
MK-8189 -005-01 Final Protocol 29-Mar-2017
Confidential 
[IP_ADDRESS] Rationale for the Use of Comparator/Placebo
Despi[INVESTIGATOR_819142], a placebo treatment arm is necessary  to evaluate 
efficacy  and safety .  Without the use of placebo, false assumptions regarding the true efficacy 
of new drugs may be made.   In the absence of a placebo control, it is nearly  impossible to 
distinguish true drug eff ects from placebo effects in this study  population.
Risperidone is an antipsychotic drug mainly  used to treat schizophrenia (including adolescent 
schizophrenia), schizoaffective disorder, and the mixed and manic states of bipolar disorder.  
Risperidone is a second -generation atypi[INVESTIGATOR_819143].  It is a dopamine antagonist 
possessing anti-serotonergic, anti-adrenergic and anti-histaminergic properties. The 
recommended starting dose of risperidone approved by [CONTACT_2165]
(FDA )for schizophrenia in adults is 2mg (QD). Further dosage adjustments in 1 to 2 mg QD 
increments are recommended if necessary , to the recommended dose of 4 to 8mg QD. 
Efficacy  with risperidone in schizophrenia was demonstrated in a dose range of 4to 16mg 
QD in clinical trials according to the US approved label . However, doses above 6mg per 
day for twice daily dosing were not demonstrated to be more efficacious than lower doses, 
were associated with more extrapy ramidal symptoms and other adverse effects, and are 
generall y not recommended.  The current trial will use a target dose of risperidone 6mg QD 
as the active control to provide validation of the trial design .
Rationale for Endpoints 4.2.3
[IP_ADDRESS] Efficacy Endp oints
The Positive and Negative Syndrome Scale (PANSS) ,is a 30-item clinician -rated instrument 
for assessing the symptoms of schizophrenia and will be used as the primary  efficacy  
endpoint measure . The positive scale consists of 7items which measure delusions, 
conceptual disorganization, hallucinations, excitem ent, grandiosit y,
suspi[INVESTIGATOR_23703]/persecution , and hostility  .  The negative subscale consists of 7items which 
measure blunted affect, emotional withdrawal, poor rapport, passive/apathetic social 
withdrawal, difficult y in abstract thinking, lack of spontan eity and flow of conversation, and 
stereot yped thinking.  The general ps ychopathology  scale consists of 16 items which measure 
somatic concern, anxiety , guilt feelings, tension, mannerisms and posturing, depression, 
motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, 
lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation ,
and active social avoidance. The change from baseline in the PANSS total score at 4 weeks 
is the primary  efficacy  endpoint. 
The Clinical Global Impression Severity  of Illness (CGI-S) is a 7-point clinician -rated scale 
for assessing the global severit y of the illness .The change in CGI-S score from baseline to [ADDRESS_1134456]:   MK -8189 20
Protocol/Amendment No.: 005-[ADDRESS_1134457] of the proportion of PANSS total responders (≥30% 
reduction in PANSS total score) , as well as the mean change from baseline to 4 weeks in the 
PAN SS negative and positive subscale scores.
[IP_ADDRESS] Safety Endpoints
Safety  and tolerability  will be assessed throughout the study  by [CONTACT_819195].  Physical examinations, vital signs, 12-lead ECGs and 
laboratory  safety  tests will be performed routinely to detect any  medically  meaningful effects 
of the MK -8189 on phy siology . 
Prospective assessment of suicidal ideation and behavior will be performed in this trial using 
the Columbia -
Suicide Severity Rating Scale (C-SSRS).  This assessment is being conducted 
in compliance with the 2012 F DA guidance requiring prospective assessment in clinical trials 
conducted under investigational new drug (IND) applications and trials that are intended for 
submission in a new drug application (NDA) to the Neurology  or Psy chiatry  Divisions of the 
FDA or biologics license application, as well as assessment in trials that fall within the 
guidance for other reasons (e.g. ,Central Nervous Sy stem [ CNS ]active/penetrant compounds, 
and known mechanisms or indications for which suicidal ideation/behavior has been 
previously  identified as a potential concern).
Extrapy ramidal symptoms will be documented with the Extrapyramidal Symptom Rating 
Scale –abbreviated (ESRS -A).
Pre-specified events of clinical interest (ECI s) (Section [IP_ADDRESS]) in this study  will include the 
following:
1.Elevated 
aspartate aminotransferase ( AST )or alanine aminotransferase ( ALT )lab value 
that is greater than or equal to 3X the upper limit of normal and an elevated total bilirubin 
lab value that is greater than or equal to 2X the upper limit of normal and, at the same 
time, an alkaline phosphatase lab value that is less than 2X t he upper limit of normal, as 
determined b y wa y of protocol -specified laboratory  testing or unscheduled laboratory  
testing.
2.Suicidal ideation and/or behaviors reported in C- SSRS scores, Treatment Emergent 
Adverse Events ( TEAEs )or an y self -injurious behavio
r.
3. D ystonia
4.Tardive d yskinesia
5.QT corrected Fridericia ( QTcF )interval of ≥500 msec (The average of the 3 QTcFs will 
be used)
[IP_ADDRESS] Pharmacokinetic Endpoints
Blood will be drawn at time points specified in the Study  Flow Chart for MK-8189 
pharmacokinetic (PK) measurements. The plasma samples will be used to evaluate the 
pharmacokinetics of MK-[ADDRESS_1134458] population, and to enable the characterization of 
the pharmacokinetic/pharmacod ynamic (PK/PD) and pharmacokinetic/adverse event 
(PK/AE) relationships.  Additional metabolites based on ongoing metabolites in safety  
  04MZQR 
  04YKSX
Product:   MK -8189 21
Protocol/Amendment No.: 005-01 
MK-8189-005-01 Final Protocol 29-Mar-2017
Confidentialtesting (MIST) analysis, may also be evaluated . Thesedata willbe used in pharmacokinetic 
model development and anal ysis.
The final decision as to which plasma samples will be assay ed will be ma
de by [CONTACT_1034]'s
Department of Pharmacokinetics, Pharmacod ynamics, and Drug Metabolism ([COMPANY_003]M) and
the Clinical Monitor.  Information regarding the collection and shippi[INVESTIGATOR_819144].
[IP_ADDRESS] Pharmacodynamic Endpoints
An exposure -response analy sis of PANSS total score data will be performed to substantiate 
the efficacious dose range of MK-[ADDRESS_1134459] of factors such as exposure, patient population and drop-out on outcomes with 
MK-8189.
[IP_ADDRESS] Planned Exploratory Biomarker Research
Planned Genetic Analysis
Understanding genetic determinants of drug response is an important endeavor during 
medical research.  This research will evaluate whether genetic variation within a clinical trial 
population correlates with response to the treatment(s) under evaluation.  If genetic variation 
is found to predict efficacy  or adverse events, the data might inform optimal use of therapi[INVESTIGATOR_401117]. Knowledge of the molecular basis of disease contributes to the 
development of novel biomarkers and the identific ation of new drug targets.   This research 
contributes to understanding genetic determinants of efficacy  and 
safet y associated with the 
treatments in this study . 
[IP_ADDRESS] Future Biomedical Research
The Sponsor will conduct Future Biomedical Research on specimens collected for future 
biomedical research during this clinical trial.  This research may include genetic analyses 
(DNA), gene expression profiling (RNA), proteomics, metabolomics (serum, plasma) and/or 
the measurement of other anal ytes.
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol (as part of the main trial) and will only be conducted on specimens from 
appropriatel y consented subjects. The objective of collecting specimens for Future 
Biomedical Research is to explore and identify  biomarkers that inform the scientific 
understanding of diseases and/or their therapeutic treatments. For instance, exploratory 
pharmacogenetic (PGt) studies may be performed if significant 
Pharmacokin etic/Pharmacody namic (PK/PD) relationships are observed or adverse events 
are identified.  Genomic markers of disease may also be investigated.  Such retrospective 
pharmacogenetic studies will be conducted with appropriate biostatistical design and analy sis 
and compared to PK/PD results or clinical outcomes. Any significant PGt relationships to 
outcome would require validation in future clinical trials. The overarching goal is to use such 
information to develop safer, more effective drugs /vaccines, and/or to ensure that subjects  
  04MZQR 
  04YKSX
Product:   MK-8189 22
Protocol/Amendment No.: 005-[ADDRESS_1134460] drug /vaccine at the correct time.  The details of this 
Future Biomedical Research sub-trial are presented in Section 12.2 -Collection and 
Management of Specimens for Future Biomedical Research .  Additional informational 
material for institutional review boards/ethics committees (IRBs/ERCs) and investigational 
site staff is provided in Section 12.3.
Benefit/Risk 4.3
The safet y monitoring practices employ ed by [CONTACT_3181] (i.e., physical examinatio n, vital 
signs, 12-lead ECG, laboratory  safety tests, C-SSRS assessments, and adverse events 
monitoring) are adequate to protect the subjects’ safet y and should detect all adverse events.
There may  be no direct health benefit for study  participants from re ceipt of study  medication, 
since it is still to be determined if treatment will improve, worsen or have no effect on the 
symptoms of schizophrenia.  We may learn more about this drug from this study  that might 
benefit people in the future .
Additional detai ls regarding specific benefits and risks for subjects participating in this 
clinical trial may be found in the accompan ying Investigators Brochure (IB) for MK-8189, 
the label for risperidone and Informed Consent documents.
5.0METHODOLOGY
Entry Criteria 5.1
Diagnosis/Condition for Entry into the Trial 5.1.[ADDRESS_1134461]. All psychiatric diagnoses specified in the inclusion/exclusion criteria will be made 
according to the DSM -5 ™ criteria by a qualified psychiatrist (Doctor of Medicine [MD]) or 
psychologist (Doctor of Philosophy  [PhD]) or other equivalent degree . The diagnosis will be 
confirmed using the Mini International Neuropsy chiatric Interview for Schizophrenia and 
Psychotic Disorders (MINI; Version 7).  Male or female subjects with schizoph renia
according to the DSM -5 ™ criteria (295.90) who are ≥18 to ≤50 yearsof age, currentl y 
experiencing an acute epi[INVESTIGATOR_114331] (worsening of active symptoms as listed in 
DSM -5 ™ Criterion A)will be enrolled in this trial.
Subject Inclusion Criteria 5.1.[ADDRESS_1134462]:
1. Provide written informed consent for the trial.  The subject may also provide consent 
for Future Biomedical Research.  However, the subject may  participate in the main tria l 
without participating in Future Biomedical Research. Note: the subject must have a 
level of decision -making capacity  needed to make a meaningful choice about whether  
  04MZQR 
  04YKSX
Product:   MK -8189 23
Protocol/Amendment No.: 005-01 
MK-8189-005-01 Final Protocol 29-Mar-2017
Confidentialor not to participate in the study  (i.e, if lack of decisional capacit y is evident, the subject 
shall be excluded from the study ).
2. Be fluent in the language of the investigator, trial staff (including raters), and the 
informed consent.
3. Be ≥18 to ≤50 years of age at Screening and of minimal legal age for signing the 
consent form .
4. Meet oneof the following categories:
a) The subject is a male (there are no requirements pertaining to reproductive 
potential or contraceptive method)
.
b) The subject is a female who is not of reproductive potential, defined as a female 
who either: (1) is postmenopausal (defined as at least 12 months with no menses 
in women ≥45 years of age); (2) has had a hysterectom y and/or bilateral 
oophorectom y, bilatera l salpi[INVESTIGATOR_8820] y, or bilateral tubal ligation/occlusion at 
least 6 weeks prior to Screening ; OR (3) has a congenital or acquired condition 
that prevents childbearing.
c) The subject is a female who is of reproductive potential and agrees to avoid 
becoming pregnant while receiving study  drug and for [ADDRESS_1134463] dose 
of study  drug by [CONTACT_260759]:  (1) practice abstinence†
from heterosexual activity  OR (2) use (or have her partner use) acceptable 
contraception during heterose xual activity .  Acceptable methods of contraception 
are‡:
Combination method (requires use of two of the following):
• diaphragm with spermicide (cannot be used in conjunction with cervical 
cap/spermicide)
• cervical cap with spermicide (nulliparous women only)
• contraceptive sponge (nulliparous women only ) 
• male condom or female condom (cannot be used together)
†Abstinence (relative to heterosexual activity ) can be used as the sole method of 
contraception if it is consistently  employ ed as the subject’s preferred and usual lifesty le 
and if considered acceptable by [CONTACT_176742]/I RBs.  Periodic 
abstinence (e.g., calendar, ovulation, sy mpto -thermal, post -ovulation methods, etc.) and 
withdrawal are not acceptable methods of contraception. 
‡If a contraceptive method listed above is restricted by [CONTACT_427]/guidelines, 
then it does not qualify  as an acceptable method of contraception for subjects 
participating at sites in this country /region .
5. Currently  meet the diagnostic criteria for schizophrenia according to the DSM-5™
criteria (295.90) ; have a past diagnosis of schizophrenia with the onset of the first 
epi[INVESTIGATOR_277196] ≥1 year prior to study  entry ;andillness duration of 
≤20 years.
6. Be confirmed (documented in the psychiatric intake evaluation form by [CONTACT_1275], and reviewed /approved by [CONTACT_819196]  
  04MZQR 
  04YKSX
Product:   MK -8189 24
Protocol/Amendment No.: 005-01 
MK-8189-005-01 Final Protocol 29-Mar-2017
Confidentialexpert [SDME ]prior to randomization) to be experiencing an acute epi[INVESTIGATOR_819145], as evidenced b y ALL of the following:
a) Onset of the cu rrent acute epi[INVESTIGATOR_154806] ≤ 4 
weeks prior to Screening ,
b) the subject ’s current symptoms represent a marked and substantial change 
compared with the subject ’s symptomatic state prior to the emergence of the 
current epi[INVESTIGATOR_1865],
c) the subject is in need of increased medical attention to treat worsening acute 
epi[INVESTIGATOR_819146] .
7. Have a minimum PANSS total score of ≥ 80 at Screening (note the Screening minimum 
PANSS total score must be independentl y verified by [CONTACT_819197] b y the Sponsor) .
8. H ave a score of ≥ 4 ( moderate ) in three or more of the following items (delusions, 
conceptual disorganization, hallucinatory  b ehavior, grandiosity , 
suspi[INVESTIGATOR_23703]/perse cution) in the positive subscale of the PANSS at Screening (note 
the Screening minimum scores in at least three PANSS positive items must be 
independentl y verified by [CONTACT_819198] b y the Sponsor) .
9. H ave a CGI -S score of ≥ 4 ( moderatel y ill) at Screening .
10. Be able to taper off psychotropic medications (including antips ychotics, antidepressants
and mood stabilizers) without significant destabilization or increased suicidality  in the 
opi[INVESTIGATOR_871] (see Section 5.5) with the last dose taken no later than the 
evening prior to the Baseline visit (Visit 2 / Day 1) (the dosing cycle of depot 
neuroleptics must end no later than the day prior to Baseline). For subjects who can 
skip the tapering period, last dose is to be taken no later than the day of Screening (the 
dosing cy cle of depo t neuroleptics must end no later than the day  of Screening ).  
11. Have responded positively  to an antips ychotic medication other than clozapi[INVESTIGATOR_050] 
(Clozaril ®) in a prior psychotic epi[INVESTIGATOR_1865] . Subjects who have responded to another 
antipsy chotic onl y when paired wi th clozapi[INVESTIGATOR_819147] .
12. B e willing and considered able by [CONTACT_819199], including recordings of interviews, adhere to dose and visit schedules ,
study  procedures and restrictions
.
13. Subject must have an identified responsible person (e .g., family  member, social worker, 
case worker, case manager, or nurse), referred to as the “external contact [CONTACT_9702]” in the 
protocol, who has agreed to provide information about the subject’s location if needed 
during outpatient portion of the trial.  The site personnel must consider this identified 
responsible person a reliable contact [CONTACT_819200] (th
e external contact [CONTACT_819201], and this frequency of conta ct is anticipated to continue 
(either in person or via telephone) during the follow -up period as well as the outpatient 
treatment period if the subject is discharged on Day 21.  If the subject does not have an 
external contact [CONTACT_819202], the site may designate a  
site representative to act as the subject’s external contact [CONTACT_9702], with the same 
responsibilities as described above. 
  04MZQR 
  04YKSX
Product:   MK-8189 25
Protocol/Amendment No.: 005-[ADDRESS_1134464] :
1. Is currently  participating in or has participated in an interventional clinical research 
study ≤[ADDRESS_1134465] i s considered a danger 
to themselves or others.
3. Is unwilling to remain hospi[INVESTIGATOR_819148].
4. Has participated in more than one interventional clinical trial research stud ywithin 12 
months prio r to Screening based on site experience or patient self -report .
5. Is unwilling to allow audio/video tapi[INVESTIGATOR_819149]/or PANSS interview at 
Screening and Baseline .
6. Has a history  of malignancy  ≤five years prior to signing informed consent except for 
adequatel y treated basal cell or squamous cell skin cancer or in situ cervical cancer.
7. Has a bod y mass index (BMI) <18.5 or > 40.0kg/m2.
8. Has a history  of treatment resistance exhibited by  [CONTACT_486463]:
a)no or minimal response to at least two periods of treatment in the past with 
antipsy chotic agents (from at least twodifferent chemical classes) at the maximally  
tolerated dose in treatments lasting six weeks or more.
b)history  of Electroconvulsive Therap y (ECT) treatment for treatment resistant 
schizophrenia within the past 5 y ears.
c)past or current use of clozapi[INVESTIGATOR_819150] [ADDRESS_1134466] on CYP3A and/or CYP2C9 and/or sensitive 
substrates of CYP2B6 or in the opi[INVESTIGATOR_871], cannot be safely  tapered off 
these medications prior to Randomization .
10. Haslaboratory  and/or clinical evidence of clinically  significant hepatic conditions such 
as:
a) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2x upper 
limit of normal (UL N) and total bilirubin > 1.5x ULN.
b) ALT or AST >3x ULN 
c) A history  of hepatitis or liver disease that, in the opi[INVESTIGATOR_871] , has 
been active within the six months prior to Screening.
11. Has a prolactin laboratory  value of ≥ [ADDRESS_1134467] at Screening.
12. Has known cardiovascular disease (history  of angina, myocardial infarction or 
ischemia, heart failure, or conduction abnormalities ) or cerebrovascular disease . 
13. Has a risk factor for QTc prolongation as defined by : 
  04MZQR 
  04YKSX
Product:   MK -8189 26
Protocol/Amendment No.: 005-01 
MK-8189-005-01 Final Protocol 29-Mar-2017
Confidentiala)aknown history  or current evidence ofQTc interval >450 msec for males or > 470 
msec for females
b)a known history  of risk factors for Torsades de Point es (e
.g.,heart 
failure/cardiomy opathy  or family  history  of long QT Sy ndrome)
c)hypokalemia or hy pomagnesem ia
(Note: Determination of QTc interval at Screening as a pretreatment reference will be 
based on the average of three measurements, using the Fridericia formula [QTcF ]for 
correction. The average will be calculated b y the site.)
14. Has known renal disease or is exper iencing renal insufficiency as defined by:
a)Estimated glomerular filtration rate (eGFR) of <70 mL/min/1.73m2[as measured 
by [CONTACT_126271] (MDRD) formula]
15. Has adverse events or clinically  significant abnormal laboratory , vital sign, or physical 
examination, or ECG finding during Screening phase indicative of emerging or 
unstable medical conditions that potentially  interfere with the ability  to evaluate the 
safet y, tolerability and the efficacy  of the trial medication , according to the judgment of 
the investigator .
16. As a female, has a positive serum pregnancy  test at Screening or is nursing or plans to 
nurse children.
17. Hasa known history  of untreated narrow angle glaucoma .
18. Has ever been diagnosed with epi[INVESTIGATOR_819151] .
19. Has known serological evidence of human immunodeficiency  virus (HIV) antibody .
20. Has a history  of neuroleptic malignant s yndrome.
21. Has a primary  current diagnosis other than schizophrenia ora comorbid diagnosis that 
is primarily  responsible for the current s ymptoms and functional impairment .
22. Has a known history  of the following 
a)borderline personality  disorder, antisocial personality  disorder, or bipolar disorder. 
b)traumatic brain injury  causing ongoing cognitive difficulties, Alzheimer’s disease 
or another form of dementia, or any chronic organic disease of the central nervous 
system
c)intellectual disability  of a severity  that would impact the ability  of the subject to 
participate in the trial
23. Currently  (within the past 6 months prior to screening ) meet sthe DSM -5™ criteria for 
substance use disorder (excluding nicotine dependence ) or alcohol use disorder.
24. Has a positive urine alcohol/drug screen at the Screening visit (subjects with positive 
psychotropic medication results for drugs permitted at time of screening may be 
included provided the finding can be accounted for by  [CONTACT_819203] y with protocol requirements regarding excluded  
  04MZQR 
  04YKSX
Product:   MK -8189 27
Protocol/Amendment No.: 005-01 
MK-8189-005-01 Final Protocol 29-Mar-2017
Confidentialmedications). Subjects with positive alcohol or cannabis results on the urine 
alcohol/drug screen may be included at the investigator ’s discretion, provided the 
investigator does not feel the subject is a compliance risk and the subject does not fulfill 
the criteria for substance abuse or dependence.
25. Has a current diagnosis of a psychotic disorder (other than schizophrenia) or a 
behavioral disturbance thought to be substance- induced or due to substance a buse.
26. Is at imminent risk of self-harm or harm to others, in the investigator ’s opi[INVESTIGATOR_819152] , MINI, or responses provided on the C
-SSRS. Note that subjects 
must be excluded if they report suicidal ideation meeting the description of C-SSRS 
Type 4 or 5 (i.e., suicidal ideation with intent, with or without a plan) within the past 
two months or suicidal behavior (as described by [CONTACT_941] C-SSRS) within the past six 
months at Screening. Subjects must be excluded at Baseline if they report suicidal 
ideation of Type [ADDRESS_1134468] of violence (assaultive behavior) ≤ 2 years prior to the Screening
visit.Note: history  of assaultive behavior which resulted in commitment or 
incarceration is not necessarily  exclusionary  if the behavior was verbal abuse only or if 
the investigator has a full understanding of the nature of the assaultive behavior in 
question and judges the past assaultive behavior as not indicative of a risk to personal 
or public safety .  The investigator should exclude enrollment of subjects who may  be at 
risk for future assaultive behavior. 
28. Is known to be repeatedly  medically  noncompliant in the management of their disease
as assessed b y the investigator .
29. Has a history  of significant multiple and/or severe allergies (e.g.,food, drugs, latex  
allergy ), or has had an anaphy lactic reaction or significant intolerability  to prescription 
or non
-prescription drugs or food.
30. Has a known allergy  or sensitivity  to risperidone ,active ingredients or other inert 
ingredients. 
31. Has h ypothyroidism, diabetes, high blood pressure, or chronic respi[INVESTIGATOR_819153] e prescribed dose 
and regimen of medication are stable for 
≥ [ADDRESS_1134469] 
inappropriate for participation in the study .
33. Is or has an immediate family  member (e.g., spouse, parent/legal guardian, sibling or 
child) who is investigational site or sponsor staff directly  involved with this trial. 
  04MZQR 
  04YKSX
Product:   MK-8189 28
Protocol/Amendment No.: 005-01 
MK-8189 -005-01 Final Protocol 29-Mar-2017
ConfidentialTrial Treatment(s) 5.2
Thetreatment sto be used i n this trial areoutlined below in Table 1.
Table 1 Trial Treatment
Drug Dose/PotencyDose 
FrequencyRoute of 
AdministrationRegimen/Treat ment 
Period Use
MK-8189
(4mg)4 mg controlled 
release (CR) 
formulationQD Oral 1 tab let/day, Visit 2
/Day 1 (3 [+1]days)Experimental
treatment
Placebo for 
4-mg 
MK-[ZIP_CODE] mg QD Oral 1 tablet/day, Visit 
2/Day 1 (3 [+ 1] days)Placebo to 
experimental 
treatment
Risperidone
2mg2 mg QD Oral 1 capsule /day Visit 2 
/Day 1 (3[+1] days)Comparator
Placebo for 
2-mg 
risperidone0 mg QD Oral 1 capsule /day Visit 2 
/Day 1 (3[+1] days)Placebo to 
comparator
MK-8189
(8mg)4mg controlled 
release (CR) 
formulationQD Oral 2 tab lets/day,  Day 4
(3[+1] days)Experimental
treatment
Placebo for 
8-mg 
MK-[ZIP_CODE] mg QD Oral 2 tab lets/day, Day 4
(3[+1] days)Placebo to 
experimental 
treatment
Risperidone   
(4mg)2 mg QD Oral 2 capsules /day,  Day 4
(3[+1] days)Comparator
Placebo for 
4-mg 
risperidone0 mg QD Oral 2capsules /day,  Day 4
(3[+1] days)Placebo to 
comparator
MK-8189 
(12mg)*4 mg controlled 
release (CR) 
formulationQD Oral 3 tablets/day ,Visits 3-6 Experimental
treatment
Placebo for   
12-mg 
MK-8189 *4 mg controlled 
release (CR) 
formulationQD Oral 3 tablets/day ,Visits 3-6 Placebo to 
experimental 
treatment
Risperidone
6mg*2 mg QD Oral 3 capsules/day, Visits 
3-6Comparator
Placebo for 
6-mg
risperidone*0 mg QD Oral 3 capsules/day, Visits 
3-6Placebo to 
comparator
* Subjects may decrease dose to8mg MK-8189 / 4mg risperidone QD if 12mgMK-8189 / 6mg risperidone QD is 
not tolerated. Subjects will be discontinued from IPif they cannot tolerate the 8mg MK-8189 / 4mg risperidone
QD dose.
Each subject will be randomized to study  treatment MK- 8189 ,placebo , or risperidone and 
receive a randomization number at Visit 2(baseline visit) .Randomization should not occur 
until all eligibility  criteria have been assessed (i.e., the site has received and evaluated all 
pending reports from central ECG, central laboratory , and external SDME ’sapproval of 
eligibility  based on the information provi ded in the psychiatric intake e valuation form).
The investigator shall take responsibility  for and shall take all steps to maintain appropriate 
records and ensure appropriate suppl y, storage, handling, distribution and usage of trial 
treatments in accordan ce with the protocol and any applicable laws and regulations. 
  04MZQR 
  04YKSX
Product:   MK-8189 29
Protocol/Amendment No.: 005-01 
MK-8189 -005-01 Final Protocol 29-Mar-2017
ConfidentialDose Selection/Modification 5.2.1
[IP_ADDRESS] Dose Selection (Preparation)
The rationale for selection of doses to be used in this trial is provided in Section 4.0 –
Background & Rationale.  There are no specific calculations or evaluations required to be 
performed in order to administer the proper dose to each subject .
[IP_ADDRESS] Dose Modification (Escalation/Titration/Other)
Subjects who are found to be eligible to participate in the study will, at the Baseline (Visit 
2/Day  1) visit, be randomly  assigned to MK- 8189 ,placebo , or risperidone treatment groups 
in a 2:2:1 distributio n, respectively .  Each dose per treatment group will be given in a double -
dummy  and QD fashion .Subjects randomized to the MK- 8189 treatment group will receive ,
per dose,equal numbers of 4-mg MK-8189 active tablets and risperidone matching placebo 
capsules ; subjects randomized to the risperidone treatment group will receive ,per dose ,equal 
numbers of 2-mg risperidone active capsules and MK- 8189 matching placebo tablets; 
subjects randomized to the placebo treatment group will receive ,per dose,equal numbers of 
risperidone matching placebo capsules and MK -8189 matching placebo tablets .  
Initial doses per treatment group will be given as 1 tablet and 1 capsule: the combination of 1 
tablet and 1 capsule will therefore result in the initial QD dose 2-mg 
risperidone for subjects randomized to MK- 8189 and risperidone treatments groups, 
respectivel y, and placebo only for subjects randomized to placebo .  
For subjects in each randomized group ,titration  
 
 
  

 
 
 
 
Subjects assigned to the placebo group will be titrated to a final target of 3MK- 8189 
matching placebo tablets and 3risperidone matching placebo capsules using the 
following titration steps: on Day 4,the IPdose will be increased to 2MK- 8189 
matching placebo tablets and 2 risperidone matching placebo capsules ; on Day 7,the 
dose will again be increase dto 3MK- 8189 matching 
placebo tablets and 3
risperidone matching placebo capsules for the remainder of the trial, as tolerated.  
Subject s assigned to the risperidone group will be titrated to a final targeted dose of 
6-mg risperido ne(3 capsules )and [ADDRESS_1134470]:   MK-8189 30
Protocol/Amendment No.: 005-01 
MK-8189 -005-01 Final Protocol 29-Mar-2017
Confidentialfollowing titration steps: on Day 4,the IP dose will be increased to 2risperidone 2-
mg capsules and 2MK- 8189 matching placebo tablets for a total of a 4-mg dose of 
risperidone ; on Day 7,the dose will again be increase dto 3risperidone 2-mg capsules 
and 3MK- 8189 matching placebo tablets for a total of a 6-mg risperidone dose for 
the remai nder of the trial, as tolerated.
 
 
 
  
Subjects will be discontinued from IPin the event that subjects cannot tolerate thedose of 
/ 4-mg risperidone QD .
All dosing should occur in the morning.   The dose titration schedule in the current trial is
based on previous clinical pharmacology  trial data for the MK-[ADDRESS_1134471]’s symptomatology and tolerability . 
Once a subject has completed participation in the treatment phase at Day 28, the IP will no 
longer be available to the subject.  
Timing of Dose Administration 5.2.2
Subjects will receive double -blind IPon Visit 2 (Day 1) inthe inpatient setting if they meet 
all eligibility  criteria . The first dose will be administered after all baseline visit safety 
assessments and efficacy  assessment sare completed (including the collection of blood 
samples and pre-dose PK sample) and subsequent randomization .  Note: randomization and 
first dose must be done on the same day. While in the inpatient setting , subjects should be 
administered their IPat approximately  the same time each morning . The IP dose can be 
taken without regard to food intake .  If a dose is missed in the morning ,it can be taken any 
time up to 1 PM .  Subjects will be monitored for complianc e.
Trial Blinding/Masking 5.2.3
A double -blind /masking technique will be used. MK- 8189 and risperidone will be packaged 
identical ly relative to their respective matching placebo so that blind ing/masking is 
maintained .The subject, the investigator and Sponsor personnel or delegate(s) who are 
involved in the treatment or clinical evaluation of the subjects are unaware of the group 
assignments .
See Section [IP_ADDRESS] , Blinding/Unblinding , for a description of the method of unblinding a 
subject during the trial, should such action be warranted .
Randomization or Treatment Allocation 5.3
Treatment allocation/r andomization will occur centrally  using aninteractive voice response 
system / integrated web response system (IVRS/I WRS). There are3treatment arms.   
  04MZQR
CCI
CCI 
  04YKSX
Product:   MK-8189 31
Protocol/Amendment No.: 005-01 
MK-8189 -005-01 Final Protocol 29-Mar-2017
ConfidentialSubjects will be assigned randoml y in a2:2:1 ratio to MK- 8189 ,placebo , or risperidone for 
the duration of the 4weeks of treatment. 
Stratification 5.4
No stratification based on age, sex or other characteristics will be used in this trial .
Concomitant Medications /Vaccinations (Allowed & Prohibited) 5.5
Medications or vaccinations specifically  prohibited in the exclusion criteria are not allowed 
during the ongoing trial.  If there is a clinical indication for any medication or vaccination 
specificall y prohibited during the trial, discontinuation from trial therapy or vaccination may 
be required.  The investigator should discuss any questions regarding this with the Sponsor 
Clinical Director .  The final decision on any supportive therap y or vaccination rests with the 
investigator and/or the subject's primary  physician.  However, the decision to continue the 
subject on trial therapy or vaccination schedule requires the mutual agreement of the 
investigator, the Sponsor and the subject.
Listed below are specific restrictions for concomitant therap y during the course of the trial:
Medicat ions specificall y prohibited in the exclusion criteria are not allowed during the 
treatment period . Medications with a moderate or strong inhibiting or inducing effect on 
cytochrome P450 (CYP ) 3A and/or CYP2C9 and/or the use of medication s that aresensitive 
substrates of CYP2B6 are prohibited during the treatment period .In addition, all 
psychotropic medications (including antipsy chotics, antidepressants, mood stabilizers, other 
psychotropi[INVESTIGATOR_1102]) are prohibited during the treatment period, except as described in Table 3.  
The subject must be able to discontinue or, in the opi[INVESTIGATOR_871], safely  taper off, 
of any  prohibited treatment listed in Table 2 over 3 (+4) day s prior to the Baseline visit (Visit 
2) without significant destabilizatio n or increased suicidality.   
The following list is not to be considered an exhaustive list of the aforesaid medications. All 
current and recent medications taken by  a potential subject should be reviewed to ensure they 
are not exclusionary  to recruitment or screening.  The Investigator should seek guidance from 
the S ponsor when needed . 
  04MZQR 
  04YKSX
Product:   MK -8189 32
Protocol/Amendment No.: 005-01 
MK-8189-005-01 Final Protocol 29-Mar-2017
ConfidentialTable 2 Prohibited Medications during the Treatment Period
CYP inducers, inhibitors and sensitive substrates a
CYP3A known inhibitors: Strong: Boceprevir, clarithromycin, conivaptan, indinavir, traconazole, 
ketoconazole, lopi[INVESTIGATOR_054]/ritonavir, mibefradil, nefazodone, nelfinavir,
posaconazole, ritonavir, saquinavir,  telaprevir, telithromycin, 
voriconazole, tipranavir, cobicistat
Moderate: Amprenavi r, aprepi[INVESTIGATOR_053], atazanavir, ciprofloxacin, 
darunavir/ritonavir, diltiazem, erythromycin, fluconazole, 
fosamprenavir, imatinib, verapamil ,idelalisib, danoprevir, delavirdine
CYP3A known inducers Strong: Carbam azepi[INVESTIGATOR_050], phenytoin, rifampin , mitotane, avasimibe , 
enzalutamide, St John's Wort extract , rifabutin , phenobarbital
Moderate: Bosentan, efavirenz, etravirine, modafinil, nafcillin; ritonavir 
and St. John ’s Wort, tipranavir and ritonavir, genistein, thioridazine, 
talviraline, lopi[INVESTIGATOR_054], lersivirine
CYP2C9 known inhibitors Strong: Pi[INVESTIGATOR_5329], miconazole, phenylbutazone, tienilic acid, 
azapropazone, bucolome, sulfaphenazole, benzbromarone
Moderate: Amiodarone, fluconazole, oxandrolone
CYP2C9 known inducers Moderate: Carbamazepi[INVESTIGATOR_050], rifampin ,enzalutamide, ritonavir
CYP2B6 known substrates with 
sensitive therapeutic rangeBupropi[INVESTIGATOR_2394], efavirenz
Medications Supplements, Other Substances and Procedures
Antipsychotics (other than trial medication)
Antidepressants
Mood stabilizers
Stimulants such as Ritalin and amphetamines
MAO inhibitors b
Herbal drugs/dietary supplements, including and not limited to St John’s Wort, gin kgo, goldensealc
Antiemetics containing dopamine agonist
Illicit drugs
Medium and long -acting benzodiazepi[INVESTIGATOR_819154]= Monoam ine oxidase
ECT = Electroconvulsive Therapy
aSources include the FDA website 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabe
ling/ucm093664.htm#potency
bThe last dose of a MAO i nhibitor must be 1month prior to Screening.
cDietary supplements that are specifically marketed for psychiatric symptoms (e.g., valerian, Bach’s 
flower remedies) are prohibited. Supplements with broader applications for general health (such as 
omega-3-fatty acids, magnesium) are not prohibited
dFor countries where no short -acting benzodiazepi[INVESTIGATOR_819155], diazepam (up to 30 mg/day during the 
taper period and first 14 days of active treatment, up to 15 mg/day  thereafter) is perm itted to be used for 
the control of agitation, anxiety, and insomnia, if available. In the event diazepam is not available in 
countries where no short -acting benzodiazepi[INVESTIGATOR_819155], use of other benzodiazepi[INVESTIGATOR_819156]. 
  04MZQR 
  04YKSX
Product:   MK-8189 33
Protocol/Amendment No.: 005-[ADDRESS_1134472] Baselinea
As-needed use non -psychotropic medications Aspi[INVESTIGATOR_248], Nonsteroidal anti-inflammatory drugs 
(NSAIDs ), acetaminophens  
Chronic use medication Chronic use of certain medications are allowed if the 
history of its use and subject’s condition meets 
specifications of the eligibility criteria 
Approved extrapyramidal symptoms ( EPS)
medicationsAnticholinergic or any other medications to treat 
EPS ongoing at the time of screening should be 
maintained through the treatment phase.  If EPS 
worsens, doses should be adjusted to treat symptoms 
during the trial as needed 
Lorazepam up to 6 mg/day durin g the taper period 
and the first 14 days of active treatment or the 
equivalent dose of short -acting benzodiazepi[INVESTIGATOR_819157], anxiety Remainder of days 
on active treatment : lorazepam up to 4 mg/day or an 
equivalent dose of short -acting benzodiazepi[INVESTIGATOR_72301] a 
daily basis.b,cTo be used only on as -needed basis. For recording in 
the CRF, enter total daily dose for each day when 
recording benzodiazepi[INVESTIGATOR_2597]. If a daily dose is the 
same for greater than a single dayover consecutive 
days, recording of the consecutive date range for the 
same daily dose is acceptable .
Partial benzodiazepi[INVESTIGATOR_819158],d
SuvorexanteZolpi[INVESTIGATOR_6730] (2.5 to 10 mg/day), zaleplon (5 to 
20mg/day), zopi[INVESTIGATOR_11123] (7.5 to 15 mg/day), or any 
equivalent short half -life non -benzodiazepi[INVESTIGATOR_819159]/sleep
disturbance if zo lpi[INVESTIGATOR_6730] , zaleplon, or zopi[INVESTIGATOR_819160]. To be used only 
on an as -neede d basis :Suvorexant (10 mg -20 mg)
aChronic use of certain medications are allow ed if the subject’s condition is stable, and the dose w as 
stabilized prior to the first dose on Day 1 and they are not strong or moderate CYP3A known inhibitors 
and inducers, strong or moderate CYP2C9 known inhibitors and  inducers ,and CYP2B6 known 
substrates with sensitive therapeutic range.
bTo be used on as -needed basis. For countries where no short -acting benzodiazepi[INVESTIGATOR_819155], 
diazepam (up to 30 mg/day during the taper period and first 14 days of active treatment, up to 15mg/day 
thereafter) is permitted to be used for the control of agitation, anxiety, and insomnia. In the event 
diazepam is not available in countries where no shor t-acting benzodiazepi[INVESTIGATOR_819155], use of other 
benzodiazepi[INVESTIGATOR_819161].
cThe use of drugs to treat agitation, anxiety, or insomnia or with known sedative effects have the potential 
to impact effica cy assessments.  The sites should consider avoiding their use within the 4 to 8  hours 
prior to efficacy assessments.
dAny equivalent short half -life non -benzodiazepi[INVESTIGATOR_819162]/sleep 
disturbance if zo lpi[INVESTIGATOR_6730] , zaleplon, or zop iclone are not available in specific countries.
eIn countries where approved ([LOCATION_003], Japan).
All medications used in the last 3 months prior to screening should be recorded. Reasons for 
use for each medication (prior and concomitant) should also be recorded.
Rescue Medications & Supportive Care 5.[ADDRESS_1134473]:   MK-8189 34
Protocol/Amendment No.: 005-[ADDRESS_1134474] of care treatment for the 
disease under stud y.
Diet/Activity/Other Considerations 5.7
Subjects should refrain from the consumption of more than 1grapefruit or 1glass (8 ounces) 
of grapefruit juice a day , throughout the entire study  period. Otherwise, subjects are allowed 
to consume their usual diet throughout the stud y period.
Subject Withdrawal/Discontinuation Criteria 5.[ADDRESS_1134475]’s last scheduled follow -up, even if the 
subject has discon tinued treatment .  Therefore, all subjects who discontinue trial treatment
prior to completion of the treatment will still continue to participate in the trial as specified in 
Section 6.0 -Trial Flow Chart and Section 7.1. 4.1.–Withdrawal/Discontinuation .
Subjects may discontinue treatment at any time for any reason or be dropped from treatment
at the discretion of the investigator should any untoward effect occur.  In addition, a subject 
may be discontinued from treatment by [CONTACT_819204], the trial plan is violated, or for administrative and/or other safety  reasons.  
Specific details regarding procedures to be performed at treatment discontinuation are 
provided in Section 7.1.4 –Other Procedures.
A subject must be discontinued from treatment but continue to be monitored in the trial for 
any of the following reasons:
○The subject or subject’s legally  acceptable representative requests to discontinue 
treatment .
oThe subject has a medical condition, or personal circumstance which, in the opi[INVESTIGATOR_19348]/or Sponsor, places the subject at unnecessary  risk or does not allow 
the subject to adhere to the requirements of the protocol. 
oThe subject experie nces a further increase of psychotic symptoms or suicidal 
ideation/behavior during the study  which, in the opi[INVESTIGATOR_11922]/or 
Sponsor, places the subject at unnecessary  risk or does not allow the subject to adhere to 
the requirements of the protocol.
oThe subject has a positive serum pregnancy  test.
oThe subject has a positive urine alcohol/drug screen (excluding allowed concomitant 
medications) with the exception of the screening visit urine alcohol/drug screen, as 
described in Section 7.1.3. 3. 
  04MZQR 
  04YKSX
Product:   MK-8189 35
Protocol/Amendment No.: 005-[ADDRESS_1134476] experiences one of the following elevated liver enzy me conditions, which is 
confirmed b y repeat testing:
oALT or AST >3x ULN and total bilirubin >2x ULN,
oALT or AST >5x UNL
oALT or AST >3x ULN for more than [ADDRESS_1134477] >3x UL N with the appearance of jaundice, worsening of fatigue, 
nausea, vomiting, right upper quadrant pain or tenderness, fever, rash or 
eosinophilia.
o The subject has an absolute neutrophil count of <1000 per mm3, and after repeat testing 
within 48 hours, the values are not normalized or increased.
o Subjects who report suicidal ideation with intent, with or without a plan or method (i.e., 
a positive response to items 4 or 5 in the assessment of suicidal ideation on the C-SSRS) 
or suicidal behavior may meet discontinuation criteria. Please refer to Section [IP_ADDRESS]. [ADDRESS_1134478] has eGFR of < 60 mL /min/1.73m2.
o The subject has aQTcF interval of ≥500 msec (The average of the three QTcFs will be 
used) .
oThe subject cannot tolerate a dose of 8 -mg MK -8189 QD/4 -mg risperidone QD.
In the event of any reason for discontinuation from treatment , all procedures for the study 
discontinuation visit (V6) should be performed.  The subject should be followed -up per the 
Study  Flow Chart Post -Treatment period to assess for safety . 
For subjects who are discontinued from treatment but continue to be monitored in the trial, 
see Section 6.0 – Trial Flow Chart, and Section [IP_ADDRESS]–Withdrawal/Discontinuatio nfor 
those procedures to be completed at each specified visit .
Discontinuation from treatment is “permanent.” Once a subject is discontinued, he/she shall 
not be allowed to restart treatment .
Withdrawal from the Trial 5.8.[ADDRESS_1134479] be withdrawn from the trial if:
○The subject or subject’s legall y acceptable representative withdraws consent from the 
trial.
○The subject is lost to follow -up.
Specific details regarding procedures to be performed at the time of withdrawal from the trial 
including specific details regarding withdrawal from Future Biomedical Research are 
outlined in Section 7.1.4 –Other Procedures. 
  04MZQR 
  04YKSX
Product:   MK-8189 36
Protocol/Amendment No.: 005-[ADDRESS_1134480] to follow -up (i.e. the subject is unab le to be contact[CONTACT_551701]).
Clinical Criteria for Early Trial Termination 5.11
The clinical trial may be terminated early if the extent (incidence and/or severity ) of 
emerging effects/clinical endpoints is such that the risk/benefit ratio to the trial population as 
a whole is unacceptable.  In addition, further recruitment in the trial or at (a) particular trial 
site(s) may be stopped due to insufficient compliance with the protocol, GCP and/or other 
applicable regulatory  requirements, procedure -related problems or the number of 
discontinuations for administrative reasons is too high. 
  04MZQR 
  04YKSX
Product:   MK -8189 37
Protocol/Amendment No.: 005-01 
MK-8189-005-01 Final Protocol 29-Mar-2017
Confidential6.0TRIAL FLOW CHART
Trial Period: Screening Treat ment Post-treatment
Inpatient
Visit Number/ Title:1
Screening
Taperinga2
Baselineb
Rand3
Treat ment4
Treat ment5
Treat mentc6
End of 
Treat mentd/DCe7
TCf8
Follow -
up9
TCf
Scheduled Days: -[ADDRESS_1134481] 14 
days
Scheduling Window, Days: +4 ±1 ±1 ±1 ±1 ±1 ±3 ±3
Administrative Procedures
Informed Consent X
Informed Consent for Future Biomedical Research 
(FBR) X
Inclusion/Exclusion Criteria X X
Subject Identification CardgX
Medical and Psychiatric History X
Substance, Alcohol /Smoking History X
Social History X
Psychiatric Intake EvaluationhX
MINIiX
Identify external contact [CONTACT_819205] X X X X X X X X X
Treatment Allocation/Randomization X
Call/log into IVRS/IWRS X X X X X X
IP Dispensing via IVRS/IWRS X X X X
Clinical Procedures/Assessments
Physical Examination X X
Height X
Weight, Waist Circumference X X X
12-Lead ElectrocardiogramkX X X
Vital Signs (heart rate, blood pressure) X X X X X X
PANSSi,lX X X X X X
CGI-S X X X X X X
C-SSRSmX X X X X Xn
ESRS -A X X X X X X
Monitor compliance with Trial Medication X X X X X
Adverse Events Monitoring X X X X X X X X X 
  04MZQR 
  04YKSX
Product:   MK -8189 38
Protocol/Amendment No.: 005-01 
MK-8189-005-01 Final Protocol 29-Mar-2017
ConfidentialTrial Period: Screening Treat ment Post-treatment
Inpatient
Visit Number/ Title:1
Screening
Taperinga2
Baselineb
Rand3
Treat ment4
Treat ment5
Treat mentc6
End of 
Treat mentd/DCe7
TCf8
Follow -
up9
TCf
Scheduled Days: -[ADDRESS_1134482] 14 
days
Scheduling Window, Days: +4 ±1 ±1 ±1 ±1 ±1 ±3 ±3
Laboratory Procedures/Assessments
Blood DrawoX X X X
Insulin X X X
Lipid Panel X X X
Prolactin X X X
Serum β-Human Chorionic Gonadotropin (β-hCG) –
if applicablep X
Serum Follicle Stimulating Hormone (FSH) -if 
applicablep X
HIV Screen (Per site SOPs and at the discretion of 
the investigatorX
Hepatitis Screen (Per site SOPs and at the discretion 
of the investigatorX
Blood for Genetic Analysisq  X
Thyroid Stimulating Hormone (TSH) X X X
Urine Specimen CollectionrX X X X
Additional Urine Specimen Collection –if applicablerX X
Urine Alcohol/Drug Screenp, rX X
Urine Pregnancy Test –if applicablep, rX X X X X X
Urinalysis X X X X
Residual urinesX X
PK Sampleb,tX X Xu
TC= Telephone contact, DC= discontinuation, MINI = Mini International Neuropsychiatric Interview for Schizophrenia and Psychotic Disorders, PANSS = Positive and Negative 
Syndrome Scale, CGI-S = Clinical Global Impression Scale -Severity, C-SSRS = Columbia Suicide Severity Rating Scale, ESRS -A= Extrapyramidal Symptoms Rating Scale -
Abbreviated ,PK= Pharmacokinetics
a) During this tapering period, any psychotropic medications prohibited in Section 5.5 of the protocol (antipsychotics, antidepressants, and mood stabilizers) should be tapered 
under the direct supervision of the investigator (last dose to be taken no later than the evening prior to baseline )(Visit 2).  If it is the clinical judgment of the investigator that 
the -3(+4) day tapering period may be skipped for an individual subject, trial medication may begin as early as the morning after the Screening procedures , provided all of the 
eligibility criteria have been met .  
b) For subjects who skip the tapering period, the Baseline PK assessment smust be completed on the screening day .  Screening assessments that are normally repeated at Base line 
need not be repeated for subjects who skip the tapering period with the following exceptions: blood draw should be repeated on the morning of Day 1, prior to the first dose of  
trial medication, if the Screening blood draw was not taken in a fasting s tate (no food or drink other than water ≥10 hour s). 
  04MZQR 
  04YKSX
Product:   MK -8189 39
Protocol/Amendment No.: 005-01 
MK-8189-005-01 Final Protocol 29-Mar-2017
Confidentialc) Hospi[INVESTIGATOR_819163] 21if the subject is ready for discharge according to the specifications of the protocol. Subjects that are discharged on Day 21will be 
discharged after completion of assessments and may continue in the treatment phase as outpatients.   The day after discharge andapproximately mid-week after discharge , the 
subject should be telephoned to ensure that he or she has understood dosing instructions ,to assess adverse events , and to remind the subject of the Day [ADDRESS_1134483] their end of treatment assessments on Day 28.
d) Subjects that are discharged on Day [ADDRESS_1134484] Day 28.
e) In the event of premature discontinuation from treatment , end of treatment assessments (V6) are administered at the time of treatment discontinuation and all post-
treatment 
follow -up phone contacts and site visit will be conducted unless there is withdrawal of consent.
f) Virtual phone visits will be conducted [ADDRESS_1134485] completes or discontinues from treatment.  
g) Subject will receive a subject identification card at Screening. If the subject is randomized, the card will be updated with t he subject’s randomization number.
h) The Psychiatric Intake Evaluation must be reviewed /approved by [CONTACT_819206].   
i) PANSS and MINI interview process will include video and/or audio technology which must be reviewed /approved by [CONTACT_819206] .
j) Subjects must have an identified responsible person (e.g., family member, social worker, case worker, case manager, or nurse) , referred to as the “external contact [CONTACT_9702]” in 
this protocol, to be considered eligible for enrollment. Site personnel must assure that the external contact [CONTACT_819207] a 
phone contact [CONTACT_819208].  
k) Determination of QTc interval at Screening and QTc prolongation will be based on the average of three measurements, using the Fridericia formula for correction .
l) To avoid the influence of subject fatigue on the diagnostic and primary outcome data, the PANSS interviews should be conducted early in each ap plicable visit.
m) During the Screening visit, the subject’s symptoms and actions over the past 6 months should be evaluated with the C -SSRS (C-SSRS Screening Version). For all other visits , 
the subject’s symptoms and actions since the last assessment should be evaluated (C-SSRS Since Last Visit Version) . 
n) The investigator should be aware of the C -SSRS scores upon discontinuation from treatment . Subjects with scores showing suicidality (e .g., any suicidal ideation of Type 4 or 5 
and/or any suicidal behavior) should be thoroughly evaluated by [CONTACT_093] .  
o) Blood collected at all time points for “blood draw” isused for analysis of Chemistry and Hematology (as specified in Table 4). Insulin, TSH, Lipid Panel, Prolactin, Serum β-
hCG, FSH, and Genetic Analy sis are analyzed attime points specified in this F lowChart. HIV screening and/or viral hepatitis panel screen may be performed (at discretion of  
investigator). Fasting blood draws at Screening are encouraged. During the inpatient phase, including Baseline , blood samples (for clinical laboratory evaluations and pre -dose 
PK) are drawn with subjects in the fasting state before breakfast prior to the morning dose .  It is anticipated thatblood samples for laboratory and pre-dose PK evaluations are 
draw n at the same time .  
p) In addition to the testing at the required times specified in the table, urine /alcohol/ drug tests, urine pregnancy tests, and serum pregnancy tests may be performed at the 
investigator’s discretion throughout the course of the trial . Urine and serum pregnancy tests will be performed for only women of child -bearing potential.   Note that local urine 
alcohol drug screen can be done for determining eligibility if the central laboratory results are pending.  
q) This sample should be drawn for planned analysis of the association between genetic variants in DNA and drug response.  If there is either a documented lawor regulation 
prohibiting collection, or if the institutional review board/ethics committees (IRB/IEC )does not approve the collec tion of the sample for these purposes, then this sample will 
not be collected at that site. If the sample is collected, leftover extracted DNA will be stored for future biomedical research if the subject sign s the FBR consent. If the planned 
genetic analysis is not approved, but FBR is approved and consent is given, this sample will be collected for the purpose of FBR .
r) Urine is collected for all subjects at every visit except visits 3 and 5, when urine is collected only for women of child bearing potential. Collected urine will be used for  urine
alcohol/drug tests ,urine pregnancy tests , and u rinalysis (as specified in Table 4)  at time points specified in the Flow Chart.   Residual urine at time points specified in the Flow  
Chart will also be sent to the central laboratory.  
s) Leftover residual urine will be stored for future biomedical research, if the subject consents to future biomedical research .  
t) PK samples are collected at time points relative to dosing as follows: Day 1 pre -dose (baseline); Day [ADDRESS_1134486] -dose; and Day 28 pre -dose .
u) PK sample will not be collected if the subject discontinues from treatment . 
  04MZQR 
  04YKSX
Product:   MK-8189 40
Protocol/Amendment No.: 005-01 
MK-8189 -005-01 Final Protocol 29-Mar-2017
Confidential7.0TRIAL PROCEDURES
Trial Procedures 7.1
The Trial Flow Chart -Section 6.0summarizes the trial procedures to be performed at each 
visit.  Individual trial procedures are described in detail below.  It may be necessary  to 
perform these procedures at unscheduled time points if deemed clinically necessary  by [CONTACT_1275].
Furthermore, additional evaluations/testing may  be deemed necessary  by [CONTACT_26357] . In some cases, such evaluation/testing 
may be potentially  sensitive in nature (e.g., HIV, Hepatitis C, etc.), and thus local regulations 
may require that additional informed consent be obtained from the subject.  In these cases, 
such evaluations/testing will be performed in accordance with those regulations.
Administrative Procedures 7.1.1
[IP_ADDRESS] Informed Consent
The investigator or qualified designee must obtain documented consent from each potential 
subject or each subject’s legally  acceptable representative prior to participating in a clinical 
trialor Future Biomedical Research .
[IP_ADDRESS].[ADDRESS_1134487]’s dated signature [INVESTIGATOR_4388] [CONTACT_423]’s legally 
acceptable representative’s dated signature [INVESTIGATOR_2394] a consent form along with the dated signature 
[CONTACT_63564]. 
A copy  of the signed and dated consent form shoul d be given to the subject before 
participation in the trial.
The initial informed consent form, any subsequent revised written informed consent form 
and any written information provided to the subject must receive the IRB/ERC’s 
approval/favorable opi[INVESTIGATOR_19349].  The subject or his/her legally  acceptable 
representative should be informed in a timel y manner if new information becomes available 
that may be relevant to the subject’s willingness to continue participation in the trial.  The 
communicat ion of this information will be provided and documented via a revised consent 
form or addendum to the original consent form that captures the subject’s dated signature [CONTACT_90096] [CONTACT_423]’s legall y acceptable representative’s dated signature.
Specifics about a trial and the trial population will be added to the consent form template at 
the protocol level.  
The informed consent will adhere to IRB/ERC requirements, applicable laws and regulations 
and Sponsor requirements. 
  04MZQR 
  04YKSX
Product:   MK -8189 41
Protocol/Amendment No.: 005-01 
MK-8189-005-01 Final Protocol 29-Mar-2017
Confidential7.[IP_ADDRESS] Consent and Collection of Specimens fo r Future Biomedical Research
The investigator or qualified designee will explain the Future Biomedical Research consent 
to the subject, answer all of his/her questions, and obtain written informed consent before 
performing an y procedure related to the Future Biomedical Research sub -trial.  A copy  of the 
informed consent will be given to the subject.
[IP_ADDRESS] Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed at Visit [ADDRESS_1134488] qualifies for the trial.  For assessments that 
require reviewing by  a central reader or vendor for eligibility  qualification, please refer to the 
specific guidance documents relating to that particular assessment.
[IP_ADDRESS] Subject Identification Card
All subjects will be given a Subject Identification Card identify ing them as participants in a 
research trial.  The card will contain trial site contact [CONTACT_3031] (including direct telephone 
numbers) to be utilized in the event of an emergency .  Theinvestigator or qualified designee 
will provide the subject with a Subject Identification Card immediately  after the subject 
provides written informed consent.
The subject identification card 
also contains contact [CONTACT_75345] a health care provider can obtain information about trial 
medication/vaccination in emergency  situations where th e investigator is not available.
[IP_ADDRESS] Medical History
A medical history (including any pre-existing clinically  significant medic al conditions) will 
be obtained by [CONTACT_27404] .  Clinicall y significant findings in 
physical examination, laboratory  tests, ECGs, and other physical evaluations during 
Screening are to be noted in the medical history  page of the electronic case report form 
(eCRF). Clinically  significant changes from the Screening evaluation during the trial should 
be captured on the AE page of the eCRF. Psychiatric conditions and symptoms including 
those captured in the M INI evaluation should be recorded in the medical history  form.
[IP_ADDRESS].1 Substance/Alcohol/Smoking History / Social History
Personal and social history  such as living/emplo yment/arrest and substance/alcohol/smok ing 
will be reviewed
. Arrest history  will also be assessed. Note: history  of assaultive behavior 
which resulted in commitment or incarceration which was verbal abuse only 
(not violent, 
aggressive or physical in nature )is not necessarily  exclusionary . The investigator should 
exclude enrollment of subjects who may be at risk for future assaultive behavior.
[IP_ADDRESS] Psychiatric History
Diagnostic eligibility  will be assessed based on a psychiatric evaluation ofthe subject by
[CONTACT_819209]'s psychiatric history  including other information sources (e.g., medical  
  04MZQR 
  04YKSX
Product:   MK -8189 42
Protocol/Amendment No.: 005-01 
MK-8189-005-01 Final Protocol 29-Mar-2017
Confidentialcharts, health care provider or paraprofessional ), and confirmation of the diagnosis of 
schizophrenia using the MINI Version 7.  All psychiatric diagnoses specified in the 
inclusion/exclusion crite ria will be made according to the DSM -5™.
[IP_ADDRESS].[ADDRESS_1134489]’s history  of the presenting problem, a detailed description of the current acute 
exacerbation (onset, duration, precipi[INVESTIGATOR_32895], differentiation from symptom status prior to the 
current epi[INVESTIGATOR_1865], functional impairment, and corroboration of a current acute exacerbation by 
[CONTACT_819210] [e .g
., medical charts, health care provider , or paraprofessional ]), psy chiatric 
and treatment history (response/nonresponse to previous antipsy chotics as described in the 
inclusion criteria ), medical history , mental status, diagnosis and treatment plan must be 
documented in the source documents. Identification of the source of this information must 
be included; if this information was obtained from a verbal account by a healthcare 
professional or paraprofessional , the relationship and duration of the relationship between the  
professional and the subject must be included in the description. A family member may be 
considered as the sole source for corroboration only  in the event that corroboration cannot be 
provided through medical records or 
through a health professional, and the subject lives with 
a family  member who is considered a reliable informant by  [CONTACT_093].
Diagnostic eligibility  will be assessed based on interview with the subject, review of the 
subject's history  including other information sources (listed above ) and documented during
psychiatric intake evaluation .
All psychiatric diagnoses specified in the inclusion/exclusion criteria will be made according 
to the DSM -5 ™ criteria .  The diagnosis will be confirmed using the M INI Version 7.
The eligibility  criteria require an illness duration of ≤ 20 years. The PI [INVESTIGATOR_819164]/her best 
estimate, based on available resources (including medical charts, patient self-report, famil y 
member, health or paraprofessional report) to determine illness duration.
A psychiatric intake evaluation form containing key elements of the psychiatri c evaluation 
must be forwarded to 
theexternal SDME for review, to ensure that the subject meets 
diagnostic eligibility  criteria prior to randomization. Additionally , the external SDME will 
take into account the independent PANSS ratings of the central rater for the final 
determination of the subject’s eligibility .
The completed psychiatric intake evaluation form should be sent no more than 2days after 
the screening visit to ensure a timel y review by [CONTACT_819211] .Subjects cannot be 
randomized wit hout the approval of the external SDME. 
For subjects who skip the taper period, the investigator must contact [CONTACT_819212]’s acute exacerbation and diagnostic status meet 
entry  criteria. This telephone review must be documented and a copy kept in the subject’s 
source documents.  
  04MZQR 
  04YKSX
Product:   MK -8189 43
Protocol/Amendment No.: 005-[ADDRESS_1134490] an identified responsible person (e.g., famil y member, social worker, 
case worker, case manager, or nurse) to be considered 
eligible for enrollment. The subject 
must provide the name [CONTACT_3669] [CONTACT_819213]/her external contact [CONTACT_9702]. Site 
personnel must confirm that this person (referred to as the “e
xternal contact [CONTACT_9702] ”)will be 
available to locate the subject in the event that the subject cannot be contact[INVESTIGATOR_530]. The site must 
interview the potential external contact [CONTACT_819214] ;the external contact [CONTACT_819215]; either in person or via 
telephone . The source documents must record the external conta ct person ’s agreement to act 
as the subject’s contact [CONTACT_9702]. If the subject does not have a nexternal contact [CONTACT_819216], the site may designate a site representative to act as the 
subject ’s external contact [CONTACT_9702] , with the same responsibilities as described above. The 
investigator may not act as theexternal contact [CONTACT_9702] . In the event the designated external 
contact [CONTACT_819217] 1subject, the investigator is responsible for 
documenting in the source that the external contact [CONTACT_819218].
[IP_ADDRESS] Prior and Concomitant Medications Review
[IP_ADDRESS].[ADDRESS_1134491] be able to discontinue or, in the opi[INVESTIGATOR_871], safely  taper off ,
of any prohibited treatment listed in Table 2prior to the Baseline visit (Visit 2) without 
significant destabilization or increased suicidalit y. 
[IP_ADDRESS].[ADDRESS_1134492] consulting the investigator, except in cases of medical 
emergencies or other obvious exceptions.
[IP_ADDRESS] Assignment of Screening Number
All consented subjects will be given a unique screening number that will be used to identify 
the subject for all procedures that occur prior to randomization or treatment allocation.  Each 
subject will be assigned only one sc reening number.  Screening numbers must not be re -used 
for different subjects. 
  04MZQR 
  04YKSX
Product:   MK -8189 44
Protocol/Amendment No.: 005-01 
MK-8189-005-01 Final Protocol 29-Mar-2017
Confidential7.1.1.9 Assignment of Treatment/ Randomization Number
All eligible subjects will be randoml y allocated and will receive a treatment/randomization 
number.  The treatment/randomization number identifies the subject for all procedures 
occurring after treatment allocation/ randomization.  Once a treatment/ randomization number 
is assigned to a subject, it can never be re -assigned to another subject.
A single subject cannot be assigned more than 1 
treatment/randomization number.
[IP_ADDRESS] Interactive Voice Response System/Integrated Web Response System
The investigator or designee will call/log into IVRS/I WRS as specified in the Trial Flow 
Chart.  Upon confirmation of a subject’s eligibility  at Visit 2, the investigator or designee 
will call IVRS or log into IWRS to randomize the subject.  Subjects who do not meet 
eligibility  criteria at Visit 2 will be screen -failed in IVRS/IWRS.  For all randomized 
subjects, the investigator or designee will continue tocall/log into IVRS/IWRS as per the 
Trial Flow Chart.  For completed or discontinued subjects, the investigator or designee will 
make the final call/web action into I VRS/I WRS at their last treatment visit.
[IP_ADDRESS] Trial Medication Dispensing
At the visits specifi
ed in the Trial Flow Chart, the site will dispense trial medication using the
IVRS/I WRS sy stem. 
[IP_ADDRESS] Trial Compliance (Medication/Diet/Activity/Other)
Medication compliance during the trial will be monitored and determined by [CONTACT_819219] (total 
IP count as well asseparate tablet/ capsule counts) .For all subjects who are eligible for 
outpatient status, IPcount will be monitored and determined by [CONTACT_248457], entries 
into the dosing diary , and by [CONTACT_522858]/capsule count at Visit 6.  Instances of trial medication 
non-compliance should be documented as follows:
Less trial medication was taken than prescribed : Instances where a subject failed to 
take trial medication as prescribed and missed a dose should be documented .  A 
missed IP dose is defined as taki ng less of either IP ty pe (less tablets and/or less 
capsules of IP) than required in a single 24 hour period (s ee Table 1forthe number of
IP table ts and capsule s taken per QD do se).
More trial medication was taken than prescribed : Taking more medication of either 
IP type (more tablets and/or more capsules of IP) than prescribed fora subject is 
considered an AE of " overdose ".  See Section 7.2.1 for details regarding reporting of 
overdoses. An overdose of IP is defined as taking more than the maximum number of 
either IP ty pe (capsules and/or tablets) specified for a single dose in one day .
Note that a subject iscounted as an overdose and also as amissed dose if 
the subject
takes more than either IP typeand less of the other (tablets or capsules) specified in a 
dose.   
  04MZQR 
  04YKSX
Product:   MK-8189 45
Protocol/Amendment No.: 005-01 
MK-8189 -005-01 Final Protocol 29-Mar-2017
ConfidentialFor subjects who are discharged as outpatients at Day  21, overdose or under -dose 
may need to take into account the investigator’s best judgment if I P tablets/capsules 
were lost or taken in the event that the drug return, entries into the dosing diary , 
and/or subject contact [CONTACT_819220].
Interruptions from the protocol specified dosing for ≥ 3consecutive daysat any time point 
during the active treatment phase require consultation between the inves tigator and the 
Sponsor and written documentation of the collaborative decision on subject management.
All individuals who dispense trial medication to the subject should monitor the subject to 
ensure doses are taken as directed, and record relevant dosing information (including number 
of tablets /capsules and exact time taken) in source documents .
If the subject is discharged from the hospi[INVESTIGATOR_41324] 21,they will continue asoutpatient s for 
the remainder of the active treatment period (to Day 28).See Section 7.1.4. 5 (Administer 
Trial Medication) for additional instructions pertaining to outpatient training.
In addition to routine surveillance of IPcount (tablets and capsules) ,outpatient subjects will 
be given anIPdosing diary to help subjects recordthe number of tablets and capsules taken 
from each bottle and the time thateach dose was taken . 
When the outpatient returns to the clinical siteat Visit 6,the outpatient should return their 
completed dosing diary  and trial medication, including empty bottles . The site will perform 
an IP (tablet and capsule) count and also review the entries inthedosing diary  to verify  IP
count and any possible missed or extra doses taken.  If there is a discrepancy  between the 
bottle and the dosing diary , the subject verbal account and site judgment will be used to 
determine the final decision on documenting IP count in the eCRF.
Discrepancies and the reasoning for what was ultimately  recorded in the eCRF should be 
documented in the site’s source documents.  For outpatient subjects who discontinue trial 
medication earl y, site personnel should ensure the subject returns all trial me dication.
Clinical Procedures/Assessments 7.1.2
[IP_ADDRESS] Physical Assessments/Examinations
[IP_ADDRESS].1 Physical Examination/Neurological Examination
A physical examination (PE) will be performed at Screening, Endpoint or in the event of 
early discontinuation by a primary  investigato r or sub-investigator (M.D., Doctor of 
Osteopathic Medicine [D.O. ]) or by a  P hysician’s Assistant (P.A.) or Nurse Practitioner 
(N.P.) in areas where P.A.s and N.P.s are licensed to perform PEs. 
If a physical or neurological abnormality  is noted post-treatment, the investigator will 
indicate whether or not the result is clinically  significant and if it constitutes an adverse 
experience. 
  04MZQR 
  04YKSX
Product:   MK -8189 46
Protocol/Amendment No.: 005-01 
MK-8189-005-01 Final Protocol 29-Mar-2017
Confidential7.[IP_ADDRESS] Body Height/Weight /Waist Circumference 
Height (inches/centimeter [in/cm ]), body  weight (pounds/kilograms [lbs/kg ]) and waist 
circumference (in/cm ) will be collected and recorded. Measurements should be recorded to 
the nearest inch/centimeter and pound/kilogram .  Body weight data will be collected without 
shoes and with heavy  clothing (such as coats) removed.  It is recomme nded that b ody weight 
measurement should be performed on the same scale for the same individual throughout the 
study (this may not be possible if weight is measured in an inpatient versus outpatient 
setting) .  Abdominal waist circumference should be measured by [CONTACT_819221]’s 
body  at the navel with a cloth measuring tape or similar pliable measuring device.
[IP_ADDRESS].[ADDRESS_1134493]-screening visits unless there is an observation of aQTc prolongation (QTcF interval of 
≥500 msec ). An additional [ADDRESS_1134494]’s ECGs are to be repeated ideally  at 2-[ADDRESS_1134495] 
eligibility .
[IP_ADDRESS].4 Vital Signs
Heart Rate and Blood Pressure: Subjects should be resting in a semi recumbent position for 
at least [ADDRESS_1134496] positioning on the 
subjects’ arm is essential to increase the accuracy  of blood pressure measurements.
The same method for measuring heart rate and blood pressure (e.g., manual or automated) is 
recommended for all measurements for each individual subject and should be the same for all 
subjects throughout the study .
[IP_ADDRESS] Clinical Assessment
The efficacy  assessments PANSS and CGI-S as well as the safety  assessments C-SSRS and 
ESRS -A will be performed at each 
center by [CONTACT_124530]. The required qualifications of 
the ratersare specified in an external manual . Prior to the start of rating subjects in the trial, 
candidate raters will participate in rating scale training.   Certification is required for the 
PANSS raters .The Sponsor or an appointed representative, prior to the start of the trial, will 
implement the training and certification process. Quality  monitoring of the MINIand 
PANSS will include video and/or audio technology. 
  04MZQR 
  04YKSX
Product:   MK -8189 47
Protocol/Amendment No.: 005-01 
MK-8189-005-01 Final Protocol 29-Mar-2017
ConfidentialAdditional detailed information conc erning administration, scoring and recording of the 
aforesaid assessments will be provided in an external manual. 
Some or all of thePANSS recorded interviews will be reviewed and scored by [CONTACT_170789] ’s rater (referred to in this protocol as the central rater) . Site raters will be provided 
feedback on the quality  of their i nterviews and ratings b y the central rater to help develop and 
maintain good inter -rater reliability . Additionally, the site rater’s consideration of the central 
rater’s feedba ck may be used to refine the PANSSs scores entered by [CONTACT_819222].
For the screening visit, the external SDME will review the diagnos tic decisions of the site as
determined through the MI NI(seeSection [IP_ADDRESS].1 )
. 
While concerns have been raised that recording assessments via audiotapi[INVESTIGATOR_819165]’ privacy , this issue must be balanced with the need 
to conduct methodologically  adequate and scientifically  rigorous trials that are capable of 
testing key hypotheses. Given that the key endpoints in this trial involve subjective 
judgments, monitoring the adequacy  of subject interviews and ratings is essential and part of 
strong research methodology . Prior studies suggest that the failure to adequatel y monitor 
such ratings can substantially  increase the risk of failed trials [5].Recorded interviews will 
be encry pted using state of the art methods to ensure privacy .Additional steps will be taken 
to ensure anony mity of specific private health information. Recordings will be reviewed 
only by [CONTACT_819223].
Each assessment scale may require different raters, but it is strongl y encouraged that the 
same rater evaluates the same subject throughout his/her participation in the trial for a 
particular scale. 
[IP_ADDRESS].1 Positive and Negative Symptom Scale ( PANSS )
The Structured Clinical Interview for the Positive and Negative Syndrome Scale (Sci-
PANSS) , a 30- item clinician -rated instrument for assessing the symptoms of Schizophrenia
[6],will be used.   
To avoid the influence of subject fatigue on the diagnostic and primary  outcome data, it is 
recommended that the PANSS interviews be conducted early  in each applicable visit.
[IP_ADDRESS].2 Clinical Global Impression Scale -Severity (CGI
-S)
The Clinical Global Impressions Scale Severity , a 7- point clinician -rated scale for assessing 
the global severit y of the illness , will be used .
[IP_ADDRESS].3 C- SSRS
The C
-SSRS is an instrument designed to systematically  assess and track suicidal AEs 
(behavior and ideation).  The C-SSRS will be administered at each visit (as indicated in the 
  04MZQR 
  04YKSX
Product:   MK -8189 48
Protocol/Amendment No.: 005-01 
MK-8189-005-01 Final Protocol 29-Mar-2017
ConfidentialTrial Flow Chart, as well as at unscheduled visits as clinically  indicated) by a qualified, 
trained individual who has been approved b y the Sponsor to administer the instrument.  
During the Screening visit, the subject’s sy mptoms and actions over the pas t [ADDRESS_1134497] reports a prior history  of 
ideation/behavior, the assessor should also inquire and docum
ent if this is also present at the 
time of the screening visit.
For all other assessments, the subject’s symptoms and actions since the last assessment 
should be evaluated.  Subjects must be excluded if they report suicidal ideation meeting the
description of C-SSRS Type 4 or 5 (i.e., suicidal ideation with intent with or without a plan) 
within the past [ADDRESS_1134498] demonstrates emerging or increasing suicidal ideation and/or 
behavior, in the investigator’s opi[INVESTIGATOR_819166] C
-SSRS (e.g., 
any suicidal ideation of Type 4 or 5 and/or any suicidal behavior), he or she should be
thoroughl y evaluated by [CONTACT_819224].  Subjects should continue treatment only if their suicidal ideation is passive, 
they expressly  deny any intent to act, and who, after evaluation, the investigator feels it is 
safe and in the subject’s best interest.  In case 
subjects are discontinued from treatment , sites 
should ensure adequate clinical supervision to ensure subject’s well-being.  In case subject 
withdraws consent it is recommended that clinical supervision continues outside the scope of 
the trial.
Prior to discharge from the hospi[INVESTIGATOR_41324] 21 or Day 28, the investigator should be aware of 
the C -SSRS score. For s ubjects with scores showing suicidality  (e.
g., any  suicidal ideation of 
Type 4 or 5 and/or any  suicidal behavior) , the investigator should discuss discharge readiness 
with the SDME prio r to disc harge .
In the event an AE related to suicidality  occurs during treatment , an additional C-SSRS 
should be performed and external sources (e.g
., family  members, external contact) may be 
used if patient is not available.  In addition, all adverse events of suicidal ideation or behavior 
must be recorded as an Event of Clinical I nterest (See Section [IP_ADDRESS]).   
[IP_ADDRESS].4
Monitoring of Extrapyramidal Symptoms
Extrapy ramidal symptoms include parkinsonism, dyskinesia, akathisia, and dystonia .
Extrapy ramidal symptoms will be documented with theExtrapyramidal Symptom Rating 
Scale-Abbreviated (ESRS -A).
It is strongl yencouraged that the same rater evaluates the same subject throughout his/her
participation in the trial for thescale.  
  04MZQR 
  04YKSX
Product:   MK-8189 49
Protocol/Amendment No.: 005-[ADDRESS_1134499] be recorded in the medical history . In 
addition, if a) clinicall y significant movement disorder side effects are observed by [CONTACT_819225] , or b) a clinically  significant movement 
disorder alread y prese nt at Screening increases in severit y during the stud y, or c) concomitant 
therap y for increasing or emerging EPS symptoms is initiated, increased, or reinstated while 
the subject is participating in the trial, these symptoms must be recorded as an AE .
Tardive dyskinesia and dystonia are considered events of clinical interest (ECI ) (Section 
[IP_ADDRESS] ).
Laboratory Procedures/Assessments 7.1.3
Details regarding specific laboratory  procedures/assessments to be performed in this trial are 
provided below. The total amount of blood/tissue to be drawn/collected over the course of 
the trial (from pre-trial to post-trial visits), including approximate blood/tissue volumes 
drawn/collected b y visit and by [CONTACT_819226] 12 .4.
[IP_ADDRESS] Laboratory Sa fety Evaluations (Hematology, Chemistry and Urinalysis)
Laboratory  tests for hematology , chemistry  and urinaly sis are specified in Table 4. 
Fasting blood draws /urine collection at Screening are encouraged. 
It is anticipated thatblood samples (laboratory  and pre-dose PK) should be obtained fasting 
and pre-dose. For subjects who are discharged from the hospi[INVESTIGATOR_41324] 21, as outpatients 
they will be instructed to fast overnight if possible and withhold their dose of IPprior to 
clinical labora tory sample collection at Day  28.The self-reported fasting /non- fasting state of 
the subject will be noted on the laboratory  requisition form (no food or drink other than water 
≥10 hours is considered fasting).
Subjects who skip the tapering period will have duplicate laboratory  specimens collected, 
with 1specimen being sent to the local laboratory for immediate analy sis of all Screening 
parameters and the other processed at the central laboratory . The local laboratory  results w ill 
be used as a guide to determine subject eligibility. If the Screening laboratory  samples were 
not taken in a fasting state (no food or drink other than water ≥10 hours), clinical laboratory 
assessments should be repeated on the morning of Day 1, prior to the first dose of trial 
medication.
At any time during the trial, if the investigator determines that immediat e local laboratory  
results for protocol -specified parameters are needed to further evaluate the subject’s 
condition, a duplicate set of sample (s) should be collected and sent to the central laboratory .
The site and Sponsor will remain blinded to the prolactin levels of the blood samples taken 
after the Baseline visit until database lock.  Local laboratories will not analyze prolactin 
levels after the Baseline visit. 
  04MZQR 
  04YKSX
Product:   MK -8189 50
Protocol/Amendment No.: 005-01 
MK-8189-005-01 Final Protocol 29-Mar-2017
ConfidentialTable 4 Laboratory  Tests
Hematology Chemistry Urinalysis Other
Hematocrit Albumin Appearance
(macroscopic exam)Follicle Stimulating 
Hormone (FSH) female 
only, if applicable
Hemoglobin Alkaline phosphatase Bacteria
Serum β-human chorionic 
gonadotropin (β -hCG
female only, if applicable)
Platelet count Alanine aminotransferase (ALT) Bilirubin Free Thyroxine ( T4)(TSH 
Reflex to Free T4 if TSH 
abnormal)
White Blood Cells 
(WBC )(total and 
differential)Aspartate aminotransferase (AST) Blood
Bicarbonate Color Viral hepatitis panel (at the 
discretion of the 
investigator)
Calcium Glucose HIV (at the discretion
of the investigator)
Chloride Ketone Urine Alcohol Drug Screen
(Amphetamine
Barbiturates
Cannabinoids
Cocaine metabolites
Ethyl Alcohol
Methadone
Opi[INVESTIGATOR_819167])
Creatinine phosphokinase, total Microscopic exam, if 
abnormal appearance  
results are noted (RBC, 
WBC and bacteria)
Creatinine pH
eGFR (estimate dglomerular filtration rate  
(eGFR) [as measured by [CONTACT_168716] (MDRD) formula]Protein
Glucose Red Blood Cells ( RBC)
count
Lactate Dehydrogenase Specific gravity
Phosphorus WBC count
Potassium Nitrate
Sodium Leukocyte esterase
Total Bilirubin  
Direct Bilirubin and indirect Bilirubin if 
total bilirubin is elevated above the upper 
limit of normal
Total protein
Blood Urea Nitrogen
Special Lipid Panel
Thyroid Stimulating Hormone Total cholesterol
Insulin High Density Lipoproteins 
(HDL )
Prolactin Low Density Lipoproteins 
(LDL )
Triglycerides 
  04MZQR 
  04YKSX
Product:   MK -8189 51
Protocol/Amendment No.: 005-[ADDRESS_1134500].  
[IP_ADDRESS] Pregnancy Testing
For women of childbearing potential, blood samples for β-human chorionic gonadotropin 
(β
-hCG) will be obtained at Screening . Urine pregnancy  tests will be done at all visits.  A 
positive urine pregnancy  test must be confirmed with a serum pregnancy  test.A blood 
sample for serum pregnancy  testing is to be collected for central laboratory  testing; a 
duplicate sample for local laboratory  testing is recommended if local test results would be 
made available sooner.  Dosing should be interrupted until serum pre gnancy  test results from 
either local or central laboratory  results are available, and if the serum pregnancy  test result is
negative, subject may  resume dosing. See Section [IP_ADDRESS] for information on missed doses. If 
the serum pregnancy  test result is po
sitive , note the criteria for discontinuation of treatment 
has been met (see Section 5.8.1)
.A female may forego pregnancy  testing if she is not of 
reproductive potential according to the criteria specified in Section 5.1.2.   In addition, 
pregnancy  tests may be performed at the investigator’s discretion throughout the course of 
the trial. See Section 7.2.[ADDRESS_1134501] result 
during treatment should be discontinued from trial medication.
[IP_ADDRESS] Urine Alcohol Drug Screen
A urine alcohol /drug test will be done at Screening. The urine sample will be collected along 
with the other laboratory  specimens and will be analy zed and reported by [CONTACT_11378] . Any positive finding will require confirmation by [CONTACT_819227]. At any  time during the trial, if the investigator determines 
that immediate local urine alcohol/drug screening results are needed to evaluate eligibility  or 
further evaluate the subject’s condition, a duplicate set of sample(s) should be collected and 
sent to the central laboratory . Provided there is no exclusionary  evidence of substance use 
disorder in the past 6 months (Section 5.1.3), a positive Screening finding of alcohol, 
cannabinoid drugs, or prohibited psychotropic medications will not necessarily  exclude the 
subject from participation. However, the investigator should interview the subject and ensure 
the subject understands that he/she must refrain from using cannabinoid drugs and prohibited 
psychotropic medications throughout his/her participation in the trial. Alcohol use during the 
trial should also be discouraged. This discussion must be noted in the source documents or 
on the laboratory  report. The investigator may  enroll the subject if he/she feels confident that 
the subject will comply  with instructions. Additional tests may be scheduled post-Screening 
at the discretion of the investigator. If a subject is considered to be under the influence of 
illegal drugs or is believed to have taken a prohibited ps ychoactive drug, orif he or she meets 
the DSM -
5™criteria for substance use disorder (excluding nicotine) within a 1-week period, 
the investigator may  consider the subject for discontinuation. 
  04MZQR 
  04YKSX
Product:   MK-8189 52
Protocol/Amendment No.: 005-01 
MK-8189 -005-01 Final Protocol 29-Mar-2017
Confidential7.1.3.4 Pharmacokinetic/Pharmacodynamic Evaluations
[IP_ADDRESS].1 Blood Collection for Plasma MK-8189
Sample collection, storage and shipment instructions for plasma samples will be provided in 
theoperations/laboratory manual. 
[IP_ADDRESS] Planned Genetic Analysis Sample Collection 
Sample collection, storage ,and shipment instructions for Planned Genetic Anal ysis samples 
will be provided in the laboratory  manual provided by  [CONTACT_2237] .
[IP_ADDRESS] Future Biomedi cal Research
The following specimens are to be obtained as part of Future Biomedical Research:
Leftover DNA for future research
See Appendix 12.2 for the Collection and Management of Specimens for Future 
Biomedical Research.
Leftover residual u rine will be stored for future research.
Other Procedures 7.1.4
[IP_ADDRESS] Withdrawal/Discontinuation
When a subject discontinues/withdraws from participation in the trial , all applicable activities 
scheduled for the final treatment visit (Visit 6)should be performed at the time of 
discontinuation.  Any adverse events which are present at the time of 
discontinuation/withdrawal should be followed in accordance with the safety  requirements 
outlined in Section 7.[ADDRESS_1134502] 2follow -upphone callvisits(post treatment Days 3 
and 14) and a follow -up clinic visit (post treatment Day  7) after their last dose of IP.
[IP_ADDRESS].[ADDRESS_1134503] the Sponsor using the designated mailbox 
([EMAIL_1250] ), and a form will be provided by [CONTACT_819228].  Subsequently , the 
subject's specimens will be removed from the biorepository  and be destroy ed.  A letter will 
be sent from the Sponsor to the investigator confirming the destruction. It is the 
responsibility  of the investigator to inform the subject of completion of destruction.  Any
analyses in progress at the time of request for destruction or alread y performed prior to the 
request being received by [CONTACT_819229].   No new anal yses would be generated after the request is received. 
  04MZQR 
  04YKSX
Product:   MK -8189 53
Protocol/Amendment No.: 005-01 
MK-8189-005-01 Final Protocol 29-Mar-2017
ConfidentialIn the event that the medical records for the main trial are no longer available (e.g., if the 
investigator is no longer required by [CONTACT_75357]) or 
the specimens have been completely  anony mized, there will no longer be a link between the 
subject’s personal information and their specimens.  In this situation, the request for 
specimen destruction cannot be processed.
[IP_ADDRESS] Blinding/Unblinding
When the investigator or sub -investigator needs to identify  the drug used by  a subject and the 
dosage administered in case of emergency  e.g., the occurrence of serious adverse 
experiences, he/she will contact [CONTACT_819230] 
a request for emergency  unblinding.  As requested by [CONTACT_9940]-investigator the 
emergency  unblinding call center will provide the information to him/her promptly  and 
report unblinding to the sponsor.  The emergency  unblinding callcenter will make a record 
promptly  however, the investigator or sub -investigator must enter the intensity of the adverse 
experiences observed,   their relation to study  drug, the reason thereof, etc., in the medical 
chart etc., before unblinding is perfor med.  
Additionally , the investigator must go into the IVRS system and perform the unblind in the 
IVRS system to update drug disposition.  In the event that the emergency  unblinding call 
center is not available for a given site in this trial, IVRS/I WRS should be used for emergency 
unblinding in the event that this is required for subject safet y.
In the event that unblinding has occurred, the circumstances around the unblinding (e.g., date 
and reason) must be documented promptly , and the Sponsor Clinical Director notified as 
soon as possible.  Only the principal investigator [INVESTIGATOR_819168]’s 
code should be unblinded.  Trial site personnel and Sponsor personnel directly  associated 
with the conduct of the trial should not be unblinded .
[IP_ADDRESS] Domiciling
Not applicable
[IP_ADDRESS] Calibration of Critical Equipment
The investigator or qualified designee 
has the responsibility  to ensure that any critical device
or instrument used for a clinical evaluation/test during a clinical trial that provides important
information about inclusion/exclusion criteria and/or safet y or efficacy  parameters shall be 
suitably  calibrated and maintained to ensure that the data obtained is reliable and/or 
reproducible.  Documentation of equipment calibration must be retained as source 
documentation at the trial site.
Critical Equipment for this trial includes:
The central ECG v endor will provide documentation of calibration from the ECG 
manufacture r. 
  04MZQR 
  04YKSX
Product:   MK-8189 54
Protocol/Amendment No.: 005-[ADDRESS_1134504] receive training 1) at the investigator 
meeting, 2) on-site from a Sponsor representative, or 3) on-site from trial staff or lead 
inpatient personnel who received training at the Investigator meeting or previously  from a 
Sponsor representative .
All individuals who dispense trial medication to the inpatient subject should monitor the 
subject to ensure doses are taken as directed, and record relevant dosing information 
(including number of tablets and exact time taken) in source documents.   For subjects who 
are discharged at Day 21, trial medication will be self-administered starting the dayafter 
discharge from the hospi[INVESTIGATOR_307] .  Prior to discharge, the subject will be educated by a member of 
the trial staff on dosing requirements and self- administration. Subjects will be provided with 
a dosing diary .The day after discharge from the hospi[INVESTIGATOR_41324] 21and approximately  mid-
week after discharge , the outpatient subject should be telephoned to ensure that he or she has 
understood dosing instructions ,to assess adverse events and to remind the subject of site visit 
on Day  28. 
Interruption from protocol specified dosing for ≥ [ADDRESS_1134505] management.   Failure 
to take prescribed capsules and/or tablets perIP dosing as listed in Table 1constitutes a 
missed dose .
All IPdose units ( tablets and capsules) will be administered by [CONTACT_39802] / inpatient staff
QD(approximately  8:00 AM )to the inpatient .
If a subject misses an IPmorning dose or does not take the full IP morning dose he/she 
should not complete that day’s dose after [ADDRESS_1134506] will miss that day’s dose, and will resume IP dosing the next morning with one 
IPdose.
Visit Require ments 7.1.5
Visit requirements are outlined in Section 6 .0-Trial Flow Chart.   Specific procedure -related 
details are provided above in Section 7.1 -Trial Procedures.
[IP_ADDRESS] Screening
Approximately  3(+4) days prior to treatment allocation/ randomization, potential subjects 
will be evaluated to determine ifthey fulfill the entry  requirements as described in Section 
5.1.  Screening procedures may be repeated after consultation with the Sponsor.
Informed consent should be obtained on the day  of the Screening visit prior to the start of any  
study -specific procedures.  The Screening/tapering period will begin after the consent form is 
completed.  During the Screening visit, a ps ychiatric diagnostic assessment will be performed 
and recorded using the Mini International Neuropsy chiatric Interview for Schizoph renia and  
  04MZQR 
  04YKSX
Product:   MK -8189 55
Protocol/Amendment No.: 005-01 
MK-8189-005-01 Final Protocol 29-Mar-2017
ConfidentialPsychotic Disorders (MINI, Version 7).  All psychiatric diagnoses specified in the 
inclusion/exclusion criteria will be made according to the DSM -5 ™ criteria by a qualified 
psychiatr ist (MD) or psychologist (PhD) or other equivalent degree.  The subject’s medical 
history , prior medications, and demographic information will also be obtained to determine 
eligibility  as well as additional assessments of psychiatric symptoms [Positive andNegative 
Syndrome Scale (PANSS), Clinical Global I mpression -Severity  of Illness (CGI -S) score, and 
Columbia -Suicide Severity  Rating Scale (C-SSRS)].   If the subject meets the Screening 
eligibility  criteria for which results are available , the subject will begin the tapering period. 
Note: laboratory  results, final electrocardiogram [ECG] results, corroboration of acuity  and 
prior antips ychotic treatment response by [CONTACT_819231] [SDME] may still be pending at the start of the tapering 
period. If the subject is deemed ineligible based upon review and corroboration of the 
Screening eligibility  criteria, the subject will be considered a screen failure prior to the 
Baseline visit (Visit 2).
The tapering period will begin after the Screening visit is completed and provides a period of 
time in which the subject will taper off prohibited medication. All subjects must be safel y 
tapered off prohibited medications (antips ychotics, antidepressants and mood -stabilizers, See 
Section 5.5) during the Screening/tapering period in a manner consistent with local medical 
practices.  If it is the investigator’s clinical judgment that the tapering period can be skipped 
for an individual subject, Investigational Product (IP) dosing may begin as early as the 
morning following the Screening procedures, provided all of the eligibility  criteria have been 
met.  For asses sments that are not repeated at Baseline, for those subjects skippi[INVESTIGATOR_819169] , the Screening assessments will serve as the pre
-treatment reference level.
The subject will identify  an external contact [CONTACT_819232] 21 and Day 28 (if the 
subject is an outpatient) and during the 14 -day follow -up period.  (See inclusion criterion 13) .
Note that subjects who are screen failures may  not repeat screening.
[IP_ADDRESS].1
Hospi[INVESTIGATOR_819170] y hospi[INVESTIGATOR_819171], the start of hospi[INVESTIGATOR_819172].  
For subjects who are outpatien ts when approached for recruitment into this trial, subjects 
could be admitted to the hospi[INVESTIGATOR_819173].  Subjects will remain 
hospi[INVESTIGATOR_819174]. 
Hospi[INVESTIGATOR_819175] 28 after end of treatment assessments (V6 are 
completed).  Exceptions to a 28-day inpatient stay may occur on Day 21 onl y if, after 
completion of Day 21 assessments, the follow ing conditions are met: the subject’s current 
clinical symptoms and functioning are much improved and thus continued treatment can 
occur safel y (subject is not at risk to self or others) in a less restrictive environment; the 
subject can self-administer the study  drug correctly , and can abide by [CONTACT_819233]  
  04MZQR 
  04YKSX
Product:   MK -8189 56
Protocol/Amendment No.: 005-[ADDRESS_1134507] will not be treated as an outpatient (i.e., visits 
are not to be performed in a settin g that requires the subject to leave the hospi[INVESTIGATOR_819176] ).  During the inpatient stay, an occasion 
may arise which requires the subject to leave the inpatient unit for social or personal reasons. 
In that event, subjects may be permitted to temporaril y leave the unit during the day at any 
time during the inpatient phase of the study , provided they are escorted at all times durin g 
that leave by [CONTACT_8786]
,at the discretion of the investigator and as per hospi[INVESTIGATOR_819177] .  If the subject was not discharged at Day 21, the subject will be discharged from 
the inpatient unit at Day 28 (± 1).  At Day 28 (±1), all final study  assessments (End of 
treatment visit assessments) will be performed for all subjects, whether the subject was 
discharged at Day  [ADDRESS_1134508] in person.
[IP_ADDRESS] Treatment Period Visit 2 through Visit 6
Each visit should be performed as noted in the Trial Flow Chart. For visits that require 
additional explanations, please see those specific visits below.
Visit 2
Subjects will be assessed for final eligibility  per Inclusion/Exclusion criteria as described in
Section 5.1.  The subject may be randomized into the trial and will be assigned a 
randomization number (via IVRS/IWRS) only after ensuring that the subject meets all 
criteria.  For trial IP titration , please refer to Section [IP_ADDRESS].
Visit [ADDRESS_1134509] requirements, please refer to Section 
[IP_ADDRESS].1. 
  04MZQR 
  04YKSX
Product:   MK-8189 57
Protocol/Amendment No.: 005-[ADDRESS_1134510] week of treatment will return for their final site 
visit, Visit 6.  Subjects should refrain from eating and should not take that morning dose of 
IP.  Subjects will be instructed to arrive at the site in the morning.  Subjects should be 
instructed to bring all trial supplies (e.g., dosing diary , IP) to the site for final compliance and 
accountability .
[IP_ADDRESS] Telephone Contact [CONTACT_819234] [INVESTIGATOR_819178] a site staff member, who is a healthcare professional qualified to elicit a discussion with 
the subject that will lead to a clinicall y meaningful disclosure on the subject’s well-being. 
Phone contacts must be documented imm ediately in a contact [CONTACT_819235]  [INVESTIGATOR_874] 
[ADDRESS_1134511] person , the site’s ensuing action steps must be recorded. The site must 
follow -up on any report of worsening symptoms by [CONTACT_819236]. In the event that the subject cannot be reached by [CONTACT_819237] y 
scheduled time or misses a visit, the site should make at least three attempts (in addition to 
the initial phone call) to contact [CONTACT_2690] [ADDRESS_1134512] 
(i.e., a visit to the subject’s residence, an attempt to reach theexternal contact [CONTACT_819238] )in the event that the subject cannot be reached on the 
third attempt. All phone contacts, attempted contacts, and home visits should be recorded in 
source documents .
[IP_ADDRESS] Post-Treatment C ontact (ph one and visit)
Subjects will have 2 phone calls (at 3and [ADDRESS_1134513] dose) and one clinic visit at Visit 7 ([ADDRESS_1134514] dose) after the last dose of trial drug (regardless of the date of the Discontinuation 
Visit, if applicable) to determine if any AEs have occurred during the post-trial clinic 
contacts .See Section 7.[ADDRESS_1134515] -treatment.
Refer to Section [IP_ADDRESS] regarding phone contact [CONTACT_43056].
Assessing and Recording Adverse Events 7.[ADDRESS_1134516] a causal relationship with this treatment. An adverse event can therefore be any 
unfavourable and unintended sign (including an abnormal laboratory  finding, for example), 
symptom, or disease temporally  associated with the use of a medicinal product or protocol -
specified procedure, whether or not considered related to the medicinal product or proto col-
specified procedure.  Any worsening (i.e., any clinically  significant adverse change in 
frequency  and/or intensity ) of a preexisting condition that is temporally  associated with the 
use of the Sponsor’s product, is also an adverse event. 
  04MZQR 
  04YKSX
Product:   MK-8189 58
Protocol/Amendment No.: 005-01 
MK-8189 -005-01 Final Protocol 29-Mar-2017
ConfidentialChanges result ing from normal growth and development that do not vary significantl y in 
frequency  or severit y from expected levels are not to be considered adverse events.  
Examples of this may include, but are not limited to, teething, typi[INVESTIGATOR_26336] a ph ysiologically  appropriate time.
Sponsor's product includes any pharmaceutical product, biological product, device, 
diagnostic agent or protocol -specified procedure, whether investigational (including placebo 
or active comparator medication) or marketed, manufactured by, licensed by, provided by [CONTACT_75365].
Adverse events may occur during clinical trials, or as prescribed in clinical practice, from 
overdose (whether accid ental or intentional), from abuse and from withdrawal.
All adverse events that occur after the consent form is signed but before treatment 
allocation/ randomization must be reported by [CONTACT_105943], or are the result of a protocol -specified intervention, including but 
not limited to washout or discontinuation of usual therap y, diet, placebo treatment or a 
procedure. From the time of treatment allocation/ randomization through [ADDRESS_1134517] be reported by [CONTACT_093]. Such events
will be recorded at each examination on the Adverse Event case report forms/worksheets.  
The reporting timeframe for adverse events meeting any serious criteria isdescribed in 
section [IP_ADDRESS]. The investigator will make every attempt to follow all subjects with non-
serious adverse events for outcome.
Electronic reporting procedures can be found in the EDC data entry  guidelines. Paper 
reporting procedures can be found in the Investigator Trial File Binder (or equivalent).
Definition of an Overdose for This Protocol and Reporting of Overdose to the 7.2.1
Spons or
In this trial, an overdose is any dose higher than the maximum number of either IP type 
(capsules and/or tablets) specified for a single dose in 1 calendar day (accidental or 
intentional) .
If an adverse event(s) is associated with (“results from”) the o verdose of Sponsor's product or 
vaccine, the adverse event(s) is reported as a non-serious adverse event, unless other serious
criteria are met.
If a dose of Sponsor's product or vaccine meeting the protocol definition of overdose is taken 
without any associated clinical symptoms or abnormal laboratory  results, the overdose is 
reported as a non-serious adverse event, using the terminology  “accidental or intentional 
overdose without adverse effect.”
All reports of overdose with and without an adverse event must be reported by [CONTACT_23514] 24 hours to the Sponsor either by [CONTACT_26365]. Electronic 
reporting procedures can be found in the EDC data entry  guidelines. Paper reportin g 
procedures can be found in the I nvestigator Trial File Binder (or equivalent) . 
  04MZQR 
  04YKSX
Product:   MK-8189 59
Protocol/Amendment No.: 005-[ADDRESS_1134518] 
(spontaneousl y reported to them) that occurs during the trial.
Pregnancies and lactations that occur after the consent form is signed but before treatment 
allocation/ randomization must be reported by [CONTACT_105943], or are the result of a protocol -specified intervention, including but 
not limited to washout or discontinuation of usual therap y, diet, placebo treatment or a 
procedure.  Pregnancies and lactations that occur from the time of treatment 
allocation/ randomization through 14 days following cessation of Sponsor’s product must be 
reported by [CONTACT_093].  All reported pregnancies  must be followed to the 
completion/termination of the pregnancy .Pregnancy  outcomes of spontaneous abortion, 
missed abortion, benign hydatidiform mole, blighted ovum, fetal death, intrauterine death, 
miscarriage and stillbirth must be reported as serious events (Important Medical Events). If 
the pregnancy  cont inues to term, the outcome (health of infant) must also be reported.
Such events must be reported within 24 hours to the Sponsor either by [CONTACT_819239]. Electronic reporting procedures can be found in the EDC data entry guidelines. Paper 
repor ting procedures can be found in the Investigator Trial File Binder (or equivalent) .
Immediate Reporting ofAdverse Events to the Sponsor 7.2.3
[IP_ADDRESS] Serious Adverse Events
A serious adverse event is any adverse event occurring at any dose or during any use of 
Sponsor's product that:
●Results in death;
●Is life threatening;
●Results in persistent or significant disability /incapacity ;
●Results in or prolongs an existing inpatient hospi[INVESTIGATOR_059] [Notable exceptions a) any 
admission solely  for social reasons, b)any  extended hospi[INVESTIGATOR_819179]. 
The PI [INVESTIGATOR_819180]. Extended hospi[INVESTIGATOR_819181] (SDME) and the reasons for extended 
hospi[INVESTIGATOR_819182] y until discharge.] ;
●Is a congenital anomal y/birth defect;
●Is an other important medical event .
Note: In addition to the above criteria, adverse events meeting either of the below criteria, 
although not serious per ICH definition, are reportable to the Sponsor in the same timeframe 
as SAEs to meet certain loca l requirements. 
  04MZQR 
  04YKSX
Product:   MK -8189 60
Protocol/Amendment No.: 005-01 
MK-8189-005-01 Final Protocol 29-Mar-2017
Confidential●Is a cancer;
●Is associated with an overdose .
Refer to Table 5for additional details regarding each of the above criteria.
For the time period beginning when the consent form is signed until treatment 
allocation/ randomization, any serious adverse event, or follow up to a serious adverse event, 
including death due to any  cause, that occurs to any  subject must be reported within [ADDRESS_1134519] to be excluded from the trial, or is the result of a 
protocol -specified intervention, including but 
not limited to washout or discontinuation of 
usual therap y, diet, placebo treatment or a procedure.
For the time period beginning at treatment allocation/ randomization through 14 days 
following cessation of treatment, any  serious adverse event, or follow up to a serious adverse 
event, including death due to any  cause, whether or not related to the Sponsor's product, must 
be reported within 24 hours to the Sponsor either by [CONTACT_819240] r. Electronic 
reporting procedures can be found in the EDC data entry  guidelines. Paper reporting 
procedures can be found in the I nvestigator Trial File Binder (or equivalent).
Additionally , any serious adverse event, considered by [CONTACT_819241]'s product that is brought to the attention of the 
investigator at any time outside of the time period specified in the previous paragraph also 
must be reported immediately  to the Sponsor.
All subjects with serious adverse events must be followed up for outcome.
[IP_ADDRESS] Events of Clinical Interest
Selected non-serious and serious adverse events are also known as Events of Clinical I nterest 
(ECI)  and must be reported to the Sponsor.
For the time period beginning when the consent form is signed until treatment 
allocation/ randomization, any  ECI, or follow up to an ECI , that occurs to any  subject must be 
reported within [ADDRESS_1134520] to be excluded from the trial, 
or is the result of aprotocol -specified intervention, including but not limited to washout or 
discontinuation of usual therap y, diet, placebo treatment or a procedure.
For the time period beginning at treatment allocation/ randomization through 14days 
following cessation of treatment, any ECI, or follow up to an ECI, whether or not related to 
the Sponsor’s product, must be reported within 24 hours to the Sponsor, either by [CONTACT_26366].  Electronic reporting procedures can be found inthe EDC data entry 
guidelines.  Paper reporting procedures can be found in the Investigator Trial File Binder (or 
equivalent).
Events of clinical interest for this trial include:
1.an elevated AST or ALT lab value that is greater than or equal to 3X the upper limit of 
normal and an elevated total bilirubin lab value that is greater than or equal to 2X the  
  04MZQR 
  04YKSX
Product:   MK-8189 61
Protocol/Amendment No.: 005-[ADDRESS_1134521]  of p rotocol- specified laboratory  
testin g or un scheduled laboratory  testing.*
*Note:  These criteria are based upon available regulatory  guidance documents. The 
purpose of the criteria is to specify  a threshold of abnormal hepatic tests that may  require 
an addi tional evaluation for an underl ying etiology. The trial site guidance for assessment 
and follow up of these criteria can be found in the Investigator Trial File Binder (or 
equivalent).
2.Suicidal ideation and/or behavior as reported in C -SSRS scores, TEAEs o r any  self-
injurious behavior
3.Dystonia
4.Tardive d yskinesia
5.QTcF interval of ≥500 msec (the average of the three QTcFs will be used)
Evaluating Adverse Events 7.2.[ADDRESS_1134522] to 
the elements outlined inTable 5. The investigator’s assessment of causality  is required for 
each adverse event.  Refer to Table 5for instructions in evaluating adverse events. 
  04MZQR 
  04YKSX
Product:   MK -8189 62
Protocol/Amendment No.: 005-01 
MK-8189-005-01 Final Protocol 29-Mar-2017
ConfidentialTable 5 Evaluating Adverse Events
Maximum Mild awareness of sign or symptom, but easily tolerated  (for pediatric trials, awareness of symptom, but easily tolerated)
Intensity Moderate discomfort enough to cause interference with usual activity (for pediatric trials, definitely acting like something is wrong)
Severe incapacitating with inability to work or do usual activity (for pediatric trials, extremely distressed or unable to do usual activities)
Seriousness A serious adverse event (AE) is any adverse event occurring at any dose or during any use of Sponsor's product that:
†Results in death ; or
†Is life threatening; or places the subject, in the view of the investigator, at immediate risk of death from the event as it occurred [Note: This does not include an 
adverse event  that, had it occurred in a more severe form, might have caused death.]; or
†Results in a persistent or significant disability/incapacity (substantial disruption of one’s ability to conduct normal life functions); or
†Results in or prolongs an existing inpatient hospi[INVESTIGATOR_059] (hospi[INVESTIGATOR_19357], regardless of length of stay, even if the 
hospi[INVESTIGATOR_2138] a precautionary measure for continued observation.   (Note: Hospi[INVESTIGATOR_19358] a pre-existing condition that has not 
worsened is not a serious adverse event.  A pre- existing condition is a clinical condition that is diag nosed prior to the use of a [COMPANY_006] product and is documented in t he 
patient’s medical history. ); or
†Is a congenital anomaly/birth defect  ( in offspring of subject taking the product regardless of time to diagnosis); or
Is a cancer (although not serious per IC Hdefinition, is reportable to the Sponsor within 24 hours to meet certain local requirements) ;or
Overdose, although not serious per ICH definition, whether accidental or intentional, with or without an accompanying adverse event/serious adverse event, is 
reportable to the Sponsor within [ADDRESS_1134523] and may require medical or surgical intervention to prevent one of the outcomes listed 
previously (designated above by a †).
Duration Record the start and stop dates of the adverse event.  If less than 1 day, indicate the appropriate length of time and units
Action taken Did the adverse event cause the Sponsor's product to be discontinued?
Relationship to 
Sponsor's 
ProductDid the Sponsor's product cause the adverse event?    The determination of the likelihood that the Sponsor's product caused the adverse event will be provided by [CONTACT_26368] a qualified physician.  The investigator’s signed/dated initials on the source document or worksheet thatsupports the causality noted on the AE 
form, ensures that a medically qualified assessment of causality was done.  This initialed document must be retained for the required regulatory time frame.  The 
criteria below are intended as reference guidelines to assist the inves tigator in assessing the likelihood of a relationship between the test drug and the adverse event 
based upon the available information
The following components are to be used to assess the relationship between the Sponsor's product and the AE ; the greater the correlation with the components 
and their respective elements (in number and/or intensity), the more likely the Sponsor's product caused the adverse event:
Exposure Is there evidence that the subject was actually exposed to the Sponsor's product such as:  reliable history, acceptable compliance assessment (pi[INVESTIGATOR_9650], diary, etc.), expected pharmacologic effect, or measurement of drug/metabolite in bodily specimen?
Time Course Did the AE follow in a reasonable temporal sequence from administration of the Sponsor's product? 
Is the time of onset of the AE compatible with a drug -induced effect (applies to trials with investigational medicinal product)?
Likely Cause Is the AE notreasonably explained by [CONTACT_26369], other drug(s)/vaccine(s), or other host or environmental
factors 
  04MZQR 
  04YKSX
Product:   MK -8189 63
Protocol/Amendment No.: 005-01 
MK-8189-005-01 Final Protocol 29-Mar-2017
ConfidentialRelationship The following components are to be used to assess the relationship between the Sponsor's product and the AE:  (continued)
to Sponsor's 
Product
(continued) Dechallenge Was the Sponsor's product discontinued or dose/exposure/frequency reduced?
      If yes, did the AE resolve or improve?
           If yes, this is a positive dechallenge.    If no, this is a n egative dechallenge.
(Note:  This criterion is not applicable if:  (1) the AE resulted in death or permanent disability; (2) the AE resolved/impro ved despi[INVESTIGATOR_90044]'s product; (3) the trial is a single -dose drug trial); or (4) Sponsor' s product(s) is/are only used one time.)
Rechallenge Was the subject re- exposed to the Sponsor's product in this trial?
      If yes, did the AE recur or worsen?
          If yes, this is a positive rechallenge.    If no, this is a negative rechallenge.
(Note:  This criterion is not applicable if:  (1) the initial AE resulted in death or permanent disability, or (2) the trial is a single -dose drug trial); 
or (3) Sponsor's product(s) is/are used only one time.)
NOTE:  IF A RECHALLENGE IS PLANNED FOR AN ADVERSE EVENT WHICH WAS SERIOUS AND WHICH MAY HAVE BEEN 
CAUSED BY [CONTACT_26370]'S PRODUCT, OR IF RE -EXPOSURE TO THE SPONSOR'S PRODUCT POSES ADDITIONAL POTENTIAL 
SIGNIFICANT RISK TO THE SUBJECT THEN THE RECHALLENGE MUST BE APPROVED IN ADVANCE BY [CONTACT_721988]/INDEPENDENT ETHICS COMMITTEE.
Consistency 
with Trial 
Treatment 
ProfileIs the clinical/pathological presentation of the AE consistent with previous knowledge regarding the Sponsor's product or dru g class 
pharmacology or toxicology?
The assessment of relationship will be reported on the case report forms /worksheets by [CONTACT_19427] a qualified ph ysician according to his/her best clinical judgment, including 
consideration of the above elements.
Record one of the following : Use the following scale of criteria as guidance (not all criteria must be present to be indicative of a Sponsor's product rel ationship).
Yes, there is a reasonable 
possibility of Sponsor's product 
relationship.There is eviden ce of exposure to the Sponsor's product.  The temporal sequence of the AE onset relative to the administration of the Sponsor 's 
product is reasonable.  The AE is more likely explained by [CONTACT_1034]'s product than by [CONTACT_5748]. 
No, there is not a rea sonable 
possibility of Sponsor's product 
relationshipSubject did not receive the Sponsor's product OR temporal sequence of the AE onset relative to administration of the Sponsor' s product is not 
reasonable OR the AE is more likely explained by [CONTACT_819242]’s product .  (Also entered for a subject with overdose without 
an associated AE.) 
  04MZQR 
  04YKSX
Product:  MK -8189 64
Protocol/Amendment No.:  005 -01 
MK-8189 -005-01 Final Protocol 29-Mar-2017
ConfidentialSponsor Responsibility for Reporting Adverse Events 7.2.5
AllAdverse Events will be reported to regulatory authorities, IRB/IECs and investigators in 
accordance with all applicable global laws and regulations , i.e., per ICH Topic E6 (R1) 
Guidelines for Good Clinical Pr actice .
TRIAL GOVERNANCE AND OVERSIGHT 7.3
Scientific Advisory Committee 7.3.1
This trial was developed in collaboration with a Scientific Advisory  Committee (SAC).  The 
SAC comprises both Sponsor and non-Sponsor scientific experts who provide input with 
respect totrial design, interpretation of trial results and subsequent peer-reviewed scientific 
publications.
Executive Oversight Committee 7.3.2
The Executive Oversight Committee (EOC) comprises members of Sponsor Senior 
Management.  The EOC will receive and decide upon any recommendations made by [CONTACT_819243] ( siDMC) regarding the trial.
Data Monitoring Committee 7.3.3
To supplement the routine monitoring outlined in this protocol, a separate Standing Internal 
Data Monitoring Committee (siDM C) will monitor the interim data from this trial. The 
siDMC comprises members of Sponsor Senior Management, none of whom are directly  
associated with the conduct of this trial. The siDMC will monitor the trial at an appropriate 
frequency  (see Section 8.7-Interim Anal yses) for evidence of adverse effects of trial 
treatment and efficacy /futility , as described in the detailed monitoring guidelines . The 
siDMC will determine whether the trial should continue (or other modifications, pre-
specified or otherwise, should be made) according to the protocol, considering the overall 
risk and benefit to trial participants. The siDMC will also make recommendations to the 
Sponsor protocol team regarding steps to ensure both subject safety  and the continued ethical 
integr ity of the trial.
Specific details regarding responsibilities of the siDMC will be described in a separate 
charter that is reviewed and approved b y the siDMC.
8.0STATISTICAL ANALYSIS PLAN
This section outlines the statistical analysis strategy  and procedures for the study .  If, after 
the study  has begun, but prior to any unblinding, changes are made to primary  and/or key 
secondary  hypotheses, or the statistical methods related to those hypotheses, then the 
protocol will be amended (consistent with ICH Guidelin e E-9).  Changes to exploratory  or 
other non-confirmatory  analyses made after the protocol has been finalized, but prior to 
unblinding , will be documented in the Clinical Study  Report (CSR) for the study .  Post hoc 
exploratory  anal yses will be clearly  iden tified in the CSR. 
  04MZQR 
  04YKSX
Product:  MK -8189 65
Protocol/Amendment No.:  005 -01 
MK-8189 -005-01 Final Protocol 29-Mar-2017
ConfidentialStatistical Analysis Plan Summary 8.1
Key elements of the statistical analy sis plan are summarized below; the comprehensive plan 
is provided in Sections 8.2-8.12.
Study Design Overview A Phase IIa, Randomized, Double -Blind, Placebo -Controlled Clinical 
Trial of the Efficacy and Safety of MK-8189 in the Treatment of 
Adult Subjects w ith Schizophrenia
Treatm entAssignment Subjects will be randomly assigned to MK-8189 ,placebo or 
risperidone in a 2:2:1 distribution, and will receive MK-8189  
 
 
 
 placebo (3 tablets/capsules QD) or risperidone 
(6 mg QD) for the rem ainder of the trial, as tolerated.
Analysis Populations Efficacy:  Full Analysis Set (FAS)
Safety:  All Subjects as Treated (ASaT)
Prim ary En dpoint 1) Positive and Negative Syndrome Scale (PANSS) total score –
Change from baseline at Week 4
Key Secondary Endpoints 1) Clinical Global Impression Severity of Illness (CGI -S) score –
Change from baseline at Week 4
Statistical Methods for Key 
Efficacy/Immunogenicity/ 
Pharm acokinetic AnalysesThe primary efficacy hypothesis will be evaluated by [CONTACT_819244]-[ADDRESS_1134524] to the mean change from baseline in 
PANSS total score after 4 weeks of treatment using a longitudinal 
analysis of covariance (ANCOVA) method.
Statistical Methods for Key 
Safety AnalysesThe count and percentage of adverse events will be provided.  95% 
confidence intervals for betw een-group comparisons will be 
calculated using the unstratified Miettinen and Nurminen method [7].
Interim Analyses An internal data monitoring committee will evaluate the unblinded
safety and efficacy data to assess the overall risk and benefit to trial 
participants when approximately 25%, 50%,and 75% of the subjects 
have had the opportunity to complete the study.
One interim unblinded efficacy (futility) analysis may also be performed 
in this study.  Results w ould be reviewed by [CONTACT_819245].  This interim analysis is summarized below .  Details are 
provided in Section 8.7.
Trigger : Interim analysis w ill be considered unless more than 
50% of the subjects have been enrolled 4months after the first 
subject w as randomized into the study .
Timing: To be performed when 50% of the subjects have 
completed or discontinued IPtreatment .
Testing : Inferenti al analyses for thechange from baseline in 
the PANSS total score at 4 w eeks will be provided.
Multiplicity A small amount of alpha (α=0.0001) will be allocated to each of the [ADDRESS_1134525] of the primary efficacy hypothesis is statistically 
significant (i.e., p-value is less than or equal to 0.05), then the 
secondary hypothes is will be tested to control theoverall type-I error 
at the 5% level (two-sided).  That is, MK-[ADDRESS_1134526] to the mean change from baseline inCGI-Sscore 
after 4weeks of treatment using α=0. 05(two-sided). 
  04MZQR
CCI 
  04YKSX
Product:  MK -8189 66
Protocol/Amendment No.:  005 -01 
MK-8189 -005-01 Final Protocol 29-Mar-2017
ConfidentialSample Size and Power The planned number of subjects to be randomized is 215(86, 86 and 
43 in the MK-8189 ,placebo and risperidone groups, respectively) . 
For the PANSS total score change from baseline at Week 4, the trial 
has 72% power (if no futility analysis is performed) or 65% power (if 
the planned futility analysis is performed) to demonstrate that 
MK-8189 is superior to placebo at an overall two-sided 5% alpha 
level, if the underlying treatm ent difference (MK -8189 minus 
placebo) is -8.0.  For assay sensitivity, the trial has67% power to 
demonstrate thatrisperidone is superior to placebo at an overall one-
sided 5% alpha level, if the underlying treatment difference 
(risperidone minus placebo) is -8.0.
Responsibility for Analyses/In -House Blinding 8.2
The statistical analysis of the data obtained from this study  will be the responsibility  of the 
Clinical Biostatistics department of the Sponsor .
This study  will be conducted as a double -blind study  under in-house blinding procedures.  
The official, final database will not be unblinded until medical/scientific review has been 
performed, protocol deviations have been identified, and data have been declared final and 
complete.
The Clinical Biostatistics department will generate the randomized allocation sched ule(s) for 
study  treatment assignment.  Randomization will be implemented in an interactive voice 
response s ystem (IVRS).
The planned interim analy ses aredescribed in Section 8.7.  Study enrollment is likely  to be 
ongoing at the time of the interim analyses.  Blinding to treatment assignment will be 
maintained at all investigational sites.  The results of the interim analyses will not be shared 
with the investigators prior to the completion of the study .  Subject -level unblinding will be 
restricted to an internal unblinded statistician and scientific programmer performing the 
interim analy s
es, who will have no other responsibilities associated with the study .
Treatment -level results and/or subject-level data of the interim analy ses will be provided by 
[CONTACT_819246] (siDMC) 
which consists of Sponsor personnel.  Limited additional Sponsor personnel may be 
unblinded to the treatment level results of the interim analy ses, if required, in order to act on 
the recommendations of the siDMC.  The extent to which individuals are unblinded with 
respect to results of the interim anal yses will be documented by  [CONTACT_63539].
The processes by [CONTACT_819247] .  Prior to final study  unblinding, 
individuals who have been unblinded at any level will not be involved in any discussions 
regarding modifications to the protocol, statistical methods, identifi cation of protocol 
deviations, or data validation efforts after the interim analys es.
Hypotheses/Estimation 8.[ADDRESS_1134527]:  MK -8189 67
Protocol/Amendment No.:  005 -01 
MK-8189 -005-01 Final Protocol 29-Mar-2017
ConfidentialAnalysis Endpoints 8.4
Efficacy  and safet y endpoints that will be evaluated are listed below.
Efficacy Endpoints 8.4.1
The Positive and Negative Syndrome Scale (PANSS) is a 30-item clinician -rated instrument 
for assessing the sy mptoms of schizophrenia.  Increases in the PANSS total score represent a 
worsening of symptoms.  The change from baselin e in the PANSS total score at 4weeks is 
the primary  efficacy  endpoint.
The Clinical Global Impression Severity  of Illness (CGI -S) is a 7-point clinician -rated scale 
for assessing the global severit y of the illness.  Increases in the CGI-S score represent a 
worsening of symptoms.  The change from baseline in the CGI-S score at 4weeks is a key 
secondary  efficacy  endpoint.
Exploratory  endpoints will consist of the proportion of PANSS total responders (≥30% 
reduction in PANSS total score), as well as the mean change from baseline to 4 weeks in the 
PANSS negative and positive subscale scores.
Safety Endpoints 8.4.2
Safety  and tolerability  will be assessed throughout the study  by [CONTACT_819248].  Physical/neurological examinations, vital signs, 12-lead ECGs 
and laboratory  safety  tests will be performed periodically  to detect any  medically  meaningful 
effects of MK -8189 on phy siology . 
The Columbia Suicide Severit y Rating Scale (C-SSRS) will beused to systematically  and 
prospectivel y ascertain and document the occurrence ofsuicidal events (i.e., ideation and 
behavior ).  Responses on the C-SSRS are classified according to [ADDRESS_1134528] sever e treatment -emergent ideation and behavior 
event reported at a visit will be used for analy sis and reporting.  An event is considered 
treatment -emergent during the assessment phase if it newly  emerged or is more severe 
compared to recent history  (i.e., protocol -defined recent history  prior to entering the trial as 
stated in the inclusion/exclusion criteria for suicidal ideation/behavior, up to and including 
the randomization visit).
Extrapy ramidal symptoms will be documented with the Extrapyramidal Symptom Rating 
Scale –abbreviated (ESRS -A).
Analysis Populations 8.5
Efficacy Analysis Populations 8.5.1
The Full Analy sis Set (FAS) population will serve as the primary population for the analy sis 
of efficacy  data in this study .  The FAS population consists of all randomize d subjects who:
receive at least 1dose of study  treatment 
  04MZQR 
  04YKSX
Product:  MK -8189 68
Protocol/Amendment No.:  005 -01 
MK-8189 -005-01 Final Protocol 29-Mar-2017
Confidentialhave at least 1post-randomization observation for the anal ysis endpoint subsequent to 
at least 1dose of stud y treatment
have baseline data for those anal yses that require baseline data
Subjects will be included in the treatment group to which they are randomized for the 
analysis of efficacy  data.  Details on the approach to handling missing data are provided in 
Section 8.6, Statistical Methods.
Safety Analysis Populations 8.5.2
The All Subjects as Treated (ASaT) population will be used for the analy sis of safet y data in 
this study .  The ASaT population consists of all randomized subjects who received at least [ADDRESS_1134529] 1dose of 
study  treatment is required for inclusion in the analy sis of each specific parameter.  To assess 
change from baseline, a baseline measurement is also required.
Details on the approach to handling missing data for safet y analy ses are provided in Section 
8.6, Statistical Methods.
Statistical Methods 8.6
Statistical testin g and inference for safet y analyses are described in 8.6.2 .  Efficacy  results 
that will be deemed to be statistically  significant after consideration of the Type I error 
control strategy  are described in Section 8.8, Multiplicity .  Nominal p-values may be
computed for other efficacy  analyses, but should be interpreted with caution due to potential 
issues of multiplicity , sample size, etc.  Unless otherwise stated, all statistical tests will be 
conducted at the α=0. 05(two-sided) level.
Statistical Methods f or Efficacy Analyses 8.6.[ADDRESS_1134530] to the mean change from baseline in PANSS total score after 4weeks of treatment 
using a longitudinal analy sis of covariance (ANCOVA) model.  The analy sis model will 
include terms for treatment, baseline PANSS total score, age, duration of illness, week, and 
the interaction of week by [CONTACT_3148] (Table 6).  The treatment difference in terms of the 
mean change from baseline to a given time point will be estimated and tested from this 
model.  An unstructured covariance matrix will be used to model the correlation among  
  04MZQR 
  04YKSX
Product:  MK -8189 69
Protocol/Amendment No.:  005 -01 
MK-8189 -005-01 Final Protocol 29-Mar-2017
Confidentialrepeated measurements.  The crit erion for declaring MK -8189 superior to placebo in terms of 
PANSS total score change from baseline is that the p -value is less than or equal to 0. 05.
An additional sensitivity  analysis using the tippi[INVESTIGATOR_007] -point approach will be used to assess the 
robustness of the primary  analysis approach.  The Variant 3 of the tippi[INVESTIGATOR_819183] ,et al. (2013) [8] will be applied.  In that approach, missing data are first imputed 
for all visits under the missin g-at-random (MAR) assumption, and then aworsening/shift is 
applied.  This is repeated until the result is no longer statistically  significant (i.e., p>0.05).  
This tippi[INVESTIGATOR_11300] (smallest worsening/shift in which the significant result turns non-
significa nt) provides a measure of robustness of the primary  result. 
Table 6 Analy sis Strategy  for Key  Efficacy  Variables 
Endpoint/Variable
(Description, Time Point)Primary vs. 
Supportive 
Approach†Statistical Method‡Analysis 
PopulationMissing Data 
Approach
Primary Hypothesis
Positive and Negative Syndrome 
Scale (PANSS) total score –
  Change from baseline at Week 4P Longitudinal analysis of 
covariance (ANCOVA) 
model§FAS Model -based
Positive and Negative Syndrome 
Scale (PANSS) total score –
  Change from baseline at Week 4S Longitudinal analysis of 
covariance (ANCOVA) 
model§FAS Tippi[INVESTIGATOR_007] -point 
Analysis
Secondary Hypothes is
Clinical Global Impression Severity 
of Illness (CGI -S) score –
Change from baseline at Week 4P Longitudinal ANCOVA 
model║FAS Model -based
  †P=Primary approach ;  S=Supportive approach .
  ‡Statistical model is described in further detail below:
  §Longitudinal ANCOVA model includes terms for treatment, baseline PANSS total score, age, duration of illness, 
week, and the interaction of week by [CONTACT_3148].
  ║Longitudinal ANCOVA model includes terms for treatment, baseline CGI-Sscore, age, duration of illness, week, and 
the interaction of week by [CONTACT_3148].
The strategy  to address multiplicity  issues with regard to multiple efficacy  endpoints is 
described in Section 8.8, Multiplicity .
Statistical Methods for Safety Analyses 8.6.2
Safety  and tolerability  will be assessed by  [CONTACT_113824], laboratory  tests, vital signs, an d ECG measurements.
The analysis of safet y results will follow a tiered approach (Table 7).  The tiers differ with 
respect to the analyses that will be performed.  Safety  parameters or adverse experiences of 
special interest that are identified a priori constitute “Tier -1” safet y endpoints that will be 
subject to inferential testing for statistical significance with p-values and 95% confidence 
intervals provided for between -group comparisons.  Other safet y parameters will be 
considered Tier 2 or Tier 3.  Ti er-2 parameters will be assessed via point estimates with 95%  
  04MZQR 
  04YKSX
Product:  MK -8189 70
Protocol/Amendment No.:  005-01 
MK-8189-005-01 Final Protocol 29-Mar-2017
Confidentialconfidence intervals provided for between -group comparisons; only point estimates by 
[CONTACT_819249]-3 safet y parameters.
Adverse experiences (specific terms as well assystem organ class terms) that are not pre-
specified as Tier-
1 endpoints will be classified as belonging to "Tier 2" or "Tier 3", based on 
the number of events observed.  Membership in Tier [ADDRESS_1134531] 4 subjects in any 
treatment group exhibit the event; all other adverse experiences will belong to Tier 3.
The threshold of at least 4 events was chosen because the 95% confidence interval for the 
between -group difference in percent incidence will alway s include zero when treatment 
groups of equa l size each have less than 4 events and thus would add little to the 
interpretation of potentially  meaningful differences.  Because many  95% confidence intervals 
may be provided without adjustment for multiplicity , the confidence intervals should be 
regard ed as a helpful descriptive measure to be used in review, not a formal method for 
assessing the statistical significance of the between- group differences in adverse experiences.
Continuous measures, such as changes from baseline in laboratory , vital signs, and ECG 
parameters, will be considered Tier -[ADDRESS_1134532] clinical and laboratory  AE categories consisting of the percentage of 
subjects with any  AE, a drug -related AE, a serious AE, an AE which is both drug -related and 
serious, who discontinued due to an AE, and who discontinued due to a drug -related AE will 
be considered Tier-2 endpoints.  For these endpoints, 95% confidence intervals will be 
provided for between- treatment differences (MK -8189 minus placebo) in the percentage of 
subjects with events; these analyses will be performed using the unstratified Miettin en and 
Nurminen method [7], an unconditional, asymptotic method.
The percentage of subjects with any treatment -emergent suicidal ideation, with any 
treatment -emergent suicidal behavior, or with any treatment-
emergent self-injurious 
behavior, no suicidal intent, will be analy zed per the tiered analy sis strategy  outlined above, 
and will be considered as either Tier -[ADDRESS_1134533] counts (and 
cumulative counts) for each category  will be based upon the most severe treatment -emergent 
event obser ved during the assessment period.
The percentage of subjects having their dose up -titrated (per protocol), maintained or reduced 
will also be considered as Tier -[ADDRESS_1134534]:  MK -8189 71
Protocol/Amendment No.:  005 -01 
MK-8189 -005-01 Final Protocol 29-Mar-2017
ConfidentialTable 7 Analy sis Strategy  for Safety  Parameters
Safety Tier Safety Endpoint†p-Value95%  CI for 
Treat ment 
ComparisonDescriptive 
Statistics
Tier 2Any AE X X
Any drug -related AE X X
Any serious AE X X
Any serious and drug -related AE X X
Discontinuation due to an AE X X
Discontinuation due to a drug -related AE X X
Specific AEs ,SOCs or C-SSRS treatment -emergent 
events‡(incidence ≥[ADDRESS_1134535] 1 of the 
treatment groups)X X
Tier 3Specific AEs ,SOCs or C-SSRS treatment -emergent 
events§(incidence <4 subjects in each of the 
treatment groups)X
Change from baseline resu lts (labs, vital signs, ECGs , 
ESRS -A)X
Dose up-titrated (per protocol), maintained or reduced X
†Adverse Experience references refer to both clinical and laboratory AEs.
‡Any ideation, any behavior, or any self-injurious behavior, no suicidal intent .
§Includes only those endpoints not already pre -specified as Tier -2 endpoints .
Note: SOC =System Organ Class;
C-SSRS = Columbia-Suicide Severity Rating Scale ;
ESRS -A = Extrapyramidal Symptoms Rating Scale -Abbreviated ;
X = results will be provided.
Demographic and Baseline Characteristics 8.6.3
The comparability  of the treatment groups for each relevant characteristic will be assessed by 
[CONTACT_819250].  No statistical hypothesis tests will be performed on these characteristics.  
The number and percentage of subjects screened, randomized, the primary  reasons for 
screening failure, and the primary  reason for discontinuation will be displayed.  Demographic 
variable s (e.g., age, gender, race), baseline characteristics, primary  and secondary  diagnoses, 
and prior and concomitant therapi[INVESTIGATOR_431957].
Interim Analys es 8.7
A standing internal Data Monitoring Committee (siDMC), which will consist of Sponsor
personnel not affiliated with the project, will evaluate the unblinded safety  and efficacy  data
to assess the overall risk and benefit to trial participants when approximately  25%, 50% and 
75% of the subjects have had the opportunity  to co mplete the study .
An interim unblinded efficacy  (futility ) analysis will be considered unless more than 50% of 
the subjects have been enrolled [ADDRESS_1134536]:  MK -8189 72
Protocol/Amendment No.:  [ADDRESS_1134537] , would occur when 50% of the subjects have completed or 
discontinued IPtreatment and include all data collected (including partial data from subjects 
who were randomized, but did not yet have the opportunity  to complete the study ).  The 
siDMC w ould review the analysis results and recommend whether the study  should continue.
If the study  is stopped early , the CSR will comprise all available data up to and including the 
close -out visits, which include the data used to draw the conclusion in the decisive interim 
analysis plus the remaining data obtained afterwards (from additional visits and close -out 
visits).  This approach to include all available informati on is in line with the Internation al
Council for Harmonisation (ICH)-E9 guideline, the intent -to-treat (ITT)principle and the 
Committee for Medicinal Products for Human Use ( CHMP )guideline on adaptive designs.
Futility of Primary Outcome 8.7.[ADDRESS_1134538] to the change from baseline in the 
PANSS total score at 4 weeks .  The primary  efficacy  analysis will be performe d on the Full 
Analy sis Set. The siDMC willreview the analy sis results andrecommend whether the study 
should continue. The stoppi[INVESTIGATOR_819184] [9]with parameter 1. The study  may be stopped with early 
rejection of thealternative hypothesis (i.e., MK-[ADDRESS_1134539] to the change from baseline in the PANSS total score at 4 weeks) if the
test statistic cross esthe pre -specified stoppi[INVESTIGATOR_74239] (i.e., the value of the test statistic is
greater than the value of the Gamma stoppi[INVESTIGATOR_819185], 
suggesting that MK- 8189 is not superior to placebo ).
Table 8display s the operating characteristics of the futility  analysis. Assuming that the 
futility  anal ysis is performed when 108subjects have completed or discontinued IPtreatment
and an observed standard deviation of the change from baseline in the PANSS total score of 
17.0,the study  may be stopped if the mean change in PANSS total score is <4.6better than 
thatobserved in the placebo group.   This corresponds to the conditional power of the study 
being <26% at the time of the futility  analysis (i.e., at the time of the futility  analysis, if the 
observed difference in the mean change in PANSS total score between the MK-8189 and 
placebo groups (MK-8189 minus placebo ) is -4.6, then there would be a 26% chance that 
MK- 8189 would be declared superior to placebo at the time of the final analysis). 
  04MZQR 
  04YKSX
Product:  MK -8189 73
Protocol/Amendment No.:  005 -01 
MK-8189 -005-01 Final Protocol 29-Mar-2017
ConfidentialTable 8 Operating Characteristics of the Futility Analysis†
Number of randomized subjects at the time of the futility  anal ysis 108
Observed difference between groups that would stop the study  
(futility  anal ysis)> -4.6
P-value (two -sided) for stoppi[INVESTIGATOR_10098] >0.30
Conditional power‡for stoppi[INVESTIGATOR_271436] y < 26%
Probability  that the study will be stopped
(MK- 8189 is ineffective; diffe rence§=0)70%
Probability  that the study will be stopped
(MK- 8189 is effective; difference = -8)22%
Observed difference between groups that would result in superiority  
(final anal ysis)≤ -6.2
†Sample size isthe total number of subjects randomized (2:2:1 ratio in MK -8189, placebo and risperidone 
groups, respectively); Expected d rop-out rate = 30% ;Differences and probabilities are based on the 
primary treatment comparison (i.e., MK -8189 vs. placebo).   The futility boundary is non -binding.
‡Calculated under the assumption that the observed data tr end at the time of the futility analysis will 
continue to the end of the trial.
§Difference = MK- 8189 –placebo.
Multiplicity 8.8
A small amount of alpha (α=0.0001) will be allocated to each of the [ADDRESS_1134540] of the primary  efficacy 
hypothesis is statistically  significant (i.e., p-value is less than or equal to 0.05), thus
control ling the overall type-I error over the primary  and secondary  hypotheses at the 5% 
level (two -sided).  That is, MK -[ADDRESS_1134541] to the mean 
change from baseline inCGI-Sscore after 4weeks of treatment using α=0. 05(two-sided).
If the primary  efficacy  hypothesis test is not statistically  significant, then a nominal p-value 
would be display ed for the secondary hypothesis test, but statistical significance (i.e., 
superiority  to placebo) would not be concluded for th istest.
Sample Size and Power Calculations 8.9
The planned number of subjects to be randomized is 215(86, 86,and 43in the MK-8189, 
placebo and risperidone groups, respectivel y). For the PANSS total score change from 
baseline at Week 4, the trial has 72% power (if no futility  analysis is performed) or 65% 
power (if the planned futility  analysis is performed) to dem onstrate that MK -[ADDRESS_1134542]:  MK -8189 74
Protocol/Amendment No.:  005-01 
MK-8189-005-01 Final Protocol 29-Mar-2017
ConfidentialThe power and sample size are based on the following assumptions:
α = 0. 05(two-sided)
True treatment difference (MK-8189 minus placebo) = 
−8.0
Standard deviation = 17.0
Drop -out rate = 30%
The criterion for success is that the p-value for the between- treatment difference in the mean 
PANSS total score change from baseline (MK -8189 minus placebo) will b eless than or equal 
to 0.05
.  Give n the above assumptions, this may  occur when the observed difference between 
treatment groups is approximately  ≤ -6.2.  
The power calculations for the primary 
comparison are summarized under various assumptions in Table 9(assuming that a futility  
analysis is notperformed ) and Table 10 (assuming that a futility  anal ysis isperformed) .
Table 9 Power† (%) Under Various Assumptions With [ADDRESS_1134543] 
Deviation of Change 
from  BaselineTrue Difference‡in Change from  Baseline in PANSS§Total Score
-10.0 -9.5 -9.0 -8.5 -8.0 -7.5 -7.0 -6.5 -6.0
15.0 95 93 90 87 83 78 72 65 58
16.0 92 90 86 82 78 72 66 60 53
17.0 89 86 82 78 72 67 61 55 48
18.0 86 82 78 73 68 62 56 50 44
†Assumptions:  α = 0. 05(two-sided);  drop -out rate = 30%;
60subjects per treatment group ( MK-8189 andplacebo ) expected to be included in the analysis.
‡Difference = MK- 8189 − placebo.
§PANSS = Positive and Negative Syndrome Scale. 
  04MZQR 
  04YKSX
Product:  MK -8189 75
Protocol/Amendment No.:  005 -01 
MK-8189 -005-01 Final Protocol 29-Mar-2017
ConfidentialTable 10 Power† (%) Under Various Assumptions With [ADDRESS_1134544] 
Deviation of Change 
from  BaselineTrue Difference‡in Change from  Baseline in PANSS§Total Score
-10.0 -9.5 -9.0 -8.5 -8.0 -7.5 -7.0 -6.5 -6.0
15.0 92 89 86 81 76 71 65 58 51
16.0 88 85 81 76 71 65 59 53 46
17.0 84 80 76 71 65 60 54 48 42
18.0 80 75 71 66 60 55 49 44 38
†Assumptions:  α = 0. 05 (two-sided);  drop -out rate = 30%;
60 subjects per treatment group (MK -8189 and placebo) expected to be included in the analysis.
‡Difference = MK- 8189 − placebo.
§PANSS = Positive and Negative Syndrome Scale.
For assay  sensitivity , the trial has 67% power to demonstrate that risperidone is superior to 
placebo at an overall one-sided 5% alpha level, if the underl ying treatment difference 
(risperidone minus placebo) is -8.0.
Subgroup Analyses and Effect of Baseline Factors 8.[ADDRESS_1134545] (with a nominal 95% CI) for the primary 
endpoint will be estimated within each category of the following classification variables:
Age category  (≤35years, >35years)
Gender (female, male)
Race (white, Asian, other )
Duration of illness ( ≤ 10 years, >10 years)
Baseline PANSS total score ( ≤95, >95)
Compliance (Medication Adherence) 8.[ADDRESS_1134546] 
compliance.
A day within the study will be considered an “On-Therap y” day if the subject takes the 
required number of IP tablets and capsules ,as noted in Section 5.2.
For a subject who is followed for the entire study period, the “Number of Days Should be on 
Therap y”is the total number of days from randomization to the last scheduled day for 
treatment administration for that subject.  For a subject who discontinued from the study   
  04MZQR 
  04YKSX
Product:  MK -8189 76
Protocol/Amendment No.:  005 -01 
MK-8189 -005-01 Final Protocol 29-Mar-2017
Confidentialpermanentl y, the “Number of Days Should be on Therap y” is the total number of days from 
randomization to the date the subject discontinued from the study.
For each subject, percent compliance will then be calculated using the following formula:
Summary  statistics will be provided on percent compliance by [CONTACT_819251].
Extent of Exposure 8.12
The extent of exposure to study  treatment will be evaluated by [CONTACT_40135] (N, mean, 
range ) and frequencies (number of subjects expos ed to study  treatment for various durations, 
e.g., within 1-week intervals over the course ofthe study )for the “Number of Days on 
Therap y” by [CONTACT_1570].
9.0LABELING, PACKAGING, STORAGE AND RETURN OF CLINICAL 
SUPPLIES
Investigational Product 9.[ADDRESS_1134547] Name &Potency Dosage Form
MK- [ADDRESS_1134548]:  MK -8189 77
Protocol/Amendment No.:  005 -01 
MK-8189 -005-01 Final Protocol 29-Mar-2017
ConfidentialPackaging and Labeling Information 9.2
Clinical supplies will be affixed with a clinical label in accordance with regulator y 
requirements.
For the tablet of capsule formulation, subjects will receive blinded bottles (each containing a 
1 week supply of the stud y therap y). No kitting is required . 
Clinical Supplies Disclosure 9.3
The emergency  unblinding call center will use the treatment/ randomization schedule for the 
trial to unblind subjects and to unmask treatment identity .In the event that the emergency 
unbli nding call center is not available for a given site in this trial, the central electronic 
treatment allocation/ randomization system (IVRS/I WRS) should be used in order to unblind 
subjects and to unmask treatment/vaccine identity .The Sponsor will notprovide random 
code/disclosure envelopes or lists with the clinical supplies .
Treatment identification information is to be unmasked ONLY if necessary  for the welfare of 
the subject.  Every  effort should be made not to unblind the subject unless necessary . 
In the event that unblinding has occurred, the circumstances around the unblinding (e.g., date 
and reason) must be documented promptly , and the Sponsor Clinical Director notified as 
soon as possible.  Only the principal investigator [INVESTIGATOR_819168]’s 
code should be unblinded.  Trial site personnel and Sponsor personnel directly  associated 
with the conduct of the trial should not be unblinded .
Storage and Handling Requirements 9.[ADDRESS_1134549]/Destruction/ Returns and Reconciliation 9.[ADDRESS_1134550]/destruction procedure is documented . 
  04MZQR 
  04YKSX
Product:  MK -8189 78
Protocol/Amendment No.:  [ADDRESS_1134551] access to a central electronic treatment 
allocation/ randomization system (IVRS/I WRS system) to allocate subjects, to assign 
treatment to subjects and to manage the distribution of clinical supplies. Each person 
accessing the IVRS system must be assigned an individual unique PIN.  They must use only 
their assigned PIN to access the system, and they must not share their assigned PIN with 
anyone.
10.[ADDRESS_1134552], ethics review committee (IRB/ERC) or similar 
or expert committee; affiliated institution and employ ees, only under an appropriate 
understanding of confidentiality  with such board or committee, affiliated institution and 
employ ees.  Data generated by [CONTACT_26384], 
except to the extent that it is included in a public ation as provided in the Publications section 
of this protocol.
Confidentiality of Subject Records 10.1.2
By [CONTACT_12570], the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/ERC, or regulatory  authority  representatives may consult and/or copy trial documents in 
order to verify  worksheet/case report form data.  By [CONTACT_17317], the subject 
agrees to this process.  If trial documents will be photocopi[INVESTIGATOR_75311]/case report form information , the subject will be identified by [CONTACT_19494]; 
full names/initials will be masked prior to transmission to the Sponsor.
By [CONTACT_12570], the investigator agrees to treat all subject data used and disclosed in 
connection with this trial in accordance with all applicable privacy laws, rules and 
regulations.
Confidentiality of Investigator Information 10.1.[ADDRESS_1134553] to the investigator, and all subinvestigators and trial site personnel, 
may be used and disclosed for trial management purposes, as part of a regulatory  
submissions, and as required b y law.  This information may include:
1.name, address, telephone number and e -mail address;
2.hospi[INVESTIGATOR_26342];
3.curriculum vitae or other summary  of qualifications and credentials; and
4.other professional documentation. 
  04MZQR 
  04YKSX
Product:  MK -8189 79
Protocol/Amendment No.:  [ADDRESS_1134554] laws protecting such information.  
Additionally , the investigator’s name [CONTACT_26407] [CONTACT_75387].  By [CONTACT_12570], the investigator expressly  consents to these uses and 
disclosures.
If this is a multicenter trial, in order to facilitate contact [CONTACT_26387], the Sponsor 
may share an investigator’s name [CONTACT_3669] [CONTACT_26388].
Confidentiality of IRB/IEC Information 10.1.[ADDRESS_1134555] the name [CONTACT_19525]/IEC member that 
reviews and approves this trial.  The Sponsor is also required to document that each IRB/IEC 
meets regulatory  and ICH GCP requirements by [CONTACT_537585]/IEC members and to make these records available for 
regulatory  agency  review upon request b y those agencies.
Compliance with Financial Disclosure Requirements 10.2
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure by [CONTACT_6230] (21 CFR Part 54).  It is the 
Sponsor's responsibility to determine, based on these regulations, whether a requ est for 
Financial Disclosure information is required.  It is the investigator's/subinvestigator's 
responsibility  to comply  with any  such request.  
The investigator/subinvestigator(s) agree, if requested by [CONTACT_19489] 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements.  
The investigator/subinvestigator(s) further agree to provide this information on a 
Certification/Disclosure Form, commonly  known as a financial disclosure form, provided by 
[CONTACT_131018] a secure password -protected electronic portal provided by [CONTACT_429].  The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the [LOCATION_002] for these purposes.  This may involve the 
transmission of information to countries that do not have laws protecting personal data.
Compliance with Law, Audit and Debarment 10.[ADDRESS_1134556] the trial in an efficient and 
diligent manner and in conformance with this protocol; generall y accepted standards of Good 
Clinical Practice (e.g., International Conference on Harmonization of Technical 
Requirements for Registr ation of Pharmaceuticals for Human Use Good Clinical Practice: 
Consolidated Guideline and other generally  accepted standards of good clinical practice); and 
all applicable federal, state and local laws, rules and regulations relating to the conduct of the 
clinical trial. 
  04MZQR 
  04YKSX
Product:  MK -8189 80
Protocol/Amendment No.:  005-[ADDRESS_1134557] for Clinical Trials .
The investi gator also agrees to allow monitoring, audits, IRB/ERC review and regulatory  
authority  inspection of trial-related documents and procedures and provide for direct access 
to all trial
-related source data and documents.
The investigator agrees not to seek re imbursement from subjects, their insurance providers or 
from government programs for procedures included as part of the trial reimbursed to the 
investigator b y the Sponsor.
The investigator shall prepare and maintain complete and accurate trial documentati on in 
compliance with Good Clinical Practice standards and applicable federal, state and local 
laws, rules and regulations; and, for each subject participating in the trial, provide all data, 
and, upon completion or termination of the clinical trial, submi t any other reports to the 
Sponsor as required by  [CONTACT_75389].
Trial documentation will be promptly  and fully disclosed to the Sponsor by [CONTACT_26391], 
copy ing, review and audit at reasonable times by [CONTACT_75391].  The investigator agrees to promptly  take any  reasonable steps that are 
requested b y the Sponsor as a result of an audit to cure deficiencies in the trial documentation 
and worksheets/case report forms.
The investigator must maintain copi[INVESTIGATOR_90047].  This 
documentation includes, but is not limited to, the protocol, worksheets/case report forms, 
advertising for subject participation, adverse event reports, subject source data, 
correspondence with regulatory  authorities and IRBs/ERCs, consent forms, investigator’s 
curricula vitae, monitor visit logs, laboratory  reference ranges, laboratory  certification or 
quality  control procedures and laboratory  director curriculum vitae.  By  [CONTACT_12570], 
the investiga tor agrees that documentation shall be retained until at least [ADDRESS_1134558] consult 
with and obtain written approval b y the Sponsor prior to destro ying trial and/or subject files.   
  04MZQR 
  04YKSX
Product:  MK -8189 81
Protocol/Amendment No.:  [ADDRESS_1134559]’s 
primary  physician about the subject’s participation in the trial if the subject has a primary  
physician and if the subject agrees to the primary  physician being informed.
The investigator will promptly  inform the Sponsor of any regulatory  authority  inspection 
conducted f or this trial.
Persons debarred from conducting or working on clinical trials by [CONTACT_90090]’s trials.  The investigator 
will immediately  disclose in writing to the Sponsor if any person who is involved in 
conducting the trial is debarred or if any proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened.
In the event the Sponsor prematurel y terminates a particular trial site, the Sponsor will
promptly  notify  that trial site’s I RB/IEC.
According to European legislation, a Sponsor must designate an overall coordinating 
investigator [INVESTIGATOR_8178] a multi -center trial (including multinational).  When more than one trial site 
is open in an EU country, [COMPANY_006], as the Sponsor, will designate, per country , a national 
principal coordinator (Protocol CI), responsible for coordinating the work of the principal 
investigators at the different trial sites in that Member State, according to national 
regulations.  For a single- center trial, the Protocol CI is the principal investigator.  In 
addition, the Sponsor must designate a principal or coordinating investigator [INVESTIGATOR_26344], to the best of his/her 
know ledge, the report accuratel y describes the conduct and results of the trial [Clinical Study  
Report (CSR) CI].  The Sponsor may consider one or more factors in the selection of the 
individual to serve as the Protocol CI and or CSR CI (e.g., availability  of the CI during the 
anticipated review process, thorough understanding of clinical trial methods, appropriate 
enrollment of subject cohort, timely  achievement of trial milestones).  The Protocol CI must 
be a participating trial investigator.
Compliance with Trial Registration and Results Posting Requirements 10.[ADDRESS_1134560] (FDAMA) and the 
Food and Drug Administration Amendments Act (FDAAA), the Sponsor of the trial is solely 
responsible for determining whether the trial and its results are subject to the requirements 
for submission to the Clinical Trials Data Bank, http://www.clinicaltrials.gov.  [COMPANY_006], as 
Sponsor of this trial, will review this protocol and submit the information necessary  to fulfill 
these requirements.  [COMPANY_006] entries are not limited to FDAMA/FDAAA mandated trials. 
Information posted will allow subjects to identify  potentiall y appropriate trials for their 
disease conditions and pursue participation by [CONTACT_3379] a central contact [CONTACT_26393].    
By [CONTACT_12570], the investigator acknowledges that the statutory  obligations under 
FDAMA/FDAAA are that of the Sponsor and agrees not to submit any  informat ion about this 
trial or its results to the Clinical Trials Data Bank. 
  04MZQR 
  04YKSX
Product:  MK -8189 82
Protocol/Amendment No.:  [ADDRESS_1134561] operating procedures (SOPs) to ensure that trials are conducted and 
data are generated, documented, and reported in compliance with the protocol, accepted 
standards of Good Clinical Practice, and all applicable federal, state, and local laws, rules and 
regulations relating to the conduct of the clinical trial.
Data Management 10.[ADDRESS_1134562] data.  By [CONTACT_12570], the investigator acknowledges that his/her 
electronic signature [CONTACT_75412] y binding equivalent of a written signature.  By [CONTACT_75393] g 
his/her electronic signature, the investigator confirms that all recorded data have been 
verified as accurate.
Detailed information regar ding Data Management procedures for this protocol will be 
provided separatel y.
Publications 10.7
This trial is intended for publication, even if terminated prematurel y. Publication may include 
any or all of the following: posting of a synopsis online, abstract and/or presentation at a 
scientific conference, or publication of a full manuscript.  The Sponsor will work with the 
authors to submit a manuscript describing trial results within [ADDRESS_1134563]'s last visit for the 
primary  outcome, [ADDRESS_1134564] 
marketing (dispensed, administered, delivered or promoted), whichever is later .
These timelines may be extended for products that are not yet marketed, if additional time is 
needed for analysis, to protect intellectual property , or to compl y with confidentiality 
agreements with other parties.  Authors of the primary  results manuscri pt will be provided 
the complete results from the Clinical Study  Report, subject to the confidentiality  agreement. 
When a manuscript is submitted to a biomedical journal, the Sponsor's policy  is to also 
include the protocol and statistical analy sis plan tofacilitate the peer and editorial review of 
the manuscript.  If the manuscript is subsequently accepted for publication, the Sponsor will 
allow the journal, if it so desires, to post on its website the key sections of the protocol that 
are relevant to evaluating the trial, specifically  those sections describing the trial objectives 
and hypotheses, the subject inclusion and exclusion criteria, the trial design and procedures,  
  04MZQR 
  04YKSX
Product:  MK -8189 83
Protocol/Amendment No.:  005-[ADDRESS_1134565] proprietary  information.
For multicenter trials, subsequent to the multicenter publication (or after public disclosure of 
the results online at www.clinicaltrials.gov if a multicenter manuscript is not planned), an 
investigator and his/her colleagues may publish their data independentl y.  In most cases, 
publication of individual trial site data does not add value to complete multicenter results, 
due to statistical concerns.  In rare cases, publication of single trial site data prior to the main 
paper may be of value.  Limitations of single trial site observations in a multicenter trial 
should alway s be described in such a manuscript.
Authorship credit should be based on 1) substantial contributions to conception and design, 
or acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising 
it critically  for important intellectual content; and 3) final approval of the version to be 
published. Authors must meet conditions 1, [ADDRESS_1134566] also been made to all three of the preceding authorship criteria.  Although 
publication planni
ng may begin before conducting the trial, final decisions on authorship and 
the order of authors’ names will be made based on participation and actual contributions to 
the trial and writing, as discussed above. The first author is responsible for defending the 
integrit y of the data, method(s) of data anal ysis and the scientific content of the manuscript.
The Sponsor must have the opportunity  to review all proposed abstracts, manuscripts or 
presentations regarding this trial 45days prior to submission for publication/presentation. 
Any information identified by [CONTACT_26395]; this confidentiality  does not include efficacy  and safety  results. Sponsor review 
can be expedited to mee t publication timelines.
11.[ADDRESS_1134567] OF REFERENCES
[1] Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular 
regulation to clinical use. Pharmacol Rev 2006;58:488-520.
[2] Seeger TF, Bartlett B, Coskran TM, Culp JS, James LC, Krull DL, et al. 
Immunohistochemical localization of PDE10A in the rat brain. Brain Res 
2003;985:113-26.
[3] Grauer SM, Pulito VL, Navarra RL, Kelly MP, Kelley  C, Graf R, et al. 
Phosphodiesterase 10A inhibitor activity  in preclinical models of the positive, 
cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther 
2009;331(2):574 -90.
[4] Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF, et al. 
Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new 
therapeutic appro ach to the treatment of schizophrenia. J Pharmacol Exp Ther 
2008;325(2):[ADDRESS_1134568]:  MK -8189 84
Protocol/Amendment No.:  005-01 
MK-8189-005-01 Final Protocol 29-Mar-2017
Confidential[5] Khan A, Yavorsk y WC, Liechti S, DiClemente G, Rothman B, Opler M. et al. 
Assessing the sources of unreliability  (rater, subject, time-point) in a failed 
clinical trial using items of the Positive and Negative Syndrome Scale (PANSS). 
J Clin Psy chopharmacol. 2013 Feb;33(1):109 -17.
[6] Kay SR, Fiszbein  A, Opler LA. The positive and negative syndrome scale 
(PANSS) for schizophrenia. Schizophr Bull 1987;13(2):261
-76.
[7] Miettinen O, Nurminen M. Comparative analysis of two rates. Statist Med 
1985;4:213-26.
[8] Ratitch B, O'Kelly  M, Tosiello R. Missing data in clinical trials: from clinical 
assumptions to statistical analy sis using pattern mixture models. Pharm Stat. 
2013 Nov -Dec;12(6):337 -47.
[9] Hwang IK, Shih WJ, De Cani JS. Group sequential designs using a family  of ty pe 
I error probability spending functions. Stat Med 1990;9:[ADDRESS_1134569]:  MK -8189 85
Protocol/Amendment No.:  [ADDRESS_1134570] for Clinical Trials 12.1
[COMPANY_006] *
Code of Conduct for Clin ical Trials
I. Introduction
A. Purpose
[COMPANY_006], through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing and reporting these trials in 
compliance with the highest ethical and scientific standards. Protection of subject safety is the overriding concern in 
the design of clinical trials. In all cases, [COMPANY_006] clinical trials will be conducted in compliance with local and/or 
national regulations and in accordance with the ethical principles that have their origin in the Declaration of Helsinki. 
B. Scope
Such standards shall be endorsed for all clinical interventional investigations sponsored by [CONTACT_75395] (parties) employed for their execution (e. g., contract research organizations, collaborative research efforts). This 
Code is not intended to apply to trials which are observational in nature, or which are retrospective. Further, this Code 
does not apply to investigator -initiated trials which are not under the control of [COMPANY_006].
II.Scientific Issues
A. Trial Conduct
1.Trial Design
Except for pi[INVESTIGATOR_19354] , clinical trial protocols will be hypothesis -driven to assess safety, efficacy 
and/or pharmacokinetic or pharmacodynamic indices of [COMPANY_006] or comparator products.  Alternatively, [COMPANY_006] may 
conduct outcomes research trials, trials to assess or validate various endpoint measures, or trials to determine 
subject preferences, etc.  
The design (i.e., subject population, duration, statistical power) must be adequate to address the specific purpose 
of the trial.  Research subjects must meet protocol entry criteria to be enrolled in the trial. 
2.Site Selection
[COMPANY_006] selects investigative sites based on medical expert[INVESTIGATOR_18700], access to appropriate subjects , adequacy of facilities 
and staff, previous performance in [COMPANY_006] trials , as well as budgetary considerations.  Prior to trial initiation, sites 
are evaluated by [CONTACT_75396].
3.Site Monitoring/Scientific Integrity
Trial sites are monitored to assess compliance with the trial protocol and general principles ofGood Clinical 
Practice.  [COMPANY_006] reviews clinical data for accuracy, completeness and c onsistency. Data are verified versus source 
documentation according to standard operating procedures.  Per [COMPANY_006] policies and procedures, if fraud, 
misconduct or serious GCP -non-Compliance are suspected, the issues are promptly investigated. When necessary, 
the clinical site will be closed, the responsible regulatory authorities and ethics review committees notified and 
data disclosed accordingly. 
B. Publication and Authorship
To the extent scientifically appropriate, [COMPANY_006] seeks to publish the results of trials it conducts.  Some early phase or 
pi[INVESTIGATOR_26346] -generating rather than hypothesis testing.  In such cases, publication of 
results may not be appropriate since the trial may be underpowered and the analyses complicated by [CONTACT_75397].
[COMPANY_006]’s policy on authorship is consistent with the requirements outlined in the ICH-Good Clinical Practice 
guidelines. In summa ry, authorship should reflect significant contribution to the design and conduct of the trial, 
performance or interpretation of the analysis, and/or writing of the manuscript.  All named authors must be able to 
defend the trialresults and conclusions.  Me rck funding of a trialwill be acknowledged in publications.  
  04MZQR 
  04YKSX
Product:  MK -8189 86
Protocol/Amendment No.:  005-[ADDRESS_1134571] Protection
A.IRB/ERC review
All clinical trials will be reviewed and approved by [CONTACT_75398]/ERC before being initiated at each site.  
Significant changes or revisions to the protocol will be approved by [CONTACT_1201]/ERC prior to implementation, except that 
changes required urgentl y to protect subject safety and well-being may be enacted in anticipation of IRB/ERC 
approval. For each site, the IRB/ERC and [COMPANY_006] will approve the subject informed consent form. 
B.Safety
The guiding principle in decision -making in clinical trials is that subject welfare is of primary importance.  Potential 
subjects will be informed of the risks and benefits of, as well as alternatives to, trial participation. At a minimum, trial
designs will take into account the local standard of care.  Subjects are ne ver denied access to appropriate medical care 
based on participation in a [COMPANY_006] clinical trial . 
All participation in [COMPANY_006] clinical trials is voluntary.  Subjects are enrolled only after providing informed consent for 
participation.  Subjects may withdraw from a [COMPANY_006] trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C.Confidentiality
[COMPANY_006] is committed to safeguarding subject confidentiality, to the greatest extent possible. Unless required by [CONTACT_2371], 
only the investigator, sponsor (or representative) and/or regulatory authorities will have access to confidential medical 
records that might identify the research subject by [CONTACT_2300].  
D.Genomic Research
Genomic Research will only beconducted in accordance with informed consent and/or as specifically authorized by 
[CONTACT_75399].
IV.Financial Considerations
A.Payments to Investigators
Clinical trials are time- and labor-intensive.  It is [COMPANY_006]’s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performed in support of [COMPANY_006] trials .   [COMPANY_006] does not pay incentives to 
enroll subjects in its t rials.  However, when enrollment is particularly challenging, additional payments may be made 
to compensate for the time spent in extra recruiting efforts.
[COMPANY_006] does not pay for subject referrals.  However, [COMPANY_006] may compensate referring physicians for time spent on 
chart review to identify potentially eligible subjects .
B.Clinical Research Funding 
Informed consent forms will disclose that the trial is sponsored by [CONTACT_44873], and that the investigator or sponsoring 
institution is being paid or provided a gra nt for performing the trial.  How ever, the local IRB/ERC may wish to alter 
the wording of the disclosure statement to be consistent with financial practices at that institution.  As noted above, 
publications resulting from [COMPANY_006] trials will indicate [COMPANY_006] as a source of funding.
C.Funding for Travel and Other Requests
Funding of travel by [CONTACT_19488] (e.g.,to scientific meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices including, in the U.S., those established by [CONTACT_75401] (AMA). 
V. Investigator Commit ment
Investigators will be expected to review [COMPANY_006]’s Code of Conduct as an appendix to the trialprotocol, and in signing 
the protocol, agree to support these ethical and scientific standards.
* In this document, "[COMPANY_006]" refers to [COMPANY_006] Sharp & Dohme Corp. and Schering Corporation, each of which is a 
subsidiary of [COMPANY_006] & Co., Inc.  [COMPANY_006] is known as MSD outside of the [LOCATION_002] and Canada.  As warranted by 
[CONTACT_74647], [COMPANY_006] also includes affiliates and subsidiaries of [COMPANY_006] & Co., Inc." 
  04MZQR 
  04YKSX
Product:  MK -8189 87
Protocol/Amendment No.:  005 -01 
MK-8189 -005-01 Final Protocol 29-Mar-2017
ConfidentialCollection and Management of Specimens for Future Biomedical Research 12.2
1.Definitions
a.Biomarker:  A biological molecule found in blood, other body  fluids, or tissues that is a 
sign of a normal or abnormal process or of a condition or disease.  A biomarker may be 
used to see how well the body  responds to a treatment for a disease or condition.1
b.Pharmacogenomics:  The investigation of variations of DNA and RNA characteristics as 
related to drug /vaccine response.2
c.Pharmacogenetics:  A subset of pharmacogenomics, pharmacogenetics is the influence of 
variations in DNA sequence on drug /vaccine response.2
d.DNA:  Deox yribonucleic acid.
e.RNA:  Ribonucleic acid.
2.Scope of Future Biomedical Research
The specimens collected in this trial as outlined in Section [IP_ADDRESS] –Future Biomedical 
Research will be used to study  various causes for how subjects may respond to a 
drug/vaccine .  Future biomedical research specimen(s) will be stored to provide a 
resource for future trials conducted by [CONTACT_819252] a drug/vaccine enters and is removed by [CONTACT_10489] , how a 
drug/vaccine works, other pathway s a drug/vaccine may interact with, or other aspects of 
disease.  The specimen(s) may be used for future assay  development and/or drug/vaccine 
development.
It is now well recognized that information obtained from study ing and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs /vaccines , enhance our understanding of human disease and ultimately 
improve public health through development of novel treatments targeted to populations 
with the greatest need.  All specimens will be used by [CONTACT_819253] b y a committee of our scientists and clinicians.
3.Summary of Proced ures for Future Biomedical Research
a.Subjects for Enrollment
All subjects enrolled in the clinical trial will be considered for enrollment in the 
Future Biomedical Research sub -trial.
b.Informed Consent
Informed consent for specimens (i.e., DNA, RNA, protein, etc.) will be obtained 
during screening for protocol enrollment from all subjects or legal guardians, at a trial 
visit by [CONTACT_90094].  Informed consent for Future 
Biomed ical Research should be presented to the subjects on Visit 1.  If delay ed,  
  04MZQR 
  04YKSX
Product:  MK -8189 88
Protocol/Amendment No.:  005-[ADDRESS_1134572] been 
rendered de -identi fied
A template of each trial site’s approved informed 
consent will be stored in the 
Sponsor’s clinical document repository .  Each consent will be assessed for 
appropriate specimen permissions.  
Each informed consent approved by  [CONTACT_819254] a unique tracking 
number.  The tracking number on this document will be used to assign specimen 
permissions for each specimen into the Entrusted Key holder’s Specimen Database.
c.eCRF Documentation for Future Biomedical Research Specimens
Documentation of both consent and acquisition of Future Biomedical Research 
specimens will be captured in the electronic Case Report Forms (eCRFs).  
Reconciliation of both forms will be performed to assure that only appropriatel y-
consented specimens are used for this sub-trial's research purposes. Any specimens 
for which such an informed consent cannot be verified will be destro yed.
d.Future Biomedical Research Specimen Collections
Blood specimens for DNA or RNA isolation will usually  be obtained at a time when 
the subject is having blood drawn for other trial purposes. Specimens like tissue and 
bone marrow will usually  be obtained at a time when the subject is having such a 
procedure for clinical purposes.
Specimens will be collected and sent to the labor atory  designated for the trial where 
they will be processed (e.g., DNA or RNA extraction, etc) following the [COMPANY_006] 
approved policies and procedures for specimen handling and preparation.
4. C onfidential Subject Information for Future Biomedical Research 
In order to optimize the research that can be conducted with Future Biomedical Research 
specimens, it is critical to link subject' clinical information with future test results. In fact 
little or no research can be conducted without connecting the clinical trial data to the 
specimen. The clinical data allow specific analy ses to be conducted. Knowing subject 
characteristics like gender, age, medical history  and treatment outcomes are critical to 
understanding clinical context of analy tical results.
To maintain privacy  of information collected from specimens obtained for Future 
Biomedical Research, [COMPANY_006] has developed secure policies and procedures.  All 
specimens will be de -identified as described below.  
  04MZQR 
  04YKSX
Product:  MK -8189 89
Protocol/Amendment No.:  005-[ADDRESS_1134573] code is a random number which 
does not contain any personally  identify ing information embedded within it. The link (or 
key) between subject identifiers and this first unique code will be held at the trial site.  No 
personal identifiers will appear on the specimen tube.  
This first code will be replaced with a second code at a [COMPANY_006] designated storage/lab 
facility .  The second code is linked to the first code via a second key. The specimen is 
now double coded.  Specimens with the second code are sometimes referred to as de-
identified specimens. The use of the second 
code provides additional confidentiality  and 
privacy  protection for subjects over the use of a single code.  Access to both keys would 
be needed to link any  data or specimens back to the subject's identification.
The second code is stored separately  from the first code and all associated personal 
specimen identifiers.  A secure link, the second key, will be utilized to match the second 
code to the first code to allow clinical information collected during the course of the trial 
to be associated with the specimen.  This second key will be transferred under secure 
procedures by [CONTACT_819255] d facility  to an Entrusted Keyholder at [COMPANY_006].  The 
second code will be logged into the primary  biorepository  database at [COMPANY_006] and, in this 
database, this identifier will not have identify ing demographic data or identify ing clinical 
information (i.e., race, sex, age, diagnosis, lab values) associated with it. The specimen 
will be stored in a designated biorepository  site with secure policies and procedures for 
specimen storage and usage.
The second key can be utilized to reconstruct the link between the results of future 
biomedical research and the clinical information, at the time of analy sis.  This linkage 
would not be possible for the scientist conducting the analysis, but can only be done by 
[CONTACT_819256].  The [COMPANY_006] 
Entrusted Keyholder will link the information and then issue a de-identified data set for 
analysis.  The only other circumstance by [CONTACT_819257] y linked to the full clinical data set would be those situations mandated by 
[CONTACT_10200] (e.g., EMEA, FDA), whereby  [CONTACT_819258] .
5.Biorepository Specimen Usage
Specimens obtained for the [COMPANY_006] Biorepository will be used for analyses using good 
scientific practices.  However, exploratory  analyses will not be conducted under the 
highl y validated conditions usually  associated with regulatory  approval of diagnostics.  
The scope of research performed on these specimens is limited to the investigation of the 
variability in biomarkers that may  correlate with a clinical phenot ype in subjects.
Analy ses utilizing the Future Biomedical Research specimens may be performed by 
[CONTACT_44873], or an additional third party (e.g., a university  investiga tor) designated by [CONTACT_44873].  
The investigator conducting the analysis will be provided with double coded specimens.  
Re-association of analy sis results with corresponding clinical data will only  be conducted 
by [CONTACT_819259].  Any contracted third party analyses will conform to 
the specific scope of analy sis outlined in this sub-trial.  Future Biomedical Research  
  04MZQR 
  04YKSX
Product:  MK -8189 90
Protocol/Amendment No.:  005-[ADDRESS_1134574] [COMPANY_006] using the designated 
mailbox 
([EMAIL_1250] ) and a form will be provided by [CONTACT_819260].  Subsequently , the 
subject's specimens will be removed from the biorepository  and be destroy ed. A letter 
will be sent from [COMPANY_006] to the investigator confirming the destruction. It is the 
responsibility  of the investigator to inform the subject of completion of destruction.  Any 
analyses in progress at the time of request for destruction or alread y performed prior to 
the request being received by [CONTACT_75406]. No new analy ses would be generated after the request is 
received.
In the event that the medical records for the main trial are no longer available (e.g., if the 
investigator is no longer required by [CONTACT_75407]) or the specimens have been completel y anony mized, there will no longer be a 
link between the subject’s personal information and their specimens. In this situation, the 
request for specimen destruction can not be processed. 
7. Retention of Specimens 
Future Biomedical Research specimens will be stored in the biorepository  for potential 
analysis for up to [ADDRESS_1134575] results (which include genetic data) from the clinical trial database 
thereb y maintaining a separation of subject number and these results.  The separate 
databases are accessible only to the authorized Sponsor and the designated trial
administrator research personnel and/or collaborators.  Database user authentication is 
highl y secure, and is accomplished using network security  policies and practices based in  
  04MZQR 
  04YKSX
Product:  MK -8189 91
Protocol/Amendment No.:  005-01 
MK-8189-005-01 Final Protocol 29-Mar-2017
Confidentialinternational standards (e.g., ISO17799) to protect against unauthorized access.  The 
[COMPANY_006] Entrusted Keyholder maintains control over access to all specimen data.  These 
data are collected for future biomedical research purposes only as specified in this sub-
trial will not be used for any  other purpose.
9.Reporting of Future Biom edical Research Data to Subjects
There is no definitive requirement in either authoritative ethical guidelines or in relevant 
laws/regulations globall y that research results have to be, in all circumstances, returned to 
the trial participant.  Some guidelines advocate a proactive return of data in certain 
instances.  No information obtained from exploratory  laboratory  studies will be reported 
to the subject or family , and this information will not be entered into the clinical database 
maintained by [CONTACT_819261].  Principle reasons not to inform or return results to the 
subject include: lack of relevance to 
subject health, limitations of predictive capability , 
concerns of misinterpretation and absence of good clinical practice standards in 
explora tory research t ypi[INVESTIGATOR_819186].
If any exploratory  results are definitively  associated with clinical significance for subjects 
while the clinical trial is still ongoing, investigators will be contact[CONTACT_819262] (paid for by [CONTACT_44873]) to subjects enrolled and 
will be advised that counseling should be made available for all who choose to participate 
in this diagnostic testing. 
If any exploratory  results are definitivel y associated with clinical significance after 
completion of a clinical trial, [COMPANY_006] will publish the results without revealing specific 
subject information, inform all trial sites who participated in the [COMPANY_006] clinical trial and 
post anon ymized results on our website or other accredited website(s) that allow for 
public access (e.g., disease societies who have primary  interest in the results) in order that 
physicians and patients may  pursue clinical diagnostic testing if they  wish to do so.
10. Gender, Ethnicity and Minorities
Although many diagnoses differ in terms of frequency  by [CONTACT_819263], 
every  effort will be made to recruit all subjects diagnosed and treated on [COMPANY_006] clinical 
trials for future biomedical research.  When trials with specimens are conduc ted and 
subjects identified to serve as controls, every  effort will be made to group specimens 
from subjects and controls to represent the ethnic and gender population representative of 
the disease under current investigation.
11.Risks Versus Benefits of Future Biomedical Research 
For future biomedical research, risks to the subject have been minimized. No additional 
risks to the subject have been identified as no additional specimens are being collected 
for Future Biomedical Research (i.e. onl y leftover 
samples are being retained).
The Sponsor has developed strict securit y, policies and procedures to address subject data 
privacy  concerns.  Data privacy  risks are largely  limited to rare situations involving 
possible breach of confidentiality .  In this highly unlikely  situation there is risk that the 
information, like all medical information, may  be misused. 
  04MZQR 
  04YKSX
Product:  MK -8189 92
Protocol/Amendment No.:  005-01 
MK-8189-005-01 Final Protocol 29-Mar-2017
Confidential12.Self-Reported Ethnicity
Subjects who participate in future biomedical research will be asked to provide self-
reported ethnicit y.  Subjects who do not wish to provide this data may still participate in 
future biomedical research.
13.Questions
Any questions related to the future biomedical research should be e
-mailed directl y to 
[EMAIL_1250].
14.References
1.National Cancer Institute: http://www.cancer.gov/dictionary /?searchTxt=biomarker
2.International Conference on Harmonization: DEFIN IT
IONS FOR GENOMIC 
BIOMARKERS, PHARMACOGENOMICS, PHARMACOGENETICS, GENOMIC 
DATA AND SAMPL E CODING CATEGORIES - E15; 
http://www.ich.org/LOB/ media/MEDIA3383.pdf 
  04MZQR 
  04YKSX
Product:   MK-8189 93
Protocol/Amendment No.: 005-01 
MK-8189 -005-01 Final Protocol 29-Mar-2017
ConfidentialPharmacogenetics Informational Brochure for IRBs/IECs & Investigational Site Staff 12.[ADDRESS_1134576]:   MK-8189 94
Protocol/Amendment No.: 005-[ADDRESS_1134577]:   MK-8189 95
Protocol/Amendment No.: 005-[ADDRESS_1134578]:   MK-8189 96
Protocol/Amendment No.: 005-[ADDRESS_1134579]:   MK-8189 97
Protocol/Amendment No.: 005-[ADDRESS_1134580]:   MK-8189 98
Protocol/Amendment No.: 005-[ADDRESS_1134581]:   MK-8189 99
Protocol/Amendment No.: 005-[ADDRESS_1134582]:   MK-8189 100
Protocol/Amendment No.: 005-[ADDRESS_1134583]:   MK-8189 101
Protocol/Amendment No.: 005-[ADDRESS_1134584]:   MK-8189 102
Protocol/Amendment No.: 005-[ADDRESS_1134585]:   MK-8189 103
Protocol/Amendment No.: 005-[ADDRESS_1134586]:   MK-8189 104
Protocol/Amendment No.: 005-[ADDRESS_1134587]:   MK-8189 105
Protocol/Amendment No.: 005-[ADDRESS_1134588]:   MK-8189 106
Protocol/Amendment No.: 005-[ADDRESS_1134589]:   MK-8189 107
Protocol/Amendment No.: 005-[ADDRESS_1134590]:   MK-8189 108
Protocol/Amendment No.: 005-[ADDRESS_1134591]:   MK-8189 109
Protocol/Amendment No.: 005-[ADDRESS_1134592]:   MK-8189 110
Protocol/Amendment No.: 005-[ADDRESS_1134593]:   MK-8189 111
Protocol/Amendment No.: 005-[ADDRESS_1134594]:   MK-8189 112
Protocol/Amendment No.: 005-01 
MK-8189 -005-01 Final Protocol 29-Mar-2017
ConfidentialApproximate Blood/Tissue Volumes Drawn/Collected by [CONTACT_75408] 12.4
Sample Types
Trial Visit/Cycle/etc:Screening
Visits [ADDRESS_1134595]-
Treatm ent
Blood Param eter Approxim ate Blood Volume (mL)
Hem atology 2 2 2 2
Serum/Plasma Chemistry 8.5 8.5 8.5 8.5
Serum β-Hum an Chorionic 
Gonadotropin (β -hCG)a 3.5
Serum Follicle Stimulating 
Hormone (FSH)b 3.5
HIV/Hepatitis Screen (at the 
discretion of the investigator
and/or p er site SOPs)b3.5
Blood for Genetic Analysis
(DNA) 8.5
Prolactin 3.5 3.5 3.5
PK 6 18 6
Lipi[INVESTIGATOR_805] 3.5 3.5 3.5
Fasting glucose 2 2 2 2
Insulin 2 2 2
Expected Total (mL) 32.[ADDRESS_1134596]:   MK-8189 113
Protocol/Amendment No.: 005-01 
MK-8189 -005-01 Final Protocol 29-Mar-2017
ConfidentialAbbreviations 12.5
Abbreviation Definition
AAP Atypi[INVESTIGATOR_819187]/experience
ALT Alanine aminotransferase
ANCOVA Analy sis of covariance
ASaT All subjects as treated
AST Aspartate aminotransferase
βhGC Beta human Chorionic Gonadotropin 
BL Baseline
BMI Body mass index
BUN Blood urea nitrogen Blood urea nitrogen
CGI-S Clinical Global I mpression Scale -Severity
CHMP Committee for Medicinal Products for Human Use
cm Centimeter
CNS Central Nervous S ystem
CR Controlled release
C-SSRS Columbia Suicide Severity  Rating Scale
CYP Cytochrome P450 enz yme
DC Discontinuation
DNA Deox yribonucleic Acid
DO Doctor of Osteopathic Medicine
DSM -5™ Diagnostic and Statistical Manual of Mental Disorders, Fifth 
Edition
ECG Electrocardiogram
ECI Event of Clinical Interest
eCRF Electronic Case Report Form
ECT Electroconvulsive Therapy  
eGFR Estimated Glomerular Filtration Rate 
  04MZQR
CCI
CCI
CCI
CCI 
  04YKSX
Product:   MK -8189 114
Protocol/Amendment No.: 005-[ADDRESS_1134597]
FSH Follicle Stimulating Hormone
GCP Good Clinical Practice
HDL High densit y lipoprotein
HIV Human Immunodeficiency  Virus
IB Investigator’s Brochure
ICF Informed Consent Form
ICH International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human 
Use
IEC Independent Ethics Committee
in Inches
IND Investigational New Drug
IP Investigational Product .  This term is interchangeable with 
the terms “study  drug” and “study  medicati on” as used in this 
protocol.  IP refers to MK-[ADDRESS_1134598]:   MK -8189 115
Protocol/Amendment No.: 005-[ADDRESS_1134599] Modification of Diet in Renal Disease (calculation) 
MINI Mini I nternational Neuropsy chiatric Interview for 
Schizophrenia and Psy chotic Disorders
MIST Metabol ites in Safety  Testing
NDA New Drug Application
NP Nurse Practitioner
NSAID Nonsteroidal anti -inflammatory  drug
PA Physician’s Assistant
PANSS Positive and Negative Syndrome Scale
PC Phone Call
PD Pharmacod ynamic s
PE Physical Exam
PhD Doctor of Philosophy  
pH Numeric scale to measure acidit y or basicit y
PGt Pharmacogenetic
PK Pharmacokinetic(s)
[COMPANY_003]M Department of Pharmacokinetics Pharmacod ynamics and 
Drug Metabolism
QD Once dail y
QTcF QT (waves) corrected -Fridericia 
Rand Randomization
RBC Red Blood Cell
RNA Ribonucleic acid
SAE Serious Adverse Event
(S)AE All Adverse Events, including Serious Adverse Events 
  04MZQR
CCI 
  04YKSX
Product:   MK -8189 116
Protocol/Amendment No.: 005-01 
MK-8189-005-01 Final Protocol 29-Mar-2017
ConfidentialAbbreviation Definition
SDME Sponsor designated medical expert: a medically  qualified 
sponsor representative who consults with sites on protocol -
specific activities, such as the review of the Screening 
psychiatric evaluation intake forms to verify  subject 
eligibility .An “external” S DME refers to a vendor SDME .
siDMC Standard Internal Data Monitoring Committee 
SME Subject Matter Expert
SOC System Organ Class
SOP Standard Operating Procedure
T4 Thyroxine
TEAE Treatment Emergent Adverse Events
TC Telephone Contact
[CONTACT_819264], [LOCATION_003] [LOCATION_002] of America
WBC White Blood Cell 
  04MZQR 
  04YKSX
Product:   MK-8189 117
Protocol/Amendment No.: 005-[ADDRESS_1134600]:   MK -8189 118
Protocol/Amendment No.: 005-[ADDRESS_1134601]:   MK -8189 119
Protocol/Amendment No.: 005-[ADDRESS_1134602]:   MK -8189 120
Protocol/Amendment No.: 005-[ADDRESS_1134603]:   MK -8189 121
Protocol/Amendment No.: 005-[ADDRESS_1134604]:   MK -8189 122
Protocol/Amendment No.: 005-[ADDRESS_1134605]:   MK -8189 123
Protocol/Amendment No.: 005-[ADDRESS_1134606]:   MK-8189 124
Protocol/Amendment No.: 005-[ADDRESS_1134607] Tables
Mappi[INVESTIGATOR_88653] 11 Categories of Suicidal Ideation and Behavior and the C -SSRS
Category C-SSRS Questions (from eCRF)*
Suicidal ideation
Passive1.Wish to be dead
Active –nonspecific (no method, intent or 
plan)2.Non- specific active suicidal thoughts
Active –method, but no intent or plan, 3.Active suicidal ideation with any  
methods (not plan) without intent to 
act
Active –intent, with or without a method, 
but no plan4.Active suicidal ideation with some 
intent to act, without a plan
Active –method, i ntent and plan5.Active suicidal ideation with specific 
plan and intent
Suicidal behavior
Preparatory  actions toward imminent 
suicidal behaviorsPreparatory  acts or behavior
Aborted attempt Aborted attempt
Interrupted attempt Interrupted attempt
Suicide attempt Actual attempt
Completed suicide Completed suicide
Self-injurious behavior, no suicidal 
attemptHas subject engaged in non-suicidal self-
injurious behavior?
*Data are “Yes” of “No” 
  04MZQR 
  04YKSX
Product:   MK-8189 125
Protocol/Amendment No.: 005-01 
MK-8189 -005-01 Final Protocol 29-Mar-2017
Confidential13.0 SIGNATURES
Sponsor's Representative 13.[ADDRESS_1134608] this clinical trial in accordance with the design outlined in this protocol 
and to abide by [CONTACT_19373] (including other manuals and documents 
referenced from this protocol).  I  agree to conduct the trial in accordance with generally 
accepted standards of Good Clinical Practice.  I also agree to report all information or data in 
accordance with the protocol and, in particular, I agree to report any serious adverse events 
as defined in Section 7.0–Assessing and Recording Adverse Events.  I also agree to handle 
all clinical supplies provided by [CONTACT_819265].  I understand that information that identifies me will be used 
and disclosed as described in the protocol, and that such information may be transferred to 
countries that do not have laws protecting such information.  Since the information in this 
protocol and the referenced Investigator’s Brochure is confidential, I understand that its 
disclosure to any third parties, other than those involved in approval, supervision, or conduct 
of the trial is prohibited.  I will ensure that the necessary  precautions are taken to protect such 
information from loss, inadvertent disclosure or access b y third parties.
TYPED NAME
[CONTACT_26410] 
  04MZQR 
  04YKSX